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ABSTRACT
It is now well established that gluten sensitivity comprises a spectrum of disorders, 
which affect different target organs. The small-intestine (coeliac disease), skin 
(dermatitis herpetiformis) and peripheral and central nervous systems are most 
frequently affected. These manifestations may occur alone or in combination with one 
another.
Neurological complications affect approximately 6-10% of patients with gluten 
sensitivity with ataxia being the most frequent disorder seen in these patients. It has 
recently been established that previously undiagnosed gluten sensitivity may present 
solely with ataxia (gluten ataxia) and this disease entity may account for a large number 
of patients with sporadic idiopathic ataxia. Preliminary findings suggest an immune 
pathogenesis for gluten ataxia, in common with other manifestations of gluten 
sensitivity. The studies in this thesis are concerned with investigation o f the humoral 
immune response in the pathogenesis of gluten ataxia.
Assessment using enzyme-linked immunosorbent assay, immunohistochemistry and 
western blotting has shown the presence of elevated levels of circulating gluten 
sensitivity associated antibodies (anti-gliadin and anti-tissue transglutaminase 
antibodies) in patients with gluten ataxia. Studies have also shown the cross-reaction of 
anti-gliadin antibodies with epitopes on cerebellar Purkinje cells. In addition, patients 
with gluten ataxia possess circulating antibodies directed against cerebellar Purkinje 
cells, which are distinct from anti-gliadin antibodies although the target antigen remains 
unknown. Finally, studies have also shown that patients with gluten ataxia have 
elevated levels o f circulating antibodies directed against glutamic acid decarboxylase.
These studies suggest a role for the humoral immune response in gluten ataxia. 
However, preliminary evidence is also suggestive of a T-cell mediated response and the 
relative contributions of each in the pathogenesis of gluten ataxia remains to be 
elucidated.
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CHAPTER ONE
GENERAL INTRODUCTION
1.1. Ataxia
Ataxia is a term used to describe abnormalities in the co-ordination and accuracy of 
execution of voluntary movements. It may manifest at any age and has a number of 
causes. Ataxia results from disruption of the normal functioning of the cerebellum.
1.2 The Cerebellum
The cerebellum (little brain, Latin) is located at the base of the brain and constitutes 
approximately 10% of the brain’s total volume (Kandel et al., 1991).
1.2.1 The function of the cerebellum
As early as 1809, it was noted that cerebeilar disruption resulted in disturbance of 
posture and voluntary movements (Middleton & Strick, 1998). It is now known that the 
cerebellum plays an important role in the control and timing of voluntary movement 
(Fonnum & Lock, 2000). Generally, the cerebellum has a regulatory, stabilising role, 
co-ordinating different muscle groups so that actual movements precisely match the 
intended action. It continually receives information about intended movement from 
other parts o f the brain (internal feedback) as well as information about actual 
movement from peripheral sources (external feedback). Using this information, the 
cerebellum compares the intended action with what is actually happening and makes 
any necessary adjustments, through modulation o f motor tracts, to ensure the intended 
action is executed successfully (Kandel et al, 1991).
1.2.2 The functional structure of the cerebellum
The cerebellum is composed of an outer layer o f grey matter (the cerebellar cortex), 
internal white matter and three pairs of deep nuclei (fastigial, interposed and dentate) 
situated in its core. The cerebellum is divided into three functional areas: the vestibular 
cerebellum, the spinocerebellum and cerebrocerebellum, each containing neurones that 
are arranged in a highly regular, repetitive pattern. Each of these areas acts on inputs 
from different areas o f the brain as well as also sending outputs to distinct areas (Kandel 
et al, 1991). The cerebellar cortex is pivotal to cerebellar function in receiving, 
processing and outputting information. The cortex itself is composed o f three layers: 
the molecular layer, the Purkinje cell layer and the granular layer (figure 1.1) and 
contains five types o f neurones: stellate, basket, Purkinje, Golgi and granule cells 
(figure 1.2). There are two different input systems into the cerebellar cortex, both
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Figure 1.1 Haemotoxylin and eosin stain of a section of the human cerebellar cortex
A paraffin-embedded section of post-mortem human cerebellar tissue stained with 
haemotoxylin and eosin. The molecular (M), granular (G) and Purkinje cell (P) layers 
of the cerebellar cortex are clearly visible. Purkinje cells are indicated by arrows. 
Photograph courtesy o f Dr. M. Hadjivassiliou.
Figure 1.2 The structure of the cerebellar cortex
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having the end-result o f exciting Purkinje cells, which are the sole output o f the 
cerebellar cortex (Carpenter, 1996; Kandel et al., 1991).
1.2.2.1 Cerebellar Purkinje cells
Purkinje cells are one o f the largest neurones of the central nervous system (CNS) with 
a cell body diameter o f 50-80jwn. They are unmyelinated, inhibitory neurones and use 
y-aminobutyric acid (GABA) as their neurotransmitter. During development, Purkinje 
cells form a multi-cellular layer between the molecular and granular layers of the 
cerebellar cortex. In early post-natal life, the Purkinje layer undergoes numerous 
changes and forms a unicellular structure consisting of a side by side arrangement of 
Purkinje cell bodies in the Purkinje cell layer with thick dendrites extending into the 
molecular layer. There are approximately 7-14 xlO6 Purkinje cells in the adult human 
cerebellum, the numbers of which remain relatively constant throughout life (Kandel et 
al, 1991). However, some apoptotic death does occur and, as with all neurones, some 
degree o f age-related loss is expected in individuals over 70 years o f age (Goldowitz & 
Hamre, 1998).
1.2.2.2 Cerebellar connections: pathways to and from the cerebellar cortex
The major afferent input of the cerebellar cortex comes from mossy fibres that excite 
Purkinje cells indirectly. Upon entering the cerebellar cortex, mossy fibres excite local 
populations of granule cells within the granular layer. Ascending to the molecular layer 
the granule cell axons make connections with nearby Purkinje cells then, within the 
molecular layer, they split into two thin fibres (parallel fibres) that run in opposite 
directions intersecting with the Purkinje cell dendrites (figure 1.2). Each granule cell 
receives input from many mossy fibres and, in turn, contacts a large number o f Purkinje 
cells making this input system very diffuse and non-specific. This is in contrast to the 
second afferent input system of the cerebellar cortex. The second input into the 
cerebellar cortex is provided by climbing fibres, which excite Purkinje cells directly. 
Climbing fibres enter the cortex and wrap around Purkinje cells forming numerous 
synaptic contacts, predominantly on the Purkinje cell dendrites (figure 1.2). These 
contacts are highly excitatory, each climbing fibre contacts only 1-10 Purkinje cells and 
each Purkinje cell receives input from only one climbing fibre. Inhibitory controls over 
these input systems are provided by Golgi cells, which inhibit granule cells, and basket 
and stellate cells, which inhibit Purkinje cells. Purkinje cells are the sole output o f the 
cerebellar cortex and are directly connected to the deep cerebellar nuclei, which in turn
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feed out to other regions o f the brain (Carpenter, 1996; Kandel et al, 1991). These 
connections are summarised in figure 1.3.
1.3 Symptoms Of Ataxia
Damage to the cerebellum results in characteristic signs and symptoms, related to which 
of the three functional areas is affected. Symptoms vary between individuals and 
according to the type o f ataxia. Common symptoms include abnormal jerky eye- 
movements (nystagmus), difficulties of postural co-ordination (eg. difficulties in 
standing upright, seating) and problems with abnormal gait (eg. unsteadiness when 
walking and the need to walk with the feet placed widely apart), attributable to damage 
of the vestibulocerebellum. Damage to other cerebellar areas also causes more 
generalised co-ordination problems. Frequently, difficulty co-ordinating all kinds of 
movement is experienced (asynergia), often in association with a loss of muscle tone 
(hypotonia). Consequently, individuals with ataxia often ‘overshoot’ movements 
(dysmetria), for example reaching out too far to pick up an object from a table. The 
overshoot is corrected by an overshoot in the opposite direction and a cycle is set up 
resulting in an action tremor around the desired position (intention tremor). Other 
symptoms include difficulties in executing rapidly alternating tasks with the limbs and 
difficulty co-ordinating speech resulting in slurring (dysarthria) (Carpenter, 1996; 
Kandel et al, 1991).
1.4 Causes Of Ataxia
Ataxic conditions may be inherited, acquired or be of unknown cause.
Inherited ataxias comprise a wide group of disorders, which have a collective 
prevalence of approximately 6-7 individuals per 100,000 population (Albin, 2003).
They are divided into autosomal dominant and autosomal recessive ataxias depending 
on their mode of inheritance with each class able to be further subdivided according to 
the mechanism of genetic mutation (Albin, 2003). One major group o f dominantly 
inherited ataxias is the spinocerebellar ataxias (SCAs), which are assigned different 
numbers according to the specific associated gene or chromosomal locus (Mariotti & Di 
Donato, 2001). The SCAs are caused by primarily tri, but also tetra or penta, nucleotide 
repeats in either coding or non-coding regions o f specific genes, which results in the 
formation of aberrant proteins with ‘toxic’ functions and consequent neuronal cell death
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Figure 1.3 A summary of the inputs/outputs and actions of the three functional areas of the cerebellum
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and degeneration (Albin, 2003; Mariotti & Di Donato, 2001). The affected proteins and 
associated locus have now been discovered for some, but not all, SCAs (Mariotti & Di 
Donato, 2001). Other dominantly inherited ataxias are dentatorubral pallidoluysian 
atrophy (DRPLA), which is also caused by a trinucleotide repeat, and the episodic 
ataxias (Albin, 2003). There are four types of episodic ataxias, all o f which are the 
result o f mutations in genes encoding ion channel proteins. Types 1 and 2 result in 
dysfunction o f potassium and calcium channels respectively and the genes affected in 
type 3 and 4 have yet to be isolated (Albin, 2003). The recessive ataxias are also a 
heterogeneous group, which commonly result from a loss of function of various gene 
products (Albin, 2003). The most common of this group is Friedreich’s ataxia, caused 
by a trinucleotide repeat in the frataxin gene, but other recessive ataxias include ataxia 
associated with a primary vitamin E deficiency and ataxia-telangiectasia (Albin, 2003; 
Mariotti & Di Donato, 2001).
Acquired ataxias may arise as a secondary result o f several different conditions. These 
include alcoholism, vitamin deficiencies, malignancy (paraneoplastic syndromes) and 
other neurological disorders (e.g. multiple sclerosis, MS) (Mariotti & Di Donato, 2001).
A further, significant proportion o f ataxia cases occur sporadically and the cause 
remains unknown (idiopathic ataxia). A subgroup of these patients have been reported 
to possess circulating antibodies directed against glutamic acid decarboxylase (GAD) 
and it has been suggested that, in these cases, the ataxia may have an immune-mediated 
pathogenesis. The association between ataxia and circulating anti-GAD antibodies is 
described in more detail in section 6 .1.2.4. It is also known that ataxia is the most 
common neurological manifestation of gluten sensitivity and that recent research has 
suggested that a significant number of cases of sporadic idiopathic ataxia may be due to 
previously undetected gluten sensitivity (gluten ataxia) (Hadjivassiliou et al., 1996;
1998). Identification of a cause is important, as these cases of ataxia may be potentially 
treatable or preventable if  the aetiology can be determined.
1.5 The modern epidemic of gluten sensitivity
Grain has only been a significant part o f mans’ diet since the agricultural revolution, a 
consequential event o f the climate change during the transition from the Paleolithic to 
the Neolithic age, approximately ten thousand years ago (Diamond, 2002; Greco, 1997;
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Lev-Yadun et al, 2000). Efficient agricultural systems are believed to have started 
within the ‘Fertile Crescent’ (a wide area including southern Turkey, Palestine, Lebanon 
and northern Iraq) (Diamond, 2002; Greco, 1997; Lev-Yadun et al, 2000). Advantages 
including the physical properties of grain (easy storage, plentiful harvests) and the sense 
of wellbeing induced after ingestion of wheat (from exorphins, partially digested 
peptides that exert morphine-like effects) resulted in its growth in popularity as a food 
source, despite an initial decline in the health and stature amongst peoples of the first 
farming communities (Diamond, 2002; Fukudome & Yoshikawa, 1992, 1993; Greco, 
1997; Zioudrou et al, 1979). Thereafter, agricultural practices were readily accepted 
and spread rapidly throughout the Mediterranean region before finally reaching 
Northern and Western Europe approximately five thousand years ago (Greco, 1997).
During this period, grains themselves also underwent extensive artificial selection in 
order to adapt to the changing demands of agriculture and large-scale cultivation. These 
changes resulted in the eventual production of Triticum Aestivum, the progenitor o f all 
modem wheat species, o f which there are over twenty thousand. Todays’ wheat 
contains extremely large quantities of gluten (the storage protein of wheat) as a response 
to the current demands for a product that is well adapted for baking and easily handled 
by modem agricultural machinery (Greco, 1997). The inclusion o f grains in mans’ diet, 
therefore, occurred extremely late on in evolutionary terms and many populations have 
consumed them for only several thousand years. As may be expected, not everybody 
adapted to these dramatic changes over such a short time period and a proportion of 
humans could not recognise gluten as a ‘tolerable’ protein and developed gluten 
sensitivity. Although strictly referring to the toxic proteins of wheat, the term ‘gluten’ 
used in the context o f gluten sensitivity within this thesis also encompasses the 
analogous toxic proteins, hordeins and secalins, found in barley and rye respectively.
It is now known that gluten sensitivity is a complex, immune-mediated condition with a 
strong genetic association. Onset is triggered by the combination o f genetic 
susceptibility and the interactions with various environmental factors. Gluten 
sensitivity has a highly variable clinical spectmm (figure 1.4). The first described 
manifestation of gluten sensitivity was that affecting the small intestine (coeliac disease, 
CD) and with many symptoms related to the gastrointestinal (GI) tract or malabsorption, 
it was long assumed that the gut was the sole target organ. However, it is now well- 
established that this is not always the case and that the condition may manifest as
different diseases in areas other than the small intestine, most commonly the skin 
(dermatitis herpetiformis, DH) and the nervous system. These manifestations share 
certain aetiological genetic and environmental factors and may occur alone or in 
combination with one another, with differing severity, in the same individual.
Research into gluten sensitivity has advanced considerably in recent years and, 
reflecting the wide clinical spectrum, gluten sensitivity is defined as ‘a state o f 
heightened immunological responsiveness to ingested gluten proteins in genetically 
predisposed individuals ’ (Marsh, 1995).
Figure 1.4 The spectrum of gluten sensitivity
Neurological 
Dysfunction 
(peripheral and central 
nervous systems)
Symptoms include: Ataxia, 
peripheral neuropathy 
epilepsy, migraine
Coeliac Disease 
(small intestine)
Symptoms include: 
Diarrhoea/constipation, 
abdominal pain & 
bloating, fatigue, weight- 
Ipss, vomiting, loss o f  
appetite
Derm atitis 
Herpetiform is 
(skin)
Symptoms: Itchy vesicular 
rash, predominantly on 
elbows, buttocks, knees
Gluten sensitivity has a wide-ranging clinical spectrum. Target organs are diverse and 
the condition commonly affects the intestine, skin and nervous system. These 
manifestations may occur alone or in combination with one another. Overlapping areas 
demonstrate co-existing manifestations previously reported in literature (not to scale).
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1.6 Epidemiology of gluten sensitivity
Early studies suggested that CD was an uncommon condition affecting approximately 1 
in 1000 people or less within Europe (Feighery, 1999; Guandalini & Gupta, 2002). 
However, it soon became apparent that clinically recognised cases of CD were greatly 
outnumbered by undiagnosed cases of asymptomatic or more atypical forms of CD and 
the concept of the CD ‘iceberg’ was proposed (figure 1.5).
Figure 1.5 The coeliac disease ‘iceberg’
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At present, clinically diagnosed cases of CD (the tip of the iceberg) are vastly 
outnumbered by unrecognised asymptomatic or atypical cases. Severe mucosal damage 
is not a prerequisite for diagnosis of CD although genetic susceptibility is a common 
factor. In addition, a large number of otherwise healthy individuals who are genetically 
susceptible to CD may be considered as potentially gluten sensitive.
Adapted from Maki & Collin, 1997.
Large population screening studies have confirmed a much higher prevalence o f CD 
(table 1.1), many suggesting that up to 1% of the population may be affected. Data 
suggests that for every clinically diagnosed case, another 3-14 times more cases may be 
detected by screening (Bramwell Cook et al., 2000; Catassi et al., 1996, 1997; 
Csizmadia et al., 1999; Johnston et al., 1998).
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.1.
If genetically susceptible individuals with extra-intestinal manifestations and serological 
markers o f gluten sensitivity but histologically normal intestinal mucosa are also 
included, the prevalence of gluten sensitivity as a whole is likely to be even greater than 
1% of the population. Additionally, a large number o f genetically susceptible but 
otherwise healthy individuals may also be considered at a potential risk (figure 1.5).
Gluten sensitivity tends to be most prevalent in areas where bread and pasta were 
historically adopted as the major source o f carbohydrate. Therefore, it is primarily a 
disease o f European Caucasians and their descendants in countries such as the USA, 
Australia and New Zealand (Sollid, 2000). Most non-Caucasian populations have a 
lower prevalence and the condition generally remains rare in sub-Saharan African, 
Japanese and Chinese populations, even after migration to areas o f higher prevalence 
(Cole & Kagnoff, 1985). However, gluten sensitivity has been reported in populations 
including those o f Asian Indians (Kaur et al, 2002) and Arabs (Neuhausen et al, 2002) 
and the highest reported prevalence of 1 in 20 was found amongst North African 
Saharawi people (Catassi et al, 1999). Recent screening studies in such areas suggest 
that the incidence may, in fact, be similar to many European countries and the USA 
(Shahbazkhani et al, 2003).
CD has been reported to be more common in women than men (Gomez et al, 2001; Hin 
et al, 1999) but other studies have suggested that both are affected equally (Bramwell 
Cook et al, 2000; Johnston et al, 1998; Not et al, 1998). The sex distribution of 
gluten sensitivity as a whole is not known although neurological manifestations appear 
to affect both sexes evenly (Hadjivassiliou et al, 2002a; 2003a).
1.7 Genetic susceptibility to gluten sensitivity
A strong genetic component to the aetiology of gluten sensitivity is suggested by the 
facts that gluten sensitivity has long been noted to run in families, first-degree relatives 
of sufferers have a 10-15% risk of suffering themselves and there is a high concordance 
of disease among monozygotic twins of 76% (Greco et al, 2002). An extremely strong 
association of CD with certain human leukocyte antigen (HLA) class II genes is now 
well established. Gluten sensitive individuals with DH and gluten ataxia share the same 
HLA profile as patients with CD (Hadjivassiliou et al, 2003a; Wills et al, 2002). This 
suggests that gluten sensitivity is associated with a particular susceptible HLA 
genotype, regardless of the clinical manifestations, which may be a reliable indicator for
the condition. However, the fact that these genes are expressed by approximately 15- 
30% of the population (Catassi et al, 2002; Torinsson Nalual et al, 2001), yet only a 
small minority develops gluten sensitivity despite being exposed to similar 
environmental influences, is evidence for the involvement o f other additional 
susceptibility genes. It is believed that HLA genes account for less than 40% of the 
heritability o f CD (Bevan et al, 1999). The role o f additional susceptibility genes in the 
aetiology of other manifestations of gluten sensitivity has not been investigated.
1.7.1 HLA genes
The HLA class I and class II genes are located on the short arm o f chromosome 6 and 
are inherited together as a haplotype. The HLA system is highly polymorphic, each of 
the genes possessing multiple alleles. One haplotype is inherited from each parent and 
the HLA class I and II alleles are expressed co-dominantly (Staines et al, 1994). 
Initially, gluten sensitivity was associated with HLA class I molecule, B 8 (Falchuk et 
al, 1972; Stokes et al, 1972) but stronger associations were later found with the HLA 
class II molecules, DR3 and DQ2 (Keuning et al, 1976; Solheim et al, 1976; Tosi et 
al, 1983).
It is now known that 90-99% of individuals with gluten sensitivity express the DQ2 
molecule, the percentage varying somewhat depending on the geographical region 
(Catassi et al, 2002; Ciclitira & Moodie, 2003; Guandalini & Gupta, 2002; 
Hadjivassiliou et al, 2003a; Sollid et al, 1989; Wills et al, 2002).
HLA class II molecules are composed of two polypeptide chains, designated a  and p. 
The a-chain and p-chain of the DQ2 molecule are encoded by the DQA1*05 and 
DQB1*02 alleles respectively. Depending on the genetic make-up of an individual, the 
DQ2 molecule is, most commonly, encoded in cis (where both alleles are on the same 
chromosome) or in trans (where the alleles are located on different chromosomes) 
(figure 1.6) (Sollid et al, 1989). There is some evidence that encoding of the DQ2 
molecule in trans confers an increased risk of CD, suggesting that another gene present 
on the inherited haplotypes may affect the disease risk (Fernandez-Arquero et al, 1995; 
Mazzilli et al, 1992). Several studies have also identified a gene dosage effect of the 
DQB1*02 allele whereby individuals who have inherited more than one copy of the 
allele are also at an increased risk for disease (Lopez-Vazquez et al, 2002; Ploski et al, 
1993; Sollid, 2000).
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Figure 1.6 Genetic encoding of the HLA class II DQ2 heterodimer
HLA DQ2
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DQB1 DQA1 DQBl DQA1
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Individuals who are either DR3-DQ2 or DR5/DR7 or DR3/DR7 heterozygous can 
express the same DQ2 molecule. The heterodimer is either encoded in cis- (alleles 
present on the same chromosome) in DR3-DQ2 individuals or in trans- (alleles present 
on opposite chromosomes) in DR5/DR7 and DR3/DR7 heterozygous individuals.
It is rare that the DQ2 heterodimer is encoded by any other than these haplotypes. 
Adapted from Sollid, 2002.
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Depending on the population studied, 2-10% of patients with gluten sensitivity do not 
express the DQ2 heterodimer (Ciclitira & Moodie, 2003; Guandalini & Gupta 2002; 
Hadjivassiliou et al, 2003a; Sollid, 2000; Wills et ah, 2002). It is now known that 
virtually all o f these individuals instead express the DQ8 molecule (encoded by 
DQA1*03 and D Q B l*0302 alleles).
It is accepted that DQ2 and DQ8 HLA class II molecules confer the primary genetic 
susceptibility to gluten sensitivity. As mentioned, the relative proportions of DQ2 and 
DQ8-expressing patients appear somewhat dependent on region. For example, in Chile, 
expression of the DQ8 heterodimer appears more prevalent (Perez-Bravo et al, 1999), 
whereas in Northern and Southern Europe 98% and 92% of sufferers respectively 
express DQ2 (Parnell & Ciclitira, 1999).
Research has focused on the possible effects of other HLA genes that may be inherited 
on the same haplotypes as the DQ2 or DQ8 alleles. Several specific, sometimes unique, 
haplotypes containing the DQ2 gene have been found to be expressed more frequently 
in patients with CD depending on the geographical location. Specific haplotypes have 
been associated with Asian Indian (Kaur et al, 2002), Sardinian (B18-DR3-DQ2) 
(Congia et al, 1992) and Turkish (A25-B8-DR18-DQ2) populations (Erkan et al,
1999). Other work has suggested that certain haplotypes may be more associated with 
atypical forms o f CD rather than a typical presentation with GI symptoms (Lopez- 
Vazquez et al, 2002). Expression of other HLA genes carried on certain haplotypes, 
such as the DR heterodimer, DR53, which is capable of binding to gliadin peptides with 
high affinity (Clot et al, 1999), and the DP allele (DPB1 *0101) are also reported to 
increase disease risk and severity (Clot et al, 1999; Polvi et al, 1997).
1.7.2 Non-HLA genes
Despite extensive investigation and concentrated research, to date, no non-HLA genes 
have been definitively identified as contributing to the risk o f gluten sensitivity. This 
implies that any associated non-HLA genes have only a minor influence on disease 
susceptibility and that, apart from the HLA class II genes, there is no genetic factor 
which exerts a significant effect (Ciclitira.& Moodie, 2003; Sollid, 2000). Research into 
this area has mostly been carried out using genome-wide scans to search for disease- 
associated regions and candidate-gene targeting of specific genes of interest.
The results from these studies have so far been mixed and often contradictory.
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Genome-wide scans have been carried out on Irish (Zhong et al, 1996), British 
(Houlston et al, 1997), Italian (Greco et al, 1998), Finnish (Woolley et al, 2002) and 
Scandinavian (Torinsson Nalual et al, 2001) populations. Regions on chromosomes 
4p, 5q, 7q31, 8p, 1 lq, 1 lq2, 1 lp l 1, 15q26 and 22 were highlighted as o f interest on one 
or more of these studies and are interesting in that they contain genes with various 
immunological products. Many subsequent linkage studies have been carried out, 
looking directly at these candidate regions to identify specific genes. Some associations 
with the CTLA-4 (Djilali-Saiah et al, 1998; Mora et al, 2003; Popat et al, 2002), 
tumour necrosis factor (TNF) (de la Concha et al, 2000) genes and major 
histocompatibility class I chain related gene (MIC)-A (Fernandez et al., 2002; Lopez- 
Vazquez et al, 2002; Rueda et al, 2003) have been reported although not confirmed. 
Lie and co-workers suggested that a gene in the region D6S2223 on chromosome 6 
predisposes individuals to both coeliac disease and insulin-dependent diabetes mellitus 
(IDDM) (Lie et al, 1999). However, a recent, extremely large, collaborative European 
study (Louka et al, 2003) failed to identify any additional non-HLA risk-modifying 
factors on the common DR3-DQ2 susceptibility haplotype, which notably contains the 
TNF and MIC-A genes as well as the D6S2223 region.
1.8 Environmental aetiological factors of gluten sensitivity
The most critical environmental factor is exposure to gluten and other similar cereal 
proteins. The major constituents of grains are the outer husk (bran), the germ and the 
endosperm, which are separated from one another during milling. The storage proteins, 
which are the toxic agent in gluten sensitivity, are contained within the endosperm 
(Ciclitira & Moodie, 2003). Their function is to act as stores o f the amino acids that are 
necessary during germination (Molberg et al, 2003). They contain high levels of 
nitrogen, which in turn relates to the high content o f glutamine and proline residues 
found in the proteins (up to 50% of the total content) (Vader et al, 2002) although other 
amino acids, such as glutamic acid and aspartic acid are unusually rare (Sollid, 2002). 
For this reason, the storage proteins are also known as the prolamines. Prolamines from 
wheat (gluten), rye (secalins) and barley (hordeins) all have a relative molecular mass 
(RMM) of 30-74kDa (Duggan, 1997).
Gluten is a sticky substance, made up of a complex mixture o f many different gliadin 
and glutenin polypeptides (figure 1.7). All varieties o f wheat carry several, linked 
gluten-encoding genes located in clusters on several different chromosomes (Molberg et
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al., 2003). Gliadins are monomers (-250-300 residues in length, 20-40kDa) and are of 
numerous types (Molberg et al., 2003; Sollid, 2002). The gliadins are sub-divided into 
a,p,y and co type gliadins based on their N-terminal sequence and size and mobility on 
gel electrophoresis (Molberg et al., 2003). Each variety of wheat may contain several 
different variants o f each of these gliadins. Glutenins form large polymeric structures 
within gluten and are subdivided into high-RMM (-650-800 residues in length, 70- 
120kDa) and low-RMM (-270-330 residues in length, 30-75kDa) sub-types (Molberg et 
al., 2003; Sollid, 2002). As with the gliadins many variants exist and several different 
types may be present in each variety o f wheat.
Figure 1.7 The components o f gluten
WHEAT PROTEIN
GLOBULINS SLUT
(Saline soluble) (Ethanol f
EN ALBUMINS
soluble) (W ate r soluble)
Gliadins Glutenins
( < x , P , y , cd)
Adaptedfrom Parnell & Ciclitira, 1999.
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1.9 Diagnosis of gluten sensitivity
Specific guidelines for the diagnosis of CD are in place and certain elements, such as 
determination o f mucosal damage and presence of circulating markers of gluten 
sensitivity form a central part of the diagnosis o f other manifestations of gluten 
sensitivity too.
The cornerstone of CD diagnosis remains the detection o f characteristic mucosal 
changes that result from the immunological response to gluten by examination of a 
biopsy taken from the small intestine (Feighery, 1999; Guandalini & Gupta, 2002).
The most widely adopted diagnostic criteria for CD are those originally proposed, in 
1970, by the European Society o f Paediatric Gastroenterology and Nutrition (ESPGAN) 
(Meeuwisse, 1970). Briefly, the guidelines state that a diagnosis of CD should fulfil the 
following points;
o The presence o f compatible symptoms and the demonstration of a structurally 
abnormal small intestinal mucosa on a gluten-containing diet (1st intestinal biopsy) 
o A clear, clinical response to a gluten-free diet (GFD)
o Documentation of unequivocal improvement of the villous structure after following 
a GFD for approximately 6 months (2nd intestinal biopsy) 
o Deterioration o f mucosa and reappearance of symptoms during gluten challenge (3 rd 
intestinal biopsy)
These conditions were revised in 1990 (Walker-Smith et al, 1990). As a result, gluten 
challenge with a third biopsy is not routinely performed and, in some cases, a complete 
response to a GFD with a decrease in one or more serological markers, rather than a 
second biopsy, is sufficient for diagnosis (Ciclitira & Moodie, 2003). The development 
of reliable assays to detect serological markers (specific antibodies that are produced as 
a result o f the immune response against gluten) o f gluten sensitivity has led to major 
advances in the diagnosis of the condition. These assays have proved particularly useful 
in detecting genetically susceptible patients with atypical, silent or extra-intestinal 
manifestations o f gluten sensitivity, who may have a histologically normal intestinal 
mucosa. Currently, anti-gliadin, anti-endomysial and anti-tissue transglutaminase 
antibody assays are most frequently used for detection o f gluten sensitivity. Antibody 
profile varies among patients and some have no detectable serological markers (Rostami 
et al, 1998), therefore, it is advisable to test for as wide a range of antibodies and 
isotypes as possible. Further details on serological assays for gluten sensitivity are 
given in section 3.1.
1.10 Coeliac Disease
‘Classic’ overt gluten sensitivity, affecting the GI tract, CD, was first described by 
Samuel Gee more than a century ago in 1888 in his report entitled ‘On the Coeliac 
Affection’ (Ciclitira & Moodie, 2003). However, the disease was mentioned as early as 
the second century AD, by the clinician Aretaeus the Cappadocian, the name coeliac 
originating from his description in which he used the word ‘icoi?aaKr|’ (abdominal, 
greek) (Dowd et al., 1974). The link between CD and dietary factors was first 
recognised in 1924 with the description by Sidney Haas o f a novel treatment in the form 
of a banana diet, which excluded bread, crackers, potatoes and cereals (Haas, 1924). 
During the Second World War, a Dutch paediatrician named W.K. Dicke noted that 
children with CD recovered dramatically during this period of cereal and bread scarcity 
but relapsed quickly following their re-introduction. Dicke went on to prove in 1950 
that the toxicity was caused by gluten (Dicke, 1950).
1.10.1 Symptoms of coeliac disease
CD was historically considered a disease of childhood. Infants and toddlers presented 
before 2  years o f age with classic symptoms including irritability, chronic diarrhoea, 
failure to thrive, vomiting, abdominal distension, muscle wasting and retarded growth 
(Challacombe, 1994; Ciclitira & Moodie, 2003; Feighery, 1999; Guandalini & Gupta, 
2002). However, an increasing number of cases are being diagnosed in older children 
and adults in the absence of typical GI symptoms (Bottaro et al, 1999; Feighery, 1999; 
Visakorpi & Maki, 1994). It is currently believed that almost 50% of newly diagnosed 
patients present without GI symptoms but instead with non-specific, often vague 
symptoms frequently not immediately suggestive o f CD or with other, seemingly 
unrelated conditions (Guandalini & Gupta, 2002).
1.10.2 Treatment of coeliac disease
At present, the only treatment for gluten sensitivity is complete, life-long elimination of 
wheat, barley and rye from the diet. Although well tolerated in both in vivo and in vitro 
studies (Janatuinen et al., 2000, 2002; Kilmartin et al., 2002, 2003; Lundin et al., 2002), 
elimination o f oats too is generally advised (Parnell & Ciclitira, 1999). A GFD 
provides a dramatic and rapid relief of clinical symptoms followed by improvements in 
intestinal function and return to histologically normal mucosa for the vast majority of 
patients (Ciclitira & Moodie, 2003; Parnell & Ciclitira, 1999). The risks of most
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conditions and complications associated with untreated CD also improve or disappear 
after commencement o f a GFD. Most commonly, these include risks of nutritional 
deficiencies, low bone mineral density (Bai et al, 1997; Kemppainen et al, 1999; 
Mustalahti et al, 1999) and, most importantly, the increased risk of malignancy 
(particularly enteropathy associated intestinal T-cell lymphoma, EATL) (Holmes et al, 
1989; Howdle et al, 2003). Rarely, cases of CD may be non-responsive to a GFD 
(refractory CD).
1.10.3 The association of coeliac disease with autoimmune diseases
Patients with CD appear to have a greater than expected chance o f developing certain 
autoimmune conditions (table 1.2). It is known that patients with established CD are 3- 
5 times more likely to develop an associated autoimmune condition, particularly if 
diagnosed with gluten sensitivity at a later age (Sategna Guidetti et al, 2001; Ventura et 
al, 1999). Thfe association is thought to reflect a shared genetic background or 
immune-mediated mechanism between diseases (Feighery, 1999; Maki & Collin, 1997). 
A GFD does not seem to eliminate the risk, possibly indicating that early ingestion of 
gluten may somehow modify the immunological response (Sategna Guidetti et al, 
2001).
Table 1.2 Prevalence of associated autoimmune diseases among patients with coeliac 
disease
CONDITION
PERCENTAGE OF 
SUFFERERS WHO HAVE 
OR WILL DEVELOP CD REFERENCE
IDDM 4% Sategna G uidetti e t al., 
2001; V entura  e t al., 1999
A uto im m une thyro id  
d isorders
14% Sategna G uidetti e t al., 
2001
Psoriasis 3% Sategna G uidetti e t al., 
2001
A uto im m une hepatitis 1.1% V entura  e t al., 1999
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1.10.4 The immune-mediated pathogenesis of coeliac disease
It is now known that CD is the result of an immune response, mounted against gluten, 
within the small intestine. It is widely believed that this immune response requires a 
precipitating factor for its full initiation in genetically susceptible individuals on a 
gluten-containing diet. The exact nature o f this factor remains unclear but candidate 
factors include:
o Abnormal metabolism of gluten (Biagi et al, 1999a) or a shift to deamidation of 
gluten in the intestine (Arentz-Hansen et al, 2000; Sjostrom et al, 1998) causing a 
lack of or subsequent loss o f oral tolerance to gluten, 
o An episode o f intestinal hyperpermeability either through infection or altered
expression o f permeability mediators (eg. zonulin) (Clemente et al, 2003; Fasano et 
al, 2 0 0 0 ).
o Cross-reaction o f immune responses against infectious agents with gluten 
(Nieuwenhuizen et al, 2003). 
o Increased dietary gluten (Hemell et al, 2001)
o Selective initiation o f an innate immune response against gluten (Maiuri et al, 2003; 
Schuppan et al, 2003)
Once initiated, the immune process leads to inflammation, loss o f intestinal structure 
and eventual loss of function. A histological image of a CD lesion, showing the disease 
associated hallmarks o f crypt hyperplasia and mucosal flattening (villous atrophy), is 
shown in figure 1.8. Importantly, these histological and functional changes occur along 
a continuum (figure 1.9) ranging from a histologically normal mucosa (preinfiltrative) 
to irreversible hypoplastic atrophic lesions (Marsh, 1995).
The mounting of an intestinal immune response against gluten requires the entry of 
intact peptides into the tissue for recognition by the immune system. Recent in vitro 
experiments have shown the existence of a highly stable 33-mer a-gliadin peptide, 
produced by digestion by gastric and pancreatic enzymes, which is able to resist 
subsequent digestion by small intestinal brush-border enzymes, thus passing into the 
tissue intact (Shan et al, 2002).
The immune response against gluten is thought to involve an early inflammatory 
response, activated by regions of gliadin distinct to those recognised by T-cells, 
followed by an adaptive gluten specific predominantly T-cell mediated response (Maiuri
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Figure 1.8 Histological images of a) Normal mucosa and b) A severe coeliac disease 
associated lesion
Villus
Lamina
propria
C rypt of 
L ieberkuhn
A haemotoxylin and eosin stain of a paraffin-embedded section of a duodenal biopsy. 
Complete flattening of the mucosa (villous atrophy) and infiltration o f T-cells (stained 
dark blue) into the lamina propria is evident in the coeliac disease-associated lesion (b.). 
Adaptedfrom Sollid, 2002.
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Figure 1.9 The Marsh Classification of coeliac disease associated mucosal lesions
"PRE-" ’INFILTRATIVE" "INFILTRATIVE • "FLAT "ATROPHIC •
INFILTRATIVE” HYPERPLASTIC" DESTRUCTIVE" HYPOPLASTIC"
Type 0 Type 1 Type 2 Type 3 Type 4
Type 0 (preinfiltrative) lesions have been reported in some gluten sensitive individuals 
and are associated with a normal mucosa in conjunction with genetic susceptibility and, 
in some cases, increased gluten sensitivity associated circulating antibodies.
The Type 1 lesion is associated with the infiltration of lymphocytes into the villous 
epithelium resulting in increased numbers o f intraepithelial lymphocytes (IELs) in an 
otherwise normal mucosa. A Type 2, infiltrative-hyperplastic lesion, has the additional 
characteristic o f hypertrophic crypts. The flat-destructive lesion (Type 3) is the classic 
‘text-book’ lesion with crypt hyperplasia and villous atrophy both evident. This lesion 
is divided into three sub-types (3a, b and c) depending on the degree o f villous atrophy 
(mild, partial or complete respectively). Type 4, atrophic-hypoplastic, lesions are rarely 
encountered and most frequently associated with cases of refractory CD or EATL.
Taken from Marsh, 1995.
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et al., 1996, 2003; Tuckova et al, 2002). This early response results in a rapid 
overexpression o f HLA-DR on epithelial cells and lamina propria macrophages. Other 
events include the release of interleukin (IL) -15 (mainly from the macrophage/dendritic 
type CD68+ cells of the lamina propria) and upregulation of cyclo-oxygenase (COX) -2 
from macrophages and monocytes as well as increased numbers of activated 
(CD83+/CD25+) antigen-presenting macrophages, monocytes and dendritic cells (Maiuri 
et al, 1996, 2003). T-cell migration, observed to occur 12-24 hours after gliadin 
challenge in vitro, then follows. Importantly, activated (CD25*) CD4+ T-cells were 
observed to accumlate in the lamina propria whilst only CD8+ T-cells invaded the 
epithelium, a process which did not require their activation (Maiuri et al, 1996).
Following these early responses, it is thought that lamina propria aP  CD4+ T-cells 
recognise gluten antigens, presented by HLA class IID Q 2 or DQ8 molecules located on 
specific antigen-presenting cells activated by the innate response, and mount an 
adaptive immune response (figure 1.10). DQ2 or DQ8 restricted, gluten-reactive CD4+ 
lamina propria T-cells have been isolated and propagated from the intestine of patients 
with CD but not healthy individuals (Arentz-Hansen et al, 2000; Halstensen et al,
1993; Lundin e /a/., 1993; Molberg et al, 1997; Nilsen et al, 1995).
1.10.4.1 Presentation of gluten to T-cells by DQ2 and DQ8 molecules
In its native state, gluten does not appear to have the appropriate properties required for 
successful processing and presentation by DQ2 and DQ8 molecules. Both DQ2 and 
DQ8 molecules share a preference for binding negatively charged peptides at certain 
positions of their binding clefts (Godkin et al, 1997; Johansen et al, 1996; Kwok et al, 
1996; Vartdal et al, 1996; van de Wal et al, 1996) (figure 1.11). Native gluten 
peptides have very few negatively charged residues. It is now known that gluten is 
deamidated in the intestine by the enzyme tissue transglutaminase (TG2) (section 
1.10.4.6), thereby converting its abundant glutamine residues to negatively charged 
glutamic acid residues. This results in the generation of peptides with a greater binding 
affinity to DQ2 and DQ8 molecules (Molberg et al, 1998; van de Wal et al, 1998). 
Importantly, proline residues within gluten also facilitate processing and presentation by 
DQ2 and DQ8 molecules by acting as an anchor residue at the P6 pocket of the DQ2 
binding cleft (figure 1.11) or by inducing a structure conducive to binding (Sollid, 2002; 
Vartdal et al, 1996; van de Wal et al, 1996).
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Figure 1.10 Proteins involved in the interaction between T-cells and antigen-presenting 
cells
A ntigen ^  
presenting  
cell
T-cell
The T-cell receptor (TCR) (composed of an a  and p chain) interacts with a peptide 
presented in an HLA class II molecule (also composed of an a  and p chain) on the 
surface of the antigen-presenting cell. The CD4 molecule stabilises this interaction, 
allowing a signal to be initiated by the CD3 molecule that eventually activates genes in 
the T-cell nucleus.
- peptide
Adapted from Staines et al., 1994.
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Figure 1.11 The peptide binding cleft of DQ2 indicating the preferred/not preferred 
binding positions of peptide glutamic acid and proline residues
T-cell
receptor
DQ2
P 7P 6P 4
P 9
Indicates a DQ2 anchor position where the presence of negatively 
charged residues within the peptide increases binding affinity.
DQ2
POCKET Preferred residue
# 4 Glutamic acid
# 6 Glutamic acid or proline
#7 Glutamic acid
Adapted from So 11 id, 2000; 2002
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1.10.4.2 G luten T-cell epitopes
Mapping o f the gluten molecule to identify sites of potential T-cell epitopes has 
demonstrated that the actual number of distinct epitopes is limited although there may 
be as many as fifty or more within gluten, hordein and secalin proteins (Vader et al, 
2002). Increasingly, data is available on the precise regions and sequences o f T-cell 
reactive gluten epitopes.
Epitopes recognised by both HLA DQ2 and HLA DQ8-restricted CD4+ T-cells have 
been identified within a-gliadin, y-gliadin and glutenin proteins (Arentz-Hansen et al, 
2002; Molberg et al, 2003; Vader et al, 2002; van de Wal et al, 1998, 1999).
Deamidation by TG2 and the position o f proline residues are also important factors in 
the creation of recognisable T-cell gluten epitopes. For most identified T-cell epitopes 
deamidation enhances their antigenic activity. Many are only rarely recognised in their 
native state and some not at all (Arentz-Hansen et al, 2002; Molberg et al, 2003; Vader 
et al, 2002). Further details of identified gluten T-cell epitopes are given in table 1.3.
Some T-cell epitopes are more immunodominant than others. For example, reactivity to 
DQ2 and DQ8 presented a-gliadin epitopes is also found in most, if  not all, adult CD 
patients, whereas reactivity to the DQ2 presented y-gliadin epitope is only found in a 
minority (Arentz-Hansen et al, 2000; Sollid, 2000). It is not certain how frequently the 
glutenin epitope is recognised although, in one study, none o f five children with CD 
reacted to the peptide (Sollid, 2000; van de Wal et al, 1999).
Differences are also apparent in the range o f T-cell epitopes recognised by different 
subgroups of patients with CD. Children with CD respond to a wider range of gluten 
epitopes, many o f which are recognised in the native form without the need for 
deamidation by TG2. In adults, the immune response appears more focused with only a 
few immunodominant epitopes involved, which require deamidation for recognition 
(Vader et al, 2002). It is possible that recognition of a wide range o f gluten epitopes is 
characteristic of early (potential/latent) CD in general, rather than age.
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Table 1.3 Gluten epitopes, identified to date, recognised by lamina propria CD4+ T-
cells from patients with coeliac disease
PRO TEIN HLA
restric tion
CORE SEQUENCE REFERENCE
a-gliadin DQ2 PFPQPQLPY
a-gliadin DQ2 PQPQLPYPQ Arentz-Hansen et al,
a-gliadin DQ2 PYPQPQLPY 2002
a-gliadin DQ8 SGQGSFQPSQQ van de Wal et al., 1998
y-gliadin DQ2 PQ Q SFPQ Q Q
y-gliadin DQ2 IIQ PQ Q PA Q
Arentz-Hansen et al.,y-gliadin DQ2 FPQ Q PQ Q PY PQ Q P
y-gliadin DQ2 FSQ PQ Q Q FPQ PQ 2002
y-gliadin DQ2 LQ PQ Q PFPQ Q PQ Q P
YPQQPQ
Glutenin DQ2 PFSQQQQSPF Vader et al., 2002
Glutenin DQ2 PFSQ Q Q Q Q
Glutenin DQ8 QQGYYPTS van de Wal et al., 1999
Glutamine residues targeted by TG2 are shown in red. Glutamine residues where 
deamidation is necessary for T-cell recognition are shown in green.
Indeed, it has been suggested that deamidation may be important in later stages o f the 
disease but that initially, the immune reaction may be initiated by T-cells recognising 
unmodified epitopes (Arentz-Hansen el al., 2002).
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1.10.4.3 Cytokine profile of gluten specific intestinal T-cells
In CD, there is increased cytokine production by activated a p  CD4+ lamina propria T- 
cells (Lahat et al, 1999). The cytokine profile is dominated by interferon (IFN)-y and 
there is a large increase in both the number o f IFN-y producing cells and the amount of 
IFN-y production (Kontakou et al, 1994; Lahat et al, 1999; Nilsen et al, 1995). In 
addition, messenger ribonucleic acid (mRNA) of IFN-y, IL-2, TNF-P, TNF-a, IL-10, 
IL -ip and transforming growth factor (TGF) ~p have been found in CD biopsy samples 
(Lahat et al, 1999). IL-2 and TNF-p mRNA are not normally present in the mucosa, 
suggesting a potential role in the disease pathogenesis for these cytokines (Lahat et al,
1999). Finally, the presence of mature IL-18, a crucial cytokine in maintaining the Thl 
response, is associated with CD mucosa but not controls (Salvati et al, 2002). Patients 
with active CD have increased numbers o f T-cells expressing both Thl and Th2 
cytokines, suggestive of ThO activation (Lahat et al, 1999). The cytokines TNF-a and 
migration inhibition factor (MIF) have both been detected in lamina propria T-cells 
from patients with CD (O’Keefe et al, 2001). In addition,.stimulated mucosal T-cells 
from patients with active CD have been shown to secrete high levels o f IFN-y as well as 
IL-4, IL-5, IL-6 , IL-10, TNF and TGF-p, in a ThO pattern (Nilsen et al, 1995; 
Przemioslo et al, 1994). Others secreted high levels o f IFN-y along with TNF but not 
IL-4 or IL-5, a Thl pattern (Nilsen et al, 1995).
Intraepithelial lymphocytes (IELs), too, from patients with CD have also been shown to 
express markedly increased levels o f TNF-a compared to controls (O’Keefe et al, 
2001).
1.10.4.4 Production of coeliac disease associated antibodies
Several disease-associated antibodies have been identified in patients with CD. Jejunal 
secretion rates of immunoglobulin (Ig) A (both monomeric and polymeric) and IgM are 
increased by two-fold and five-fold respectively, which parallels the observed increase 
in B-cells in the lamina propria (Colombel et al, 1990). Antigenic epitopes (which may 
be different from the recognised T-cell epitopes) are bound to specific B-cells, which 
then receive help from activated lamina propria CD4+ T-cells, through their production 
of cytokines such as IL-2, IL-4 and IL-5. In this way, the B-cells are stimulated to 
become antibody-producing cells.
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1.10.4.4.1 Anti-gliadin antibodies
Anti-gliadin antibodies are primarily of mucosal origin and are readily measured in the 
intestinal fluid of untreated patients with CD (Volta et al, 1990), although they may 
also be produced in the lymph nodes, possibly as a result o f gliadin leakage into the 
periphery (Marzari et al, 2001; Sollid et a l , 1997).
B-cell epitopes have been identified in all four of the major gliadin subtypes (a, p, y and 
cd ) and patients normally produce antibodies against multiple gliadin proteins (Levenson 
et al, 1985). The antigenic gliadin epitopes identified so far are somewhat different to 
those known to be recognised by T-cells (Krupicova et al, 1999) (table 1.4). Both 
linear and conformational epitopes have been described, indicating the secondary 
structure is of some importance (Alfonso et al, 1998). Some evidence suggests that p- 
tum motifs may be an important secondary structure for antibody recognition and two 
identified epitopes are contained within regions of gliadin that form P-turns (Alfonso et 
al, 1998; Osman et al, 2000).
TG2-mediated deamidation of gluten appears important for antibody recognition and 
has been shown to increase the in vitro recognition of gliadin peptides by circulating 
anti-gliadin antibodies (Aleanzi et al, 2001; Osman et al, 2000). However, in vivo B- 
cells recognising deamidated gliadin peptides have not been found to date (Aleanzi et 
al, 2001). Some anti-gliadin antibodies cross-react with enterocytes and regions of the 
ubiquitous calcium-binding protein, calreticulin, and it is likely that the two proteins 
share common epitopes (Krupickova et al, 1999; Tuckova et al, 1997).
1.10.4.4.2 Tissue autoantibodies
Untreated CD is frequently associated with the production o f autoantibodies directed 
against certain extracellular matrix (ECM) structures (Maki & Collin, 1997). Tissue 
autoantibodies in CD are strictly gluten driven and are regarded as target organ-related, 
predominantly IgA-class autoantibodies (Karpati et al, 1990; Maki, 1995). These 
antibodies may be detected using a variety of tissue substrates and, according to the 
tissue antigen used and the observed antibody binding pattern, the autoantibodies are 
classified as anti-reticulin (ARA), anti-endomysial (AEA) or anti-jejunal (AJA) 
antibodies (Maki & Collin, 1997). In 1997 it was discovered that the main target 
antigen o f AEA is TG2 (Dieterich et al, 1997). Very recently, Korponay-Szabo and co­
workers observed that antibodies directed against TG2 are also responsible for
Table 1.4 Gluten epitopes, identified to date, recognised by anti-gliadin antibodies
from patients with coeliac disease
PROTEIN SEQUENCE REFERENCE
a-g liad in Q X Q P F P  (X=P,Q,l )
O sm an e t al., 2000
a-g liad in W Q I P E Q
a-g liad in Q G X F Q P  ( X=F,S)
a-g liad in P Q Q L P Q
y-gliadin Q P Q Q P F
a-g liad in Q E Q V P L V Q Q Q Q F
K rupickova e t al., 1999
a-g liad in Q I L Q Q I L Q Q Q L I
a-g liad in W Q I P E Q S Q C Q A I
a-g liad in Q T L P A M C N V Y
a - gliad in A M C N V Y I P P Y C T
ARA, AEA and AJA tissue binding patterns of serum samples from patients with CD, 
indicating that these tissue autoantibodies are identical (Korponay-Szabo et al, 2000, 
2003a). Anti-TG2 antibodies are produced in the intestine (Marzari et al, 2001; Sollid 
et a l , 1997) and levels are correlated with the degree of enteropathy (Tursi et al, 2003). 
Their presence in serum is believed to be a result o f spillover into the blood from the 
intestine (Marzari et al, 2001). The proposed mechanism of anti-TG2 antibody 
production is shown in figure 1.12. As TG2-specific T-cells are unlikely to be present, 
the necessary T-cell help may be provided by gliadin-specific T-cells, which recognise 
gliadin peptides cross-linked to TG2 bound to TG2 specific-B-cells (Marsh, 1997;
Sollid et a l , 1997). Anti-TG2 antibodies recognise both conformational and linear 
epitopes (Molberg et al, 2000; Seissler et al, 2001; Sulkanen et al, 1998). Two major 
epitopes appear to be located within the N- (a.a. 1-281) and C-terminals (a.a. 473-687) 
of the protein, each of which were recognised by approximately 70% of test sera 
(Seissler et al, 2001). However, B-cell epitopes are spread across all regions of the 
protein with most patients possessing antibodies against more than one and, as a result,
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four major anti-TG2 antibody binding patterns of sera from untreated patients with CD 
have been defined,
I - Antibodies binding to N-terminus, middle region and C-terminus
II - Antibodies binding to N-terminus and C-terminus
III - Antibodies binding to N-terminus only
IV - Antibodies binding to C-terminus only 
(Seissler et al, 2001).
The production of anti-gliadin and anti-TG2 antibodies is shown in figure 1.12.
1.10.4.4.3 Other autoantibodies associated with coeliac disease 
Untreated CD is also associated with the presence of IgG and IgA-class antibodies 
directed against actin, a protein especially abundant in microvilli (Clemente et al.} 2000; 
Korponay-Szabo et al., 2003). They appear to be associated with more severe degrees 
of villous atrophy and may be a result o f unmasking of epitopes following mucosal 
damage (Clemente et al., 2000). Remarkably, these antibodies have been detected in 
90% of the adult and 60% of the childhood cases of CD that were investigated. The 
antibodies appear to be gluten driven and become undetectable within approximately 5 
months on a GFD (Clemente et al., 2000). Other autoantibodies include a novel 55-kDa 
nuclear antigen, recognised by IgA antibodies o f approximately half of examined CD 
patients in a recent study, which shares epitopes with wheat proteins and is distinct from 
both tissue transglutaminase and calreticulin (Natter et al., 2001). A recent proteomic 
study has also identified autoantibodies in the sera of patients with CD directed against 
ATP synthase beta chain and enolase alpha species (Stulik et al., 2003). The results of 
such studies are sugestive of the existence of additional, not yet discovered, 
autoantigens associated with CD.
1.10.4.5 Effector mechanisms of mucosal damage
It is still not entirely clear how, once released, the cytokines interact to cause mucosal 
damage although it seems reasonable to assume the involvement of multiple effector 
mechanisms. IFN-y is able to directly induce expression o f TG2 and HLA II molecules 
and IL-2 may promote T-cell proliferation within the intestine (Kim et al., 2002).
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Figure 1.12 The production of coeliac disease associated antibodies
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Activated T-cells release cytokines that are able to trigger nearby B-cells with bound 
antigen on their surface to produce anti-gliadin or TG2 antibodies. As the existence of 
TG2 specific T-cells is unlikely, activated gliadin specific T-cells are likely to provide 
the necessary help to TG2 specific B-cells by responding to gliadin peptides cross- 
linked with TG2 on their surface.
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Crypt hyperplasia is attributed to increased epithelial cell proliferation. It is possible 
that IFN-y and TNF-a are able to mediate this hyperplasia via their direct mitogenic 
effect on epithelial cells (MacDonald et al, 1999). Alternatively, cytokines released 
from lamina propria T-cells may increase the production of keratinocyte growth factor 
(KGF) by myofibroblasts within the lamina propria. These cells control epithelial 
renewal via KGF interaction with KGF-receptors on epithelial cells (MacDonald et al., 
1999; Salvati et al., 2001). Increased KGF mRNA is found in CD mucosa (Salvati et 
al., 2001). Thus cytokines released from lamina propria T-cells may mediate increased 
epithelial proliferation and subsequent crypt hyperplasia indirectly (Sollid, 2000).
Villous atrophy is believed to result primarily from an increased rate o f epithelial cell 
apoptosis (Ciccocioppo et al., 2000; Moss et al., 1996). An increased number of 
apoptotic epithelial cells are seen in CD mucosa, many expressing the Fas receptor 
(Ciccocioppo et al., 2002).
In addition, there is an increase in the number o f ap  CD8+ IELs expressing the Fas 
ligand and perforin, the levels of which were found to positively correlate with the 
degree o f enterocyte apoptosis (Ciccocioppo et al., 2000; di Sabatino et al, 2001). In 
addition, activated intraepithelial ap  CD8+ T-cells have lytic potential and produce IFN- 
y, IL-2, IL-8 and TNF-a (Sollid, 2000). Together with TNF produced by lamina propria 
CD4+T-cells, these high levels of TNF may result in disruption of ECM production and 
degradation. Active CD is associated with an increased degradation of ECM, which 
may contribute to villous atrophy (Sollid, 2000). Normally, ECM production by 
myofibroblasts is balanced by ECM degradation mediated by matrix metalloproteinases 
(MMPs). MMP actions are tightly controlled and mediated by release o f several 
endogenous MMP inhibitors, known as tissue inhibitors o f matrix metalloproteinases 
(TIMPs). High levels of TNF are likely to cause excess MMP production resulting in 
the net degradation of ECM causing villous atrophy (MacDonald et al., 1999). This is . 
also supported by the observation that the ratio of cells expressing TIMP-1 mRNA to 
those expressing MMP-1 and MMP-3 is decreased in active coeliac disease (Daum et 
al., 1999).
It is also possible that IELs, particularly y8 T-cells, may contribute to epithelial cell 
destruction by recognising MIC molecules expressed on their surface, which are
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induced by stress (Groh et al., 1998). These observations are suggestive of a direct role 
for IELs in the increase o f epithelial cell apoptosis, which leads to villous atrophy.
Finally, a recent study reported the increased expression o f Bak protein in CD mucosa, a 
member o f the Bcl-2 family of proteins, which acts as an endogenous promotor of 
apoptosis in enterocytes. Immunoreactivity was primarily localised to the epithelium 
and it was hypothesised that IFN-y confers increased susceptibility of enterocytes to 
undergo apoptosis through the upregulation o f this protein (Chemavsky et al., 2002).
The role of antibodies in effecting mucosal damage is unclear. Anti-gliadin antibodies 
may cross-react with calreticulin in enterocytes thus exerting a pathogenic effect 
(Tuckova et al., 1997). It has been hypothesised that anti-gliadin antibodies may cause 
intestinal damage by antibody-dependent cell-mediated cytotoxic reactions or by 
activation of the complement system (Saalman et al., 1998; Troncone & Ferguson,
1991; Unsworth et al., 1987). It has also been suggested that anti-gliadin antibodies 
may aid the gluten T-cell response by binding gliadin peptides and transporting them to 
the appropriate HLA class II expressing, antigen-presenting cells for presentation by 
DQ2 molecules to T-cells (Osman et al., 2000). IgA anti-TG2 antibodies have been 
shown to be capable of inhibiting epithelial cell differentiation and increasing epithelial 
cell proliferation in vitro by disturbing the TGF-p mediated cross-talk between 
fibroblasts and epithelial cells necessary for these functions (Halttunen & Maki, 1999), 
although other studies have suggested that anti-TG2 antibodies from patients with CD 
are not able to fully block the enzymatic activity of TG2 (Dieterich et al., 2003).
Finally, anti-actin antibodies may have the ability to disrupt the cytoskeleton, thereby 
affecting the activity o f genes such as those coding for fibronectin, collagenase, TIMP 
and TGF-P proteins, which would result in significant structural mucosal damage 
(Clemente et al., 2000).
Figure 1.13 summarises the main events in the pathogenesis o f CD.
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1.10.4.6 The role of tissue transglutaminase in coeliac disease
TG2 is one o f nine members o f the transglutaminase family, the first member of which 
was described more than 40 years ago (Fesus & Piacentini, 2002). TG2 is primarily an 
intracellular (cytoplasmic or nuclear) enzyme but also acts extracellularly when it is 
membrane-bound (Lorand & Graham, 2003). TG2 is a ubiquitous enzyme, thought to 
be involved in processes as diverse as cytoskeleton modification, ECM organisation, 
wound healing, angiogenesis, apoptosis and cell signalling (Fesus & Piacentini, 2002; 
Lorand & Graham, 2003). TG2 carries out these functions primarily via several types 
o f transamidation reactions or deamidation of specific polypeptide bound glutamine 
residues. The favoured reactions are transamidations, mainly protein crosslinking by 
means o f formation o f an isopeptide bond (Lorand & Graham, 2003) (figure 1.14) and 
they have a quicker reaction rate than the deamidation reaction (Fleckenstein et al,
2002). However, under these circumstances some deamidation occurs, even in the 
presence of excess appropriate transamidation substrates (Fleckenstein et al, 2002). The 
rate of deamidation is dramatically increased when transamidation substrates are scarce 
or in situations of low pH (Fleckenstein et al, 2002) (figure 1.14). TG2 is responsible 
for the deamidation of gluten within the intestine of patients with CD. TG2 expression 
is increased in the intestine of patients with CD compared to controls (Bruce et al.,
1985; Molberg et al, 1998), although the exact location of gluten deamidation by TG2 
is not known.
In the active intestinal lesion, TG2 is mainly present extracellularly in the subepithelial 
region but is also expressed by mature epithelial cells and at the epithelial brush border 
(Fleckenstein et al, 2002; Molberg et al, 1998; Molberg et al, 2000). TG2 is also 
expressed by activated macrophages and monocytes as well as in maturing dendritic 
cells (Akimov & Belkin, 2001; LeNaour et al, 2001). The low pH of the intestine 
( - 6 .6) favours marked TG2-mediated deamidation over protein cross-linking (Evans et 
al, 1988; Fleckenstein et al, 2002). Therefore, gluten could undergo significant 
deamidation by TG2, extracellularly, in the subepithelial space or at the brush border. 
Alternatively, macrophages, dendritic cells or TG2-specific B-cells could be involved 
directly in the deamidation of gluten if  membrane-bound TG2 is endocytosed in these 
cells (Sollid, 2002).
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Figure 1.14 Actions of tissue transglutaminase
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TG2 exerts most of its biological effects through catalysis of several different 
transamidation reactions (protein crosslinking being the preferred of these reactions) or 
by a deamidation reaction. Under normal circumstances, the predominant action o f 
calcium-activated TG2 is the catalysis of an acyl transfer reaction between a 
polypeptide bound glutamine residue and the primary amino group of a polypeptide 
bound lysine residue resulting in the formation of an isopeptide bond between or within 
proteins (1). However, in conditions of low pH or when transamidation substrates are 
scarce, the calcium-activated TG2 catalysed deamidation reaction predominates. In this 
case, TG2 uses water as a substrate to simply convert a polypeptide bound glutamine 
residue to a glutamic acid residue (2).
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1.11 Dermatitis Herpetiformis
DH is a blistering skin disease, characterised by an itchy rash, which is associated with 
granular IgA deposits in the basement membrane. Detection of these IgA deposits 
confirms diagnosis (Collin & Maki, 1994; Wills et al., 2002). There is strong evidence 
to suggest that DH is related to gluten ingestion and one identity o f the spectrum of 
gluten sensitivity, a manifestation that primarily affects an area distinct from the small 
intestine. Individuals with DH express the same gluten sensitivity associated genetic 
profile as individuals with CD (section 1.7) (Reunala, 1998) and both CD and DH may 
exist in the same family (Reunala, 1996). Patients express serological markers o f gluten 
sensitivity (section 1.9) (Reunala & Hallstrom, 1990). The majority of individuals with 
DH also show evidence of the gluten related changes in the small intestine that are 
recognised features of CD, even though the skin is the major affected site in these 
patients (Collin & Maki, 1994; Wills et al, 2002). GI symptoms are often minimal and 
skin involvement can occur even without histological evidence of intestinal 
involvement. DH provided the first evidence that the effects of gluten sensitivity need 
not be confined solely to the small intestine. Finally, it has been shown that patients 
with DH also benefit from a GFD. The rash responds to a GFD although skin changes 
may take up to two years to fully resolve, during which time the drug dapsone is 
frequently used for relief o f symptoms.
1.12 Neurological Disorders associated with gluten sensitivity
A variety of neurological disorders have been reported in association with gluten 
sensitivity. Many o f these observations are based on patients with initial GI symptoms, 
in whom neurological dysfunction occurred after varying time-periods following their 
diagnosis with CD. Data from clinical follow-up o f adult patients diagnosed with CD 
suggests that subsequent, otherwise unexplained, neurological dysfunction is a 
complication in between 6-10% cases (Holmes, 1997).
However, in recent years it has become apparent that neurological manifestations of 
gluten sensitivity need not always be associated with established CD and that 
neurological disorders may present prior to the onset of GI symptoms. Alternatively, 
neurological disorders may be the sole presenting feature o f gluten sensitivity in 
individuals with asymptomatic CD or in genetically susceptible individuals with
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serological markers of gluten sensitivity but no histological evidence o f GI involvement 
(Hadjivassiliou et al, 1998).
Early hypotheses, on the link between gluten sensitivity and neurological dysfunction, 
centred on the possibility of vitamin and trace element deficiencies, resulting from 
malabsorption, causing neurological disturbances. However, CD now tends to be 
diagnosed before malabsorption reaches such a degree and such deficiencies are rarely 
reported. Malabsorption does not explain the associated neurological complications and 
research is now focused on other possible mechanisms such as altered autoimmunity 
(Pengiran Tengah et al, 2002).
1.12.1 Neurological complications associated with established coeliac 
disease
A review o f all reports of neurological disorders associated with established CD 
published between the years 1964 and 2000 revealed that ataxia (with or without 
myoclonus) and peripheral neuropathy are the most common neurological 
manifestations occurring in patients with CD (table 1.5) (Hadjivassiliou et al, 2002a).
Other neurological complications that have frequently been reported in association with 
established CD include epilepsy, dementia and psychiatric disturbances (see below).
1.12.1.1 Ataxia
In 1966, a pivotal paper published by Cooke and Smith was the first to systematically 
detail the clinical and neuropathological characteristics of a group o f sixteen patients 
with CD that subsequently developed neurological dysfunction. The predominant 
abnormality was ataxia. All patients had gait ataxia and some also had limb ataxia. In 
addition, evidence of severe peripheral neuropathy was seen in ten o f the patients. Dick 
and co-workers reported a case o f ataxia associated with previously diagnosed CD in a 
female patient (Dick & Abraham, 1995). Reports of ataxia with myoclonus associated 
with established CD are rare. Bhatia and co-workers described four cases of 
progressive myoclonic ataxia in which the neurological syndrome presented up to 
twenty-five years after the development of CD or DH. The majority of these cases were 
phenotypically similar, dominated by action myoclonus associated with mild ataxia and
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occasional seizures. In the other cases, myoclonus was a later feature o f a 
predominantly ataxic condition (Bhatia et al, 1995).
1.12.1.2 Peripheral neuropathy
Peripheral neuropathies associated with established CD are usually of axonal or 
demyelinating type (Kaplan et al, 1988). As Cook and Smith reported, peripheral 
neuropathy may occur concomitantly with ataxia and it is frequently o f late-onset 
(Cooke & Smith, 1966). A recent study of 26 patients with treated CD found that 
23.1% showed findings o f axonal neuropathy upon examination, indicating that patients 
even without overt malabsorption are still at risk from neurological complications 
(Luostarinen et al, 2003).
Table 1.5 Summary o f common neurological complications associated with established 
coeliac disease
Patient Information:
Total num ber of patien ts 83
M ale to fem ale ratio 4 4 :3 9
M ean age (yrs) 48
Neurological Diagnosis: N u m b er
A taxia
(with or w ith o u t m yoclonus)
38
Peripheral N europathy 29
Data collected from a review of single or multiple case reports from 1964-2000. 
Adaptedfrom Hadjivassiliou et al, 2002a.
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1.12.1.3 Dementia
Dementia associated with previously diagnosed CD frequently occurs in the presence of 
other neurological symptoms. Two patients, previously described with myoclonic 
ataxia, also developed dementia (Bhatia et al, 1995). Collin and co-workers described 
five patients, all under 60 years of age, with dementia associated with CD (Collin et al, 
1991). Two of the patients also suffered from progressive ataxia. The remaining three 
were found to have brain atrophy upon examination by computerised tomography of the 
brain.
1.12.1.4 Epilepsy
The association between epilepsy and established CD is well documented. It is believed 
that epilepsy affects approximately 5% of adult CD patients, the majority o f whom 
suffer from complex partial attacks (Chapman et al, 1978). This same association does 
not appear to exist in children. A large study of children with CD found that the 
incidence o f epilepsy did not differ from that o f the general paediatric population 
(Vascotto & Fois, 1997). A well-defined subgroup o f patients has epilepsy associated 
with calcifications located in the occipital or parietal cortical and subcortical regions. In 
one study, cerebral calcifications were found in five out o f twelve (42%) patients with 
CD and epilepsy (Gobbi et al, 1992). Interestingly, this syndrome o f epilepsy 
associated with calcifications has mostly been reported in Italian patients. The 
association was not found in an Irish study (Cronin et al, 1998) and cases appear to be 
rare in the UK (Hadjivassiliou et al, 2002a).
1.12.1.5 Psychiatric disturbances
The association between CD and psychiatric disturbances has long been recognised 
although it remains unclear whether depression is more common or severe amongst 
patients with CD compared to the general population (Holmes, 1997). A study of adults 
with CD attending a UK clinic found that 10% suffered from depression (Holmes, 1997) 
and it is clear that depression remains a real risk in patients with CD.
Previous research has suggested possible associations between CD and both autism and 
schizophrenia (Coleman, 1997; Dohan, 1970; Reichelt & Landmark, 1995). However, 
in both cases, other studies have not supported this view (Holmes, 1997; Pavone et al, 
1997) and the associations remain controversial.
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1.12.1.6 Effect of treatment
Many o f the studies discussed above report that a GFD is unable to affect the 
progression of these neurological complications despite resolution of intestinal 
histology and normalisation of serological markers (Bhatia et al, 1995; Collin et al., 
1991; Cooke & Smith, 1966). Vitamin and nutritional deficiencies were not reported 
and supplementation proved mostly ineffective, with various exceptions. Mauro and 
co-workers described one case of a female patient with a cerebellar syndrome associated 
with CD who was subsequently found to have a vitamin E deficiency and responded 
well to supplements (Mauro et al, 1991). Epilepsy with cerebral calcifications tends to 
be associated with low serum levels of folate and elimination o f gluten with or without 
folate supplementation can be of benefit in these patients (Gobbi et al, 1992; Lea et al, 
1995).
1.12.2 Neurological complications associated with undiagnosed gluten 
sensitivity
In 1996, a large study investigated the prevalence of IgG and IgA anti-gliadin antibodies 
as a marker of gluten sensitivity, in two groups of patients attending the Neurology 
clinic at The Royal Hallamshire Hospital, Sheffield UK. The first group (53 patients) 
had a variety o f neurological disorders of unknown cause and the second group (94 
patients) had neurological disorders of known aetiology (including stroke, multiple 
sclerosis and Parkinson’s disease). Circulating anti-gliadin antibodies were found at a 
much higher prevalence among patients with neurological disorders o f unknown 
aetiology (57%) than among either patients with neurological disorders o f known 
aetiology (5%) or healthy control patients (12%). Subsequent duodenal biopsies from 
26 of these anti-gliadin antibody positive patients with neurological disorders of 
unknown cause revealed histological evidence of CD in 35%, non-specific duodenitis in 
38% and normal mucosa in the remaining patients (Hadjivassiliou et al, 1996). Since 
that date, a total of 131 patients with gluten sensitivity presenting with neurological 
disorders o f unknown aetiology have been identified (table 1.6) (Hadjivassiliou et al, 
2002a). Interestingly, in these patients too, ataxia and peripheral neuropathy are the 
most common manifestations.
Since then, several studies have been carried out by different research groups in an 
attempt to determine the proportion of neurological disorders o f unknown cause, which 
may actually be due to undetected gluten sensitivity. Disorders, o f otherwise unknown
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Table 1.6 Presenting neurological conditions of patients attending the gluten
sensitivity/neurology clinic at The Royal Hallamshire Hospital, Sheffield 
UK
Total number of patients : 131
NEUROLOGICAL CONDITION NUMBER OF PATIENTS
A taxia 56 (four with myoclonus)
Sensorim otor axonal n europa thy 26
M ononeuropathy  m ultiplex 15
M otor neu ro p a th y 10 (three motor neurone disease-like)
Small fibre neu ro p a th y 4
M ixed dem y elin atin g /ax o n a l neu ropathy 2
M yopathies 8
Episodic headache and  w hite  m atter 
abnorm alities
19
Stiff-person syndrom e 4
N eurom yotonia 1
Adaptedfrom Hadjivassiliou et al., 2002a.
cause, that have been reported in association with previously undetected gluten 
sensitivity include ataxia (discussed further below), neuropathy, epilepsy and headache. 
Recently, Volta and co-workers found neurological disorders (including epilepsy, ataxia 
and peripheral neuropathy) in 8% of 160 patients with CD. In all but two cases, the 
neurological disorder had preceded the CD diagnosis (Volta et al, 2002). A recent 
study of adult patients with neuropathy found that 2.5% had undetected CD, most with 
no GI symptoms (Chin et al, 2003). Gobbi and co-workers found a high incidence o f 
undiagnosed CD in adult patients with unexplained cerebral calcifications and epilepsy 
(24/31) (Gobbi et al, 1992). A study of patients presenting with episodic headaches 
and otherwise unexplained white matter abnormalities on magnetic resonance imaging 
(MRI) found previously unrecognised gluten sensitivity in all ten patients examined. A 
GFD provided symptomatic response in nine of these patients (Hadjivassiliou et al,
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2001). Another recent study of 90 patients with idiopathic migraine found that 4.4% 
had previously undiagnosed CD compared to 0.4% of a control group (Gabrielli et al,
2003).
With the possible exception o f certain types o f epilepsy (Labate et al, 2001), occult 
gluten sensitivity does not appear to be a major cause o f idiopathic neurological 
dysfunction in children (Lahat et al, 2000), which is consistent with published 
descriptions o f predominantly adult patients with later onset o f neurological symptoms.
1.12.3 Gluten Ataxia
O f the 25 patients with idiopathic ataxia included in the initial study by Hadjivassiliou 
and co-workers (1996), 6 8% were found to have circulating IgG and/or IgA anti-gliadin 
antibodies. The term gluten ataxia was subsequently proposed to describe cases of 
apparently idiopathic ataxia actually due to previously unknown gluten sensitivity 
(Hadjivassiliou et al, 1998).
Following the original studies by Hadjivassiliou and co-workers, describing the 
condition of gluten ataxia, a number o f studies have been carried out involving the 
screening of adult patients with idiopathic ataxia for undiagnosed gluten sensitivity. 
These studies are summarised in table 1.7. Results are somewhat variable, however a 
general trend of a greater than expected incidence of undiagnosed gluten sensitivity 
among patients with idiopathic sporadic ataxia is evident. This notion is not without 
controversy. One study concluded that there is no association between idiopathic 
sporadic ataxia and gluten sensitivity (Combarros et al, 2000). However, without 
comparative information on the general prevalence of gluten sensitivity in that 
population, it is difficult to draw such conclusions. In their study o f 32 patients, Abele 
and co-workers concluded that the observed association was not strong enough to justify 
recommendation of a GFD to such patients as significance was not reached (Abele et 
al, 2003). However, the general association is evident in their results and may prove 
significant if  a greater number of patients were examined. In all studies, malabsorption 
and vitamin deficiencies were excluded as possible causes o f ataxia. Consistent with 
other published studies of ataxia associated with established CD, sporadic ataxia was 
often found with concomitant peripheral neuropathy, which was not always clinically 
evident (Hadjivassiliou et al, 2003a; Luostarinen et al, 2001; Pellechia et al, 1999a).
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Table 1.7 A summary of studies investigating the prevalence of gluten sensitivity 
amongst adult patients with ataxia
Anti-gliadin antibody positive/Total number 
tested (percentage positive)
Study Details Sporadic
ataxia
Familial
ataxia
Healthy
controls
Hadjivassiliou et al, 2003a 
(UK)
59/143 (41%) 8/51 (14%) 149/1200
(1 2 %)
Pellechia et al, 1999a 
(Italy) 3/24 (13%) 0/23 (0%) -
Combarros et al, 2000 
(Spain) 0/32 (0%) - -
Luostarinen et al., 2001 
(Finland) 44 (17%) - (2 % )
Burk et al., 2001a 
(Germany) 12/104 (12%) - (5% )
Bushara et al, 2001 
(USA) 7/26 (27%) 9/24 (37%) -
Lim et al, 2001 
(Ireland) 3/7 (43%) - -
Abele et al, 
(Germany) 13/98 (13%) 1/15 (6 % ) (5% )
Abele et al, 2003 
(Germany) 6/32 (19%) 63 (8-15%) 6/73 (8 % )
(-) indicates data was not available.
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Isolated case reports include an early report o f a 56-year old man with a cerebellar 
syndrome that was the presenting and predominant feature o f CD (Finelli et al, 1980), a 
description o f a 31-year old woman presenting with gait disorder, myoclonus and 
abnormal eye-movement (Hanagasi et al, 2001) and a 37-year old woman with a 12- 
year history of progressive dysarthria and ataxia (Sander et al, 2003), which were also 
both associated with a subsequent diagnosis of gluten sensitivity.
1.12.3.1 Effect of treatment
A recent large-scale study of the effect of a GFD in patients with gluten ataxia found 
significant improvement in ataxia amongst patients following the diet as compared to 
those who did not (Hadjivassiliou et al, 2003c). Importantly, this study demonstrates 
gluten ataxia as a treatable cause o f sporadic ataxia. Previously, in much smaller 
studies, a GFD had been reported to be of some benefit for patients with gluten ataxia, 
mainly for individuals with less severe symptoms where diagnosis was prompt 
(Hadjivassiliou et al, 1996; Pellechia et al, 1999b). A small study o f intravenous Ig 
therapy in four ataxia patients with circulating anti-gliadin antibodies, but without 
histological evidence of CD, also suggested some benefit with improvement o f 
symptoms seen in all patients after several weeks (Burk et al., 2001b). Intravenous Ig 
was also reported to have a beneficial effect in the female patient recently described in a 
case report by Sander (Sander et al, 2003).
1.12.3.2 Evidence that gluten ataxia is immune-mediated
The pathogenesis o f gluten ataxia remains obscure. In agreement with other published 
studies, patients with gluten ataxia attending the neurology/gluten sensitivity clinic in 
Sheffield, which form the study base for the work in this thesis, do not exhibit any 
vitamin or nutritional deficiencies and prove negative for other possible causes of 
sporadic ataxia (Hadjivassiliou et al, 1998). This finding makes malabsorption or 
vitamin deficiency an unlikely cause of gluten ataxia.
Preliminary evidence however, is suggestive o f an immunological mechanism resulting 
in cerebellar damage and associated symptoms (Hadjivassiliou et al, 1998). Immune 
involvement is central in gluten sensitivity and the notion o f an immune-based 
pathogenesis of gluten ataxia is supported by the immunological pathogenesis of other 
manifestations o f the condition, such as in CD and DH and also the association between 
CD and other autoimmune diseases (section 1.10.3). Other researchers have suggested
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an inflammatory process as the likely cause o f a neurological syndrome, involving the 
brainstem and cerebellum, in a patient with established CD (Ghezzi et al., 1997). 
Interestingly, in the series of 160 CD patients examined by Volta, 61% of the patients 
with neurological dysfunction were found to have central nervous system anti-neuronal 
antibodies compared to 5% of patients with CD only and 0% of healthy controls (Volta 
et al., 20 0 2 ).
Research from our group strongly suggests the involvement o f both T-cell mediated and 
humoral immune responses. Hadjivassiliou and co-workers previously reported the 
presence of perivascular cuffing and lymphocytic infiltration of cerebellar tissue by 
CD4+ and CD8+ positive T-cells and lesser numbers o f B-cells and macrophages in two 
cases of gluten ataxia studied at post-mortem (Hadjivassiliou et al, 1998). Later work 
revealed that the chemokine IP-10, a T-cell chemoattractant, was upregulated in the 
cerebrospinal fluid (CSF) o f ten patients with gluten ataxia compared to a headache 
control group (Hadjivassiliou et al., 2003b). This evidence is strongly supportive of the 
involvement o f a cell-mediated response and other recent work from our group has 
demonstrated a role for a humoral immune response in gluten ataxia too (Hadjivassiliou 
et al., 2 0 0 2b).
1.13 Aims of this thesis
Gluten ataxia appears to account for a large number o f cases of sporadic idiopathic 
ataxia and therefore may represent a potentially treatable cause of ataxia. Preliminary 
evidence is suggestive o f an immune-mediated pathogenesis, in common with other 
manifestations o f gluten sensitivity such as CD and DH. Although much research has 
been carried out into the immunological mechanisms o f CD, the mechanisms of neural 
damage, occurring within the CNS of patients with gluten ataxia, remains unknown.
The aim of this thesis is to investigate the role of the humoral immune response in 
gluten ataxia. This knowledge is important as elucidation of the underlying 
immunological mechanisms may give an insight into any relationship or similarities 
between gluten ataxia and other manifestations o f gluten sensitivity. Secondly, this 
knowledge may provide means for the detection o f gluten sensitive patients likely to 
develop gluten ataxia enabling treatment to be initiated at the earliest opportunity. 
Broadly, to achieve this aim the following objectives were set,
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o Determination, by enzyme-linked immunosorbent assay (ELISA), of the profile of 
serum antibody markers of gluten sensitivity expressed by patients with gluten 
ataxia and comparison with patients with CD without neurological complications, 
familial ataxia, sporadic ataxia (non-gluten) and healthy controls (chapter 3). 
o Investigation o f the specificity of serum antibodies from patients with gluten ataxia 
to cerebellar tissue, using immunohistochemistry (IHC) and sodium dodecylsulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) with western blotting (chapters 4 
& 5).
o Investigation o f any association of gluten ataxia with circulating anti-GAD 
antibodies, using ELISA and SDS-PAGE with western blotting (chapter 6 )
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CHAPTER TWO
MATERIALS AND METHODS
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2.1 Selection And Monitoring Of Patients
2.1.1 Differential diagnosis of patients with ataxia
From January 1994, all patients with the diagnosis o f cerebellar degeneration attending 
the ataxia clinic, based within the Department of Neurology at the Royal Hallamshire 
Hospital, Sheffield (n=224), were prospectively screened and followed-up at 6  monthly 
intervals. Patients were questioned about family history o f neurodegenerative disease, 
alcohol consumption and drug ingestion. Patients with a history o f alcohol abuse, 
prolonged use o f the medication phenytoin (an anticonvulsant) or laboratory evidence of 
multiple sclerosis, vitamin E deficiency, paraneoplastic cerebellar degeneration (PCD) 
or viral cerebellitis were excluded. All patients underwent genetic testing for SC A (1,
2, 3, 6 and 7) and Friedreich’s ataxia, screening for circulating anti-gliadin antibodies 
and a detailed neurological examination. These were recorded as the baseline 
assessments (Hadjivassiliou et al, 2003a). Based on these assessments, patients were 
divided into three groups:
o Group 1 consisted o f patients with a familial history of ataxia and/or positive genetic 
testing for SCA or Friedreich’s ataxia (n=59). 
o Group 2 consisted o f patients with sporadic idiopathic cerebellar ataxia without 
clinical evidence o f cerebellar variant of multiple sytem atrophy (MSA-C) (n=132). 
o Group 3 consisted of patients with clinically probable MSA-C (n=33).
Patients with sporadic idiopathic cerebellar ataxia (Group 2, above) who were positive 
for circulating anti-gliadin antibodies (IgG, IgA or both) were identified. Other causes 
of ataxia in these patients were excluded by further investigation including estimation of 
serum vitamin E and B 12 levels, thyroid and liver function tests, lipid profile and 
autoimmune profile. Additional tests were performed, when clinically indicated 
(Hadjivassiliou et al, 1998). Therefore, patients positive for circulating anti-gliadin 
antibodies (IgG, IgA or both) and not excluded by any o f the above criteria were 
diagnosed with gluten ataxia (n=54) (Hadjivassiliou et al, 2003a). All gluten ataxia 
patients then underwent HLA genotype testing and duodenal biopsy to establish 
whether an enteropathy was also present. A GFD was recommended for all gluten 
ataxia patients regardless of the presence or absence o f enteropathy. Detailed dietary 
advice by a dietician, with expertise in gluten-sensitivity, was given to all patients and 
reviewed at follow-up visits. If requested by the patient, a GFD was commenced 
following the baseline assessment of neurological dysfunction. Dietary compliance was
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monitored through measurement o f serum anti-gliadin antibody levels at each follow-up 
visit.
2.1.1.1 Serum collection and storage
Serum samples were taken on the initial visit and at all follow-up visits from all 224 
patients. Serum taken from the initial visit to the ataxia clinic was recorded as the 
baseline sample. Following collection from -70°C storage at the Royal Hallamshire 
Hospital, serum was separated into aliquots o f 500pl, catalogued and stored long-term 
at -70°C. Working aliquots o f 20-100pl were stored at -20°C. Repeated freeze- 
thawing o f samples was avoided as much as practically possible although, due to the 
limited amounts o f some samples, samples were sometimes subjected to several freeze- 
thaw cycles.
2.1.1.2 Anti-gliadin antibody measurement
Serum samples were screened, initially, by the Immunology Department o f the Northern 
General Hospital, Sheffield. Screening was originally by an in-house ELISA method, 
which was subsequently replaced with a commercially available ELISA (Hycor 
Biomedical Ltd, UK).
2.1.1.3 HLA typing
HLA typing was performed at the National Blood Service, Sheffield.
2.1.1.4 Duodenal biopsy collection and storage
Duodenal biopsies were taken by Dr. D. Sanders in the Gastroenterology Clinic at the 
Royal Hallamshire Hospital, Sheffield. Briefly, four biopsies were taken from the distal 
duodenum using biopsy forceps, through a conventional forward viewing endoscope . 
(Key-Med, UK). The presence o f gluten-sensitive enteropathy was established by 
histological examination looking for characteristic changes associated with CD (crypt 
hyperplasia, villous atrophy and an increase in intraepithelial lymphocytes), which was 
carried out within the Histopathology Department at the Royal Hallamshire Hospital, 
Sheffield. Patients with gluten ataxia, in the presence or absence of overt mucosal 
damage, were included in subsequent studies. Biopsies were wrapped in foil, placed in 
an airtight container and stored at -70°C.
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2.1.1.5 Cerebrospinal fluid collection and storage
CSF samples were taken from a number o f gluten ataxia patients, when clinically 
indicated during the diagnostic process, although this was not done routinely. CSF 
samples were stored at -70°C.
2.1.2 Monitoring Of Gluten Ataxia Patients
In common with other patients attending the ataxia clinic, patients with gluten ataxia 
were followed-up every six months by appointments at the clinic. Follow-up visits 
involved collection o f serum, review by a dietician and clinical assessment o f ataxia as 
outlined below. In order to minimise inter-observer variability and patient bias, clinical 
assessment was undertaken by one consultant neurologist (Dr. M. Hadjivassiliou), 
without knowledge o f baseline results or current anti-gliadin antibody titre.
2.1.2.1 Clinical assessment of ataxia
The ataxia assessment tests used were based on the standard neurological examination 
which had been validated in patients with progressive ataxia and were, as far as 
possible, objective (Notemans et al, 1994). Briefly, the tests, as described in a recent 
paper by Hadjivassiliou and co-workers (2003c), were as follows:
1. Computerised finger nose test
This was an adaptation o f the motor screening test from the Cambridge Automated 
Neuropsychological Test Battery (CANTAB) (Sahakian & Owen, 1992). The patient 
was positioned at arm’s length from a touch-sensitive screen. The patient was then 
asked to place their right index finger on the tip o f their nose and to touch, as quickly 
and as accurately as possible, the centre o f a flashing cross that repeatedly appeared 
nine times in different positions on the screen. The patient was instructed to place their 
finger back on the tip of their nose until the image reappeared on the screen (at equal 
time intervals). The mean response latency in milliseconds was recorded by the 
computer. The test was then repeated using the left index finger.
2. Grooved pegboard test
This test required the patient to insert pegs into a board consisting o f 25 holes with 
randomly positioned locating slots (Lafayette Instruments, USA). The pegs, which 
have a key along one side, must be rotated to match the slot position before they can be 
inserted. The subject was asked to insert the pegs, using only one hand as quickly, as
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possible. The time taken to fill all the holes was recorded and the task was then 
repeated using the other hand.
3. Tapping test
This test uses a device consisting of two manually operated counters fixed 35cm apart 
on a wooden platform. The patient was positioned with the device positioned at arm’s 
length and asked to press the two counters alternately, with their right index finger, as 
quickly as possible for 30secs. The total count from the two counters after 30secs was 
recorded. The task was repeated using the left hand and, with the device placed on the 
floor, the patient using each foot in turn.
4. Quantitative Romberg’s test
The patient was asked to stand with feet together and close their eyes. They were 
instructed to try and keep their eyes closed and their feet together for as long as 
possible. The time from start to first corrective foot movement and/or opening the eyes 
was recorded. Because o f pronounced ‘floor’ and ‘ceiling’ effects in this test (ie. some 
patients were unable to attempt the test, others could stand indefinitely), changes in 
performance during the study were recorded as ‘better’ or ‘worse or same’.
5. Subjective global clinical impression
The patient was asked to mark on a visual analogue scale their impression of their 
symptoms o f imbalance over the last month. No change was marked at the centre o f the 
line, better towards the right and worse towards the left end o f the line. The distance 
from the left end o f the line to the mark made by the patient was recorded as a 
proportion of the total length of the line.
2.1.3 Patients with gluten ataxia included in studies within this thesis
Study protocols for patients with gluten ataxia were approved by the South Sheffield 
Research Ethics Committee. Patients who refused or abandoned a GFD within a month 
of starting were included in the gluten ataxia (untreated) group of any studies. Patients 
with CD without neurological complications, familial ataxia (Group 1 as described in 
section 2.1.1), sporadic idiopathic ataxia (non-gluten ataxia) (Group 2 as described in 
section 2 .1.1), other neurological disorders and normal controls were included, when 
relevant, as control groups. Serum samples were collected (as detailed in section 
2.1.1.1) from patients attending Neurology or Gastroenterology clinics at the Royal
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Hallamshire Hospital, Sheffield or obtained from the National Blood Service, Sheffield. 
All patients gave written informed consent before inclusion in any study.
Detailed clinical characteristics o f the randomly selected subset o f untreated gluten 
ataxia patients included in the studies contained within this thesis are given in table 2 .1.
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Table 2.1 Clinical characteristics of untreated gluten ataxia patients included in the studies within this thesis
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- CD-associated changes defined as crypt hyperplasia, villous atrophy or increase in intraepithelial lymphocytes 
* - Results as determined by the Immunology department of the Northern General Hospital, Sheffield UK
Table 2.1 cont’d Clinical characteristics of untreated gluten ataxia patients included in the studies within this thesis
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- CD-associated changes defined as crypt hyperplasia, villous atrophy or increase in intraepithelial lymphocytes 
* - Results as determined by the Immunology department of the Northern General Hospital, Sheffield UK
Table 2.2 Summary o f clinical characteristics o f patients with untreated gluten 
ataxia
Clinical characteristic
Male: female patient numbers 21 : 13
Average age (yrs) (Range, yrs) 66  (38 - 83)
Average duration o f ataxia (yrs) (Range, yrs) 1 2 (3 -4 5 )
GI symptoms (%) 18
Evidence o f CD associated changes on biopsy (%) 21
HLA genotype (%):
DQ2 76
DQ8 3
DQ1 21
Yrs - Years
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2.2 Enzyme-Linked Immunosorbent Assay
2.2.1 Principles of the technique
ELISA is an extremely versatile technique, which has replaced radioimmunoassay 
(RIA) in many applications. The ELISA technique is simple and results are obtained 
quickly. Virtually any antigen or antibody may be assayed using ELISA. For example, 
ELISA is used in clinical laboratories routinely to screen for hormones, infectious 
diseases and anti-viral antibodies (Wilson & Walker, 1995), as well as for antibodies 
associated with disease processes, such as CD.
The majority o f laboratories, particularly clinical, use widely available commercial 
ELISA kits to screen for antibodies o f interest. These give the reassurance o f thorough 
validation, excellent reproducibility and reliability as well as provision o f standardised 
controls and calibrants. These properties are particularly useful in situations where 
large numbers o f samples need to be rapidly and accurately screened and aid 
comparison of results between different laboratories.
The basic principle o f ELISA makes use of the sensitive and specific interaction that 
occurs between antigen and antibody. Either the antigen or antibody is bound to a 
solid-phase support (coating). Most frequently, the solid-phase is a disposable 96-well 
polystyrene microtitre plate, which allows large numbers o f samples to be assayed 
simultaneously. Antigen or antibody adsorbs to the surface via formation of 
hydrophobic bonds with the plastic matrix. In this thesis, all ELISAs involve detection 
of antibodies and therefore antigen-coated plates are used. The antigen is usually 
applied in a ‘coating buffer’, which minimises non-specific binding to the plate by other 
reagents at later stages in the assay. Typical ‘coating buffers’ include carbonate, tris- 
hydrochloride and phosphate-buffered saline (PBS) based solutions. Coating o f the 
solid-phase is affected by a variety of conditions including temperature, pH, incubation 
time and concentration of antigen or antibody in the coating mixture. Coating may be 
enhanced by certain factors but care must be taken to optimise conditions whilst 
avoiding deleterious results. For example, too dense a coating may result in impairment 
of subsequent reagent binding due to steric inhibition (Crowther, 1995). Following 
coating o f the solid-phase, samples containing an unknown amount o f the antibody of 
interest are added and incubated for a specified length o f time. During this period, the 
antibodies bind to the antigen coated on the plate. Most often this sample is serum but
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ELISAs designed for other test fluids such as urine or CSF are available. Unbound 
antibody within the sample is washed off. Following a series of steps, which vary 
depending on the ELISA type used, binding of the antibody o f interest to the solid- 
phase is visualised using an enzyme (usually horseradish peroxidase (HRP) or alkaline 
phosphatase (ALP)) conjugated secondary antibody that is specific for the primary 
antibody bound to the plate. Addition of a suitable substrate results in the formation of 
a coloured, soluble product. Commonly used substrates include /?-nitrophenylphosphate 
(p-NPP), converted to yellow p-nitrophenol by ALP and o-phenylenediamine or
3,3 ’ 5,5 ’-tetramethylbenzidine (TMB), which are converted to green and blue products 
respectively by peroxidase enzymes. Finally, the reaction is usually stopped by addition 
of a strong (molar concentration) acid or base to quickly denature the enzyme and stop 
activity to allow results to be read in a spectrophotometer at an appropriate wavelength. 
Samples of known concentrations of antibody, from which a calibration curve is 
prepared to allow unknown sample antibody levels to be calculated, are included in all 
assays. This indirect ELISA procedure is the method used in this thesis and is 
summarised in figure 2 .1 .
2.2.2 General ELISA methods
Measurements o f anti-gliadin IgG or anti-gliadin IgA antibodies were carried out using 
an in-house ELISA method or by AUTOSTAT™II Anti-Gliadin IgG or AUTOSTAT™II 
Anti-Gliadin IgA ELISA kits respectively, both from Hycor Biomedical Ltd, UK. Anti- 
TG2 IgA serological antibodies were assayed using Tissue Transglutaminase IgA 
ELISA Kits from Genesis Diagnostics, UK. Measurements o f anti-glutamic acid 
decarboxylase (GAD) IgG antibodies were carried out using Isletest™-GAD IgG ELISA 
kits from Biomerica, US (distributed by IDS, UK).
2.2.2.1 ELISA kit storage
All kits were stored at 4°C until used. After use, any remaining components were 
resealed, stored at 4°C and used within 3 months of opening. The expiry date on all kits 
was checked prior to use. Kits were not used after the expiry date. Reagents were not 
interchanged between kits with different lot numbers nor were any reagents from 
different manufacturers used. All kits were allowed to reach room temperature (RT) 
(18-25°C) for a minimum of 30min before use.
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Figure 2.1 The indirect ELISA method for determination of antibody levels
o  o  o Specific antigens adsorbed to 
solid phase (96-well plate).
Sample containing a mixture of 
antibodies, including antibody of 
interest is added. The plate is 
incubated and then washed.
Only the specific antibody of 
interest is bound.
Enzyme labelled secondary antibody 
directed against Fc portion of 
antibody of interest is added. The 
plate is incubated and then washed.
Secondary antibody, binds to the 
bound antibody of interest
Enzyme substrate added and 
plate incubated.
M easured enzyme activity is directly proportional 
to the am ount of antibody in the test sample.
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2.2.2.2 Sample preparation
Serum samples were collected and stored as in section 2.1.1.1. Any samples showing 
signs o f haemolysis were not used as this would affect assay results. If necessary, 
samples were defrosted prior to use. All samples were allowed to reach room 
temperature and vortexed before use. CSF samples were collected and stored as in 
section 2.1.1.5. Again, samples were allowed to reach room temperature and vortexed 
before use.
2.2.2.3 Assay Plan
All ELISA kits were supplied with 96-well microplates, coated with the appropriate 
antigen, as the solid phase of the assay. The sample ELISA template shown in figure
2.2 was used as the plan for each assay. All samples standards and assay controls were 
assayed in duplicate. As shown in figure 2.2, wells A l and A2 of the plate were filled 
with sample diluent only, to act as a blank. Wells HI 1 and H I2 were filled with a 
repeat sample of either standard 1 or positive control. This allowed intra-assay 
variability to be calculated and to control for any effects of time taken to load the plate. 
Using this template, up to 40 samples could be assayed on each plate supplied with the 
anti-gliadin IgG and IgA kits, 38 samples could be assayed on each plate from the anti- 
TG2 IgA kits and 41 samples could be assayed on each plate from the anti-GAD IgA 
kits.
Figure 2.2 96-well microplate loading template used in ELISA experiments
1 2 3 4 5 6 7 8 9 10 11 1 2
A © 4 1® (% 1 o o o o o o o o
B C 5r c ® 0 ! ' © o o o o o o o o
C 0 1 1 0 o o o o o o o o o o
D <3f D ® o o o o o o o o o o
E X i) o o o o o o o o o o
F O ' > o o o o o o o o o o o
G 0 1;o o o o o o o o o o o
H ( g ) ■ f© o o o o o o o o o ) 0
STD = Assay standard, POS = Positive control, NEG = Negative control. 
Test samples were assayed in duplicate in all remaining wells.
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2.2.2.4 Assay controls
After each assay, validity was ensured by confirming that the values o f the positive and 
negative control serum samples, provided with the kit, fell within the range specified by 
the manufacturers. If the values were not within this range, the plate was considered 
invalid and the results not used. In addition, to maintain assay reproducibility, it was 
ensured that the percentage coefficient of variation (%CV) o f the duplicate absorbances 
for the standards, controls and samples was <20%. Any sample with a %CV of >20% 
was re-assayed. The cut-off figure o f 20% was selected in order to allow the maximum 
numbers o f samples to be recorded as valid whilst eliminating sample readings that 
were not close enough to guarantee an accurate value. In practice, most samples had a 
%CV of <10%.
2.2.3 Anti-gliadin antibody ELISAs
2.2.3.1 In-house anti-gliadin ELISA
■ 96-well microtitre plate (Costar, UK)
■ PBS (pH 7.41
1.54M Sodium Chloride
0.13M Potassium Phosphate (K2HPO4)
0.02M Potassium Phosphate (KH2PO4)
■ Carbonate Buffer (pH 9.6):
0.015M Sodium Carbonate 
0.035M Sodium Hydrogen Carbonate
■ Wash Buffer:
0.5% Tween20 in PBS
■ Blocking solution:
5% bovine serum albumin (BSA) (made using a 30% IgG-free BSA solution) in PBS
■ Crude gliadin (Ting/mD:
Crushed crude gliadin in carbonate buffer
■ HRP-conjugated goat anti-human IgG (affinity purified, y-chain specific)
■ HRP-conjugated goat anti-human IgA (affinity purified, a-chain specific)
■ TMB substrate fO.lmg/ml):
lm g TMB tablet in 0.05M Phosphate-citrate buffer with 0.03% 
sodium perborate (pH5)
■ Stop solution (0.1M H2SO4)
All reagents from Sigma, UK unless stated.
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The crude gliadin solution was prepared by crushing the required amount of crude 
gliadin into a fine powder using a pestle and mortar and adding to the corresponding 
volume o f carbonate buffer. The resulting solution was stirred on a magnetic stirrer 
whilst being heated gently until the gliadin had dissolved. It was ensured that the 
temperature o f the solution did not rise above 60°C to avoid denaturation o f the gliadin. 
The 96-well microtitre plate was coated with the gliadin solution by adding lOOpl to 
each well and incubation overnight at 4°C. After incubation, the gliadin solution was 
decanted and the plate washed three times in wash buffer. During each wash, 200pl of 
wash buffer was added to each well, the plate was inverted and then excess buffer 
removed by tapping the plate several times on a paper towel. 2 0 0 f.il blocking solution 
was added to each well and the plate was incubated at RT for 60min. Serum samples 
were diluted in PBS and vortexed to ensure thorough mixing. The blocking solution 
was discarded from the wells and the plate washed three times in wash solution. lOOpl 
of diluted sample or blank was added to the appropriate wells and the plate incubated at 
RT for 60min. Meanwhile, either goat anti-human IgG or IgA HRP-conjugates were 
diluted in PBS. The plate was washed three times in wash buffer. lOOpl o f the 
appropriate conjugated-antibody solution was added to each well and the plate 
incubated at RT for 60min. The working TMB substrate was prepared and used within 
30min. The plate was washed three times in wash buffer. lOOpl working TMB 
substrate solution was added to each well and the plate incubated at RT for 20mins. 
Following incubation, 50jil o f stop solution was added to each well. The plate was read 
at 450nm within 15min on a Wallac 1420 plate reader (Version 2.00, PerkinElmer Life 
Sciences, USA). Data were reported as mean OD values.
2.2.3.2 Commercial anti-gliadin IgG ELISA
The plate and all reagents were supplied with the kit,
■ 96-well microplate coated with purified gliadin
■ Mouse anti-human IgG HRP-conjugate
■ Human anti-gliadin standards calibrated to arbitrary units;
Standard 1 (5U/ml), Standard 2 (20U/ml), Standard 3 (50U/ml),
Standard 4 (lOOU/ml)
■ Human anti-gliadin positive control serum
■ Human anti-gliadin negative control serum
■ Sample diluent buffer
■ TMB substrate solution
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■ Wash buffer concentrate
■ Stop solution (0.25M H2SO4)
Assays were performed according to the manufacturers’ instructions. All reagents and 
test samples were brought to RT. Meanwhile, 50ml of wash buffer concentrate was 
measured and diluted to one litre with d.fkO. All serum samples and positive/negative 
assay controls were diluted 1:100 with sample diluent by adding 5 pi sample or controls 
to 495pl sample diluent and vortexed to ensure thorough mixing. CSF samples were 
used undiluted. The protective covering was then removed from the gliadin-coated 
microtitre plate and sufficient wells selected to accommodate patient samples, standards 
and assay controls, all o f which were tested in duplicate. lOOpl o f standards, assay 
controls or samples were pipetted into the wells, according to a pre-determined plate 
plan based on the template shown in figure 2.2, and the plate incubated at RT for 30min. 
Following incubation, the well contents were discarded and the plate washed three times 
with diluted wash buffer using a multi-channel pipette. During each wash, 200pl of 
wash buffer was added to the wells and then emptied, the plate was inverted and tapped 
several times on a dry paper towel to remove excess wash buffer. lOOpl of HRP- 
conjugated mouse anti-human IgG was added to each well. The plate was incubated for 
15min at RT, the well contents discarded and the plate washed a further three times. 
IOOjlxI of TMB substrate was added to each well and the plate incubated for 15min at 
RT. After this time, 50pl of stop solution was added to each well and the plate tapped 
gently to ensure uniform colour distribution. The plate was read at 450nm, within 
15min, on a Wallac 1420 plate reader (Version 2.00, PerkinElmer Life Sciences, USA).
2.2.3.3 Commercial anti-gliadin IgA ELISA
Assays were performed according to the manufacturers’ instructions. The materials and 
methods for the anti-gliadin IgA ELISA were as for the anti-gliadin IgG ELISA except 
the HRP-conjugated mouse anti-human IgG reagent was replaced with HRP-conjugated 
mouse anti-human IgA reagent.
2.2.4 Commercial anti-tissue transglutaminase IgA ELISA
The plate and all reagents were supplied with the kit,
■ 96-well microplate coated with calcium-activated guinea pig tissue transglutaminase
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■ Sample diluent concentrate (150mM Tris-buffered saline (TBS), pH 7.2)
■ HRP-conjugated rabbit anti-human IgA
■ Human serum IgA anti-tissue transglutaminase standards in lOmM TBS, calibrated 
to arbitrary units
Standard 1 (OU/ml), Standard 2 (5U/ml), Standard 3 (lOU/ml)
Standard 4 (25U/ml), Standard 5 (50U/ml), Standard 6  (lOOU/ml)
■ Human IgA anti-tissue transglutaminase positive control serum in lOmM TBS
■ Human IgA anti-tissue transglutaminase negative control serum in lOmM TBS
■ TMB substrate (aqueous solution of TMB and hydrogen peroxide)
■ Stop solution (0.25M H2SO4)
Assays were performed according to the manufacturers’ instructions. All reagents and 
test samples were brought to RT. Meanwhile, working strength wash and sample 
diluent buffers were prepared by diluting each concentrate 1:15 with d.H2 0 . All serum 
samples and positive/negative assay controls were diluted 1:100  with sample diluent by 
adding 5pi sample or controls to 495pi sample diluent and vortexed to ensure thorough 
mixing. Sufficient wells to accommodate patient samples, standards and assay controls, 
all o f which were tested in duplicate, were assembled. lOOpl o f standards, assay 
controls or samples were pipetted into the wells according to a pre-determined plate 
plan based on figure 2.2. The plate was incubated at RT for 30min. After 30min, the 
well contents were discarded and the plate washed three times. During each wash 200pl 
of wash buffer was added to each well, the plate inverted and excess buffer removed by 
tapping the plate on a paper towel several times. lOOpl of HRP-conjugated anti-human 
IgA reagent was added to each well and the plate incubated for a further 30min at RT. 
The well contents were then discarded and the plate washed four times with wash 
buffer. lOOpl of TMB substrate was added to each well and the plate incubated for 
lOmin at RT after which lOOpl of stop solution was added to each well. The plate was 
read at 450nm within lOmin on a Wallac 1420 plate reader (Version 2.00, PerkinElmer 
Life Sciences, USA).
2.2.5 Commercial anti-glutamic acid decarboxylase IgG ELISA
The plate and all reagents were supplied with the kit,
■ 96-well microplate coated with purified porcine GAD antigen
■ Isletest Sample diluent concentrate
■ Isletest Conjugate diluent concentrate
■ ALP-conjugated goat anti-human IgG concentrate
■ Human serum IgG anti-GAD standards calibrated to arbitrary units (Ready to use)
■ Human serum IgG anti-GAD negative control (Ready to use)
■ Human serum IgG anti-GAD positive control (Ready to use)
■ Isletest Substrate solution (p-NPP) (Ready to use)
■ Isletest Washing buffer concentrate
■ Isletest Stopping solution (IN  NaOH) (Ready to use)
Assays were performed according to the manufacturers’ instructions. All reagents and 
test samples were brought to RT. Meanwhile, reagents were prepared. Working 
strength wash and sample diluent buffers were prepared by diluting the concentrates 
1:24 or 1:4 respectively with d.H2 0 , taking care to rinse out any crystals o f concentrate. 
The ALP- goat anti-human IgG conjugate was prepared by transferring a 5ml aliquot of 
the supplied conjugate diluent into each of the two bottles containing 1ml of the enzyme 
conjugate concentrate and mixing well. All serum samples were diluted 1:100 with 
working sample diluent by adding lOpl serum to 1ml sample diluent and vortexed to 
ensure thorough mixing. Sufficient wells to accommodate patient samples, standards 
and assay controls, all o f which were assayed in duplicate, were assembled. lOOpl of 
standards, assay controls or diluted serum samples were dispensed into the appropriate 
wells according to a pre-determined plate plan based on figure 2.1. The plate was 
incubated for 60min at RT. After the incubation, the well contents were discarded and 
the plate washed three times. During each wash 200pl o f wash buffer was added to 
each well, discarded from the wells and excess buffer removed by tapping the plate on a 
paper towel several times. 1 OOpl of reconstituted goat anti-human IgG ALP- conjugate 
was added to all wells. The plate was incubated in the dark for 60min at RT. Following 
the incubation, well contents were discarded and the plate washed a further three times 
with wash buffer. lOOpl of substrate solution was added to all wells and the plate was 
incubated in the dark for 30min at RT. At the end o f 30min, 50 pi of the stop solution 
was added to each well. The plate was read at 405nm on a Wallac 1420 plate reader 
(Version 2.00, PerkinElmer Life Sciences, USA) within lOmin o f addition o f the stop 
solution.
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2.2.6 Calculation of antibody levels
In the case of the in-house gliadin ELISA, the average optical densities (OD) of all 
duplicate wells were calculated and the average blank reading subtracted from each to 
obtain the average, blank-corrected OD for each sample.
In the case of all commercial ELISA kits, the mean OD of duplicate wells were 
calculated and the mean blank reading was subtracted from the mean OD of the 
standards, controls and patient samples. The corrected OD of the standards were plotted 
against the corresponding levels (log axis) using a curve-fitting system for Windows 
(CurveExpert 1.34, Microsoft). The mean blank OD was used as the zero standard.
The antibody levels of the patient samples were determined, using the OD values, from 
this calibration curve by the program. It was ensured that the positive and negative 
assay controls fell within the stated ranges (which are established by the manufacturer 
and vary slightly between lot numbers). Patient samples were also recorded as positive, 
negative or borderline according to the manufacturers’ cut-off values (table 2.3). 
Additionally, the standard deviation (SD) of the duplicates was calculated and used to 
calculate the %CV for each standard, control and sample using the formula,
% CV = (SD/Mean reading) xlOO
Table 2.3 Cut-off values o f commercial ELIS As, as supplied by kit manufacturers.
ELISA
ANTIBODY LEVEL (U/ml)
POSITIVE BORDERLINE NEGATIVE
IgG anti-gliadin >9 7-9 <7
IgA anti-gliadin > 6 5-6 <5
IgA anti-tissue transglutaminase > 10 - < 10
IgG anti-GAD >1.05 1-1.05 <1
2.2.7 Calculation of intra- and inter-assay variability
Inter-assay variability for each commercial ELISA was calculated as the average 
variability of the top standard supplied with each kit. For each ELISA type, the
69
unadjusted, average OD of the top standard was recorded from each plate that had been 
assayed for each ELISA type and averaged to obtain an overall mean OD of the top 
standard. The average SD of the individual ODs was also calculated to obtain an 
overall SD. The %CV was then calculated using the formula in section 2.2.6. In this 
way, for each ELISA type, a %CV value corresponding to the inter-assay variability 
was obtained.
Intra-assay variability was calculated for each individual plate. The unadjusted, average 
ODs of the positive control or standard 1 and its repeat sample in the last two wells of 
the plate were recorded. The mean and SD of these two readings were then calculated 
and the %CV corresponding to the intra-assay variability calculated according to the 
formula in section 2.2.6. Finally, for each ELISA type, an average intra-assay 
variability was calculated by averaging the individual plate variabilities o f that ELISA 
type.
2.2.8 Statistical analysis
Significant differences in antibody levels between patient groups were determined using 
non-parametric statistical tests. Non-parametric tests were used as the sample 
distributions are likely to be skewed and not normally distributed. In this situation, 
parametric tests are invalid and non-parametric tests are the more powerful.
Initially, for all ELISA types, Kruskal-Wallis one-way analysis of variance by ranks 
(with tied ranks) was performed to determine whether median antibody levels differed 
between patient groups. If  the null hypothesis was rejected a non-parametric multiple 
comparison test (with tied ranks) (Dunn test) was performed to determine between 
which of the groups significant differences occurred. Significant results were recorded 
as below:
p Rating Description
0.0KP<0.05 * Significant
0.001<P<0.01 ** Very significant
PO.OOl • k r kk Highly significant
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Antibody levels within each group were summarised according to their ranked order in 
box and whiskers plots. Any changes in distribution of the data between groups are 
evident from these plots and data series are usefully defined by several parameters all on 
one plot. Briefly, horizontal lines represent the median, upper (75%) and lower (25%) 
quartiles and the maximum and minimum values. The quartiles are ‘boxed’, enclosing 
50% of the data range, and finally single vertical lines extend ‘whiskers’ to the limits. 
Therefore, the range o f the data is also clearly represented on the plot.
Any correlations between antibody levels were determined using the Spearman’s rank- 
order correlation, a non-parametric alternative to Pearson’s correlation coefficient.
Finally, any significant differences between the results o f the in-house and commercial 
anti-gliadin ELIS As were determined using the Mann-Whitney U test. This test was 
selected as it is a non-parametric substitute for the Student’s t-test and is suitable for 
comparing two samples.
2.3 Immunohistochemistry
2.3.1 Principles of the technique
IHC can be used to identify specific proteins (both membrane-bound and cytosolic) 
within tissue sections. The basic principle o f the method (figure 2.3a) exploits the 
ability o f cellular components to act as antigens and interact specifically with antibodies 
directed against them. Briefly, tissue sections are placed onto glass or plastic 
microscope slides. A ‘blocking’ serum is applied to minimise non-specific binding by 
the primary antibody and secondary detection antibody during later stages. Excess 
‘blocking’ serum is washed off and a primary antibody, directed against the protein of 
interest, is applied to the section. Unbound antibodies are washed off and a secondary 
detection antibody, directed against the Fc portion o f the primary antibody, is applied to 
the tissue section. Visualisation o f antigen location is achieved by conjugating the 
secondary detection antibody to a variety of labels. Alternatively, but less frequently, 
the primary antibody may be labelled and visualised directly. Commonly used labels 
include fluorescent chromophores, such as fluoroscein, or enzymes that form insoluble 
coloured precipitates upon addition of a suitable substrate. Frequently, ALP and HRP 
are used with either 5-Bromo-4-chloro-3- indolylphosphate /nitro blue tetrazolium
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(purple precipitate) or 3,3’-Diaminobenzidine (DAB) (brown precipitate) substrates 
respectively. The resultant staining is permanent and can be readily seen using a light 
microscope.
In situations where the amount of antigen in the tissue is low, certain modifications of 
the technique allow an amplified end signal thus facilitating detection. One such 
modification is the avidin-biotin complex (ABC) system (Vector laboratories, UK) 
(figure 2.3b), which exploits the high binding affinity these two proteins have for one 
another. The secondary antibody is biotinylated and therefore adds biotin at primary 
antibody binding sites. Unbound biotinylated antibody is then washed off the section 
and enzyme-labelled avidin/biotin complex is added. The complex consists of 
biotinylated enzyme molecules and avidin, which form a large 3-D structure due to the 
fact that each avidin molecule is capable of binding four biotin molecules 
(www.vectorlabs.com). Staining is enhanced due to the fact that many enzyme 
molecules end up attached to each secondary antibody.
2.3.2 General immunohistochemistry methods
2.3.2.1 CNS tissue
Human cerebellar tissue was obtained from normal control or motor neurone disease 
patients at post-mortem, with informed consent from next o f kin, from Professor P. Ince 
in the Pathology Department of The Royal Hallamshire Hospital, Sheffield. Post­
mortem CNS tissue was snap-frozen in liquid nitrogen at the hospital and stored at 
-70°C, in an air-tight container.
Rat cerebellar tissue was removed from an adult rat, following cervical dislocation, 
mounted onto a cork-board using Cryo-M-Bed tissue embedding compound (Bright 
Instrument Company Ltd., UK) and immediately snap-frozen in isopentane cooled on 
liquid nitrogen. The tissue was wrapped in foil and stored at -70°C, in an air-tight 
container.
As required, cerebellar tissue was cut into 10pm sections in a cryostat (Leica, Italy) at 
-20°C, and collected on polysine-coated microscope slides (BDH, UK). If  necessary, 
slides were stored at -70°C, in an air-tight container, until use.
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2 3 .2.2 Sample preparation
Serum samples were collected and stored as in section 2.1.1.1. If necessary, samples 
were defrosted prior to use. All samples were allowed to reach room temperature and 
vortexed before use. CSF samples were collected and stored as in section 2.1.1.5. 
Again, samples were allowed to reach room temperature and vortexed before use.
2.3.3 Avidin-Biotin amplified immunohistochemistry
After warming to room temperature, sections were fixed by immersion in acetone at 4°C 
for lOmin, removed and air-dried. Sections were then blocked for 60mins at RT with 
normal horse (if a monoclonal primary antibody was used) or goat serum (if serum was 
used as primary antibody) (Mouse or rabbit Vectastain Elite ™ Kits respectively,
Vector Laboratories, UK) (lOOpl/section), diluted 3:200 in PBS, in a humid chamber to 
prevent the tissue drying out. Excess blocking serum was discarded by gently tapping 
the slides on tissue. Sections were then incubated with primary antibody, diluted in 
PBS (pH 7.4, see section 2.2.3.1 for preparation), for 60mins at RT (lOOpl/section). 
Sections incubated with PBS as a substitute for primary or secondary antibodies were 
included as negative controls. Excess antibody was removed by gently tapping the 
slides on tissue and the sections then washed twice in PBS for 5mins. Control slides 
were washed separately to avoid cross contamination. Primary antibody binding was 
detected by subsequent incubation of sections for 60mins at RT with either biotinylated 
goat anti-human IgG antibody, or biotinylated horse anti-mouse IgG antibody diluted in 
PBS,(100pl/section), in a humid chamber. Excess antibody was removed by gently 
tapping the slides on tissue and the sections then twice washed in PBS for 5mins.
Bound antibody was visualised using an avidin-biotin complex containing horseradish 
peroxidase (‘ABC’ reagent, Vectastain Elite™ Kit, Vector Laboratories, UK). ABC 
reagent was made up 30mins prior to use to allow formation o f the avidin-biotin 
complex by combining equal amounts of reagents A and B with PBS so that each 
reagent reached a final dilution of 1 in 100. Sections were incubated with ABC reagent 
(lOOpl/section) for 60mins at RT in a humid chamber. Excess complex was removed 
by gently tapping the slides on tissue and the sections then twice washed in PBS for 
5mins. Finally, sections were immersed in a solution o f 0.2mg/ml DAB (Sigma, UK) in 
PBS, containing 0.015% hydrogen peroxide (Sigma, UK), for 5mins. After briefly 
rinsing in tap-water to quench the enzyme reaction, sections were counterstained with 
Mayer’s haematoxylin (Sigma, UK) for 2mins and then rinsed in tap-water for a further 
5mins. The sections were moved to a fume-cupboard and dehydrated by immersion in
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an ethanol gradient (placed for 2mins in each o f 70%, 80%, 95% and 100% ethanol 
solutions) followed by immersion in xylene for 2mins. After being air-dried, the slides 
were mounted in DPX (BDH, UK).
2.3.4 Indirect immunohistochemistry
Tissue sections were warmed to RT and then washed in PBS-Tween (PBST) (0.05% 
Tween20 (Sigma, UK) in PBS (see section 2.2.3.1 for preparation) for lOmins at RT 
with gentle shaking using an orbital shaker.
Sections were then incubated for 60mins at RT in a humid chamber, to stop sections 
drying out, with either commercial antibodies or patient serum (lOOpl/section) diluted 
in PBST. Sections incubated with PBST as a substitute for primary or secondary 
antibodies were included as negative controls. After the incubation period, excess 
antibody was removed by gently tapping the slides on tissue paper and sections were 
washed three times in PBST with gentle shaking, each wash lasting 5mins. Following 
this wash, sections were incubated for 30mins at RT with appropriate HRP-conjugated 
secondary antibody, diluted in PBST. Excess secondary antibody was removed by 
gently tapping the slides on tissue paper and sections were again washed as above. 
Finally, sections were developed for up to 20mins in a solution of 0.4mg/ml DAB 
(Sigma, UK) in PBST with 0.0135% hydrogen peroxide (Sigma, UK). After a quick 
rinse in tap-water to quench the enzyme reaction, sections were moved into a fume- 
cupboard and dehydrated in methanol (15secs) followed by methanol/xylene (1 :1) 
(30secs) and xylene (2mins). After being air-dried, the slides were mounted in DPX 
(BDH, UK).
2.3.5 Visualisation and image capture
After staining, slides were viewed using an Olympus BX60F-3 light microscope and 
images captured using a colour video camera (JVC 3-CCD) attached to the microscope.
2.4 Gel Electrophoresis And Western Blotting
2.4.1 Principles of the techniques
Electrophoresis is a widely used analytical technique for the separation o f charged 
molecules from complex mixtures. SDS-PAGE is most commonly used for separation
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and qualitative analysis o f protein mixtures. The technique is also very useful for 
determination o f protein RMM as proteins are separated by size. Proteins can be 
separated in this way as, once dissolved in high concentrations o f SDS, their 
electrophoretic mobility in polyacrylamide gels is directly related to their RMM. SDS 
(CH3-(CH2)io-CH2 0 SC>3'Na+) is a powerful anionic detergent. Prior to being loaded 
onto the gel, protein samples are heated for several minutes with a sample buffer 
containing SDS and a reducing agent (frequently P-mercaptoethanol). The tertiary 
structure of the protein unfolds due to destruction o f disulphide bridges by the reducing 
agent. The negatively charged SDS then strongly binds to the unfolded protein thus 
swamping its original native charge. All proteins bind the same amount o f SDS per 
gram, therefore, the amount o f negative charge is directly proportional to the size o f the 
original protein. Samples are then loaded into the gel, which is supported between two 
glass plates. Up to 20 protein samples may be loaded into individual wells o f a stacking 
gel, which is set on top of the main separating gel. The gels are placed into an 
electrophoresis tank and tank buffer is added. Upon application of a voltage across the 
gel, the negatively charged SDS-protein complexes start to move down the gel, towards 
the positive electrode. The stacking gel has the purpose o f concentrating the samples 
into a sharp band before they enter the separating gel. This is achieved through 
exploitation of the differences in electrophoretic mobility of ions in the various buffers 
and gels. Briefly, glycinate ions in the tank buffer move more slowly than the chloride 
ions in the sample buffer and stacking gel. The SDS-protein complexes have an 
intermediate mobility. All ionic species must migrate at the same speed to avoid 
breaking the electrical circuit. To achieve this, the ionic species alter their 
concentrations and, as only a small amount of SDS-protein complexes are present, they 
concentrate in a very tight band between the glycinate and chloride boundaries. Once 
the separating gel is reached, the glycinate ions speed up in the higher pH environment 
and the interface between the glycinate and chloride ions leaves the SDS-protein 
complexes to migrate at their own speed. The complexes continue towards the anode at 
the same speed as all have the same charge per unit length. However, frictional 
resistance within the gel opposes this movement. Larger molecules feel more resistance 
and so move more slowly than smaller molecules thus separating the complexes.
Additionally, separation is achieved through the molecular sieving properties o f the gel. 
The polyacrylamide gel has a mesh-like, porous structure through which the proteins 
pass. This structure is formed by the cross-linking o f acrylamide monomers in the
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presence of a cross-linking agent (N, N-methylene-bis-acrylamide) and the relative 
proportion o f these two reagents is the major factor in governing pore size. 
Conventionally, polyacrylamide gels are defined as a percentage, which reflects the 
amount o f acrylamide monomer and crosslinker in relation to the total gel volume. As 
the percentage o f the gel decreases, the pore size increases. In practice, the smaller the 
protein, the more easily it passes through the pores of the gel whereas larger proteins are 
eventually prevented from moving further, or from moving at all. The ability to vary 
the pore size o f the gel allows the most appropriate percentage gel to be selected 
according to the size, or likely size, of the protein of interest to be separated. The 
polymerisation reaction is initiated by ammonium persulphate (APS) and catalysed by 
N, N, N ’, N ’ -  tetramethylethylenediamine (TEMED), both o f which are added to the 
gel mixture. Finally, the protein sample buffer also contains a dye (usually 
bromophenol blue) which is a small molecule that moves through the gel unhindered 
and indicates the electrophoresis front. The separation is sensitive to any alterations in 
pH or ionic concentration within buffers or gels although the major problem is avoiding 
overheating o f the system. During the separation, most o f the power generated is 
dissipated as heat. This problem may be overcome by using a power supply capable of 
providing a constant power although this isn’t completely effective and this must be a 
consideration when selecting the most appropriate voltage for the separation. Proteins 
on gels may be detected and quantified in a variety o f ways. Often, stains such as 
Coomassie brilliant blue or Ponceau-Red are used to detect protein bands on the gel. 
Although both are highly sensitive, greater sensitivity may be achieved using the silver 
stain, which is capable o f detecting as little as lng of protein (Wilson & Walker, 1995).
Alternatively, the proteins may be further examined using the technique o f western 
blotting. Proteins are firstly transferred (‘blotted’) from the gel onto a piece of 
nitrocellulose membrane. A sandwich of gel and nitrocellulose membrane is formed, 
compressed in a cassette and immersed in transfer buffer between two parallel 
electrodes. A current is passed at right angles to the gel, causing the separated proteins 
to migrate out of the gel and onto the membrane. Certain stains, including Ponceau- 
Red, can be used to visualise proteins once they have been transferred onto 
nitrocellulose, which is useful in monitoring the success and reproducibility of the 
transfer technique. The stain may then be washed off and the blot used in further 
experiments. Such experiments include probing the blot with an antibody to detect a 
specific protein in a manner similar to both IHC and ELISA techniques. The blot is
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incubated in a protein solution to ‘block’ all remaining hydrophobic binding sites and 
avoid non-specific binding of either primary or secondary antibodies. A primary 
antibody, directed against the protein of interest, is applied and incubated with the blot 
for a period. Following this period, unbound antibody is washed off and a secondary 
detection antibody is applied, directed against the Fc portion of the primary antibody.
As with IHC and ELISA techniques, most frequently this secondary antibody is 
enzyme-labelled with peroxidase or phophatase enzymes and addition o f appropriate 
substrate results in a colour change by which binding may be visualised. Increased 
sensitivity can be achieved through use o f a chemiluminescent substrate with HRP 
enzyme resulting in light emission that can be measured by exposing the blot to 
photographic film. Alternative detection sytems include radio-labelled or fluorescently- 
labelled secondary antibodies.
Finally, the RMM of a protein on a gel or membrane can be determined by comparing 
its mobility with those contained in commercial molecular weight markers, a mixture o f 
standard proteins with known RMMs that are run on the same gel. Alternatively, certain 
commercial markers can be electrophoresed, blotted onto nitrocellulose membrane and 
then visualised after transfer.
2.4.2 Protein extraction
Rats were sacrificed by cervical dislocation and required tissues immediately removed. 
All steps were carried out on ice to minimise protease action within the tissue. All 
reagents were stored at 4°C until used. The tissue was twice rinsed briefly in PBS (see 
section 2.2.3.1 for preparation) and weighed. Working extraction buffer was then 
prepared by adding 1 Complete™ protease inhibitor cocktail tablet (provides inhibition 
of serine, cysteine and metalloproteases as well as calpains) (Roche, UK) to 50ml 
extraction buffer (5mM Tris-Base, 0.02M Tris-HCl, ImM EDTA). Working extraction 
buffer was added to the tissue in a ratio of lOpl per milligram, which was then 
homogenised using a hand homogeniser and the resultant homogenate transferred into 
1.5ml tubes. Triton X-100 (Sigma, UK) was added to the homogenate to a final 
concentration of 1% v/v and mixed well using a vortex mixer. The tissue homogenate 
was then incubated for lhour, at 4°C, during which time it was vortexed every lOmins 
for approximately 30secs. After incubation, the homogenate was spun at 1 l,000xg for 
lOmins using a microcentrifuge (13000 rpm in a MSE MicroCentaur) and the 
supernatant and pellet separated. The pellet was re-suspended in 0.5ml d.H2 0 , both
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supernatant and pellet extracts were aliquoted into fresh 0.5ml tubes and finally a 
Bicinchoninic acid protein assay performed (section 2.4.3.2) to determine the amount of 
protein present in the extracts.
2.4.3 Determination of protein concentration within extracts
The amount o f protein extracted was determined using the Bicinchoninic acid (BCA) 
protein assay (BCA assay). This is a modification of the Lowry method for protein 
detection enabling quantification o f protein levels in a sample as low as lOpg. The 
assay makes use o f the reaction between protein and an alkaline solution of copper 
sulphate, which yields a purple-coloured complex. This complex is chelated by BCA, 
making it very stable with a maximal absorption at 562nm (Holme & Peck, 1993).
Firstly, solutions o f BSA were serially diluted in d.H2 0  over the range 0.1 mg/ml to 
20mg/ml to create a calibration curve. 20pl aliquots o f BSA standards were then 
pipetted in duplicate into a 96-well microtitre plate (Falcon, UK). 20pl aliquots of tissue 
supernatant or pellet extracts and 2 0 pi aliquots o f appropriate blanks (d.H2 0  or working 
extraction buffer) were pipetted in triplicate into the plate. Working BCA reagent was 
then made up by mixing 20ml Bicinchoninic acid solution (Sigma, UK) and 0.4ml of a 
4% (w/v) copper (II) sulphate solution (Sigma, UK). 200pl working BCA reagent was 
added to each well and the plate incubated for 30mins at RT. The plate was read at 
550nm on a Wallac 1420 plate reader (Version 2.00, PerkinElmer Life Sciences, USA). 
A protein calibration curve was created by plotting the corrected mean OD of the 
duplicate BSA standards against the corresponding concentrations using a curve-fitting 
system for Windows (CurveExpert 1.34, Microsoft, USA). The protein concentration of 
the tissue extracts was calculated from this curve. In addition, it was ensured that the 
%CV o f the duplicate absorbances for the standards did not exceed 10%. %CV was 
calculated as described in section 2.2.5.
2.4.4 SDS-PAGE
All reagents from Sigma, UK unless specified.
2.4.4.1 Sample preparation
Sample buffer was prepared according to the recipe below, aliquoted and stored at 
-80°C.
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Reducing sample buffer (2x):
0.125M Tris-HCl 
0.14M SDS 
20% v/v Glycerol 
2% v/v p-mercaptoethanol 
0.03mM Bromophenol blue
Samples were diluted in d.H2 0  to a final concentration o f 7.3mg/ml. 2x sample buffer 
was added to tissue extract supernatants and re-suspended pellets in the ratio 1:1 v/v. 
This dilution provided a final amount of36pg protein loaded per lane in each lOpl 
aliquot. After mixing well using a vortex mixer, the extracts were aliquoted into 500pl 
aliquots and heated to 85°C for 2.5mins in a beaker o f water. After cooling, samples 
were stored at -80°C.
2.4.4.2 Electrophoresis
This method is based on the Laemmli technique (1970). The apparatus used was the 
Hoefer 250SE Mighty Small system (Amersham Pharmacia Biotech, UK).
■ Resolving gel buffer:
1.5M Tris-HCl (pH 8 .8)
■ Stacking gel buffer:
0.5M Tris-HCl (pH 6 .8)
■ 30% Acrylamide/bisacrylamide
- 10% SDS in d.H20
- TEMED
- 10% APS in d.H20
■ Running buffer (lOx):
0.25M Tris-Base
1.92M Glycine 
0.035M SDS
■ Wide range coloured molecular weight markers, 6.5-205 kDa
■ Wide range Sigmamarker™ molecular weight markers, 6.5-205 kDa
It was ensured that all equipment was clean and dry before use. Glass plates were 
wiped with distilled water followed by 100% ethanol to remove all traces of dirt and
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grease which may interfere with gel polymerisation. Two sets o f plates were assembled 
in the casting stand using 0.75mm spacers between the two plates. Next, a 10% 
resolving gel was cast as below,
2.5ml Resolving gel buffer 
3.3ml Acrylamide/bisacrylamide 
4.1ml d.H20  
lOOpl SDS (10%)
5 pi TEMED
50pl freshly prepared APS (10%)
The resolving gel buffer, water, acrylamide/bisacrylamide and SDS were combined and 
mixed gently to avoid introduction of air bubbles into the solution. The TEMED and 
APS were then added and the solution stirred briefly. Without delay, the mixture was 
then pipetted into the gel cast, using a plastic transfer pipette, and a thin layer o f 100% 
ethanol pipetted over the gel to exclude air, which would inhibit polymerisation. The 
gel was left to set (minimum of 45mins) at RT. Once the resolving gel had set, the 
ethanol layer was poured off and the top o f the gel rinsed several times with distilled 
water to remove any residual ethanol. The stacking gel (5%) was then prepared as 
below,
2.5ml Stacking gel buffer
1.7ml Acrylamide/bisacrylamide
5.7ml d.H20
lOOpl SDS (10%)
lOpl TEMED
50pl APS (10%)
As before, the stacking gel buffer, acrylamide/bisacrylamide, water and SDS were 
combined first and the solution mixed gently, avoiding introduction o f air into the 
mixture. The TEMED and APS were then added and the mixture stirred briefly. The 
stacking gel mixture was then quickly pipetted on top of the resolving gel using a plastic 
transfer pipette until it was level with the top of the plates. A 10 tooth comb was 
inserted between the plates and the gel left to set (minimum of 45mins) at RT. 
Meanwhile, the tank was assembled and filled with lx  running buffer. At this point, if  
necessary, samples were defrosted and mixed well using a vortex mixer. Once the 
stacking gel had set, the gels were secured into the tank. Pre-stained molecular weight
markers were defrosted, mixed well and loaded directly onto the gel without further 
preparation. The combs were gently removed and required samples (lOpl /lane) and 
molecular weight standards (lOpl/lane) loaded slowly into their allocated wells to allow 
even settling at the bottom of each well. The gels were then run at 150V for 
approximately 60mins at RT. Once the bromophenol blue dye front had reached the 
bottom of the gel, the power was switched off and the gels removed from the tank.
2.4.5 Western Blotting
Western blot transfer was carried out using a Hoefer semi-dry blotter (Amersham 
Pharmacia Biotech, UK). All reagents from Sigma, UK unless specified.
■ Towbin Transfer buffer:
0.19M Glycine 
0.025M Tris-Base 
2 0 % (v/v) methanol
■ Filter paper (Amersham Pharmacia Biotech, UK)
■ Hybond™-c extra; Supported nitrocellulose membrane (Amersham Pharmacia 
Biotech, UK)
On completion o f electrophoresis, gels were soaked in transfer buffer at RT for 
approximately lOmins. Sufficient filter paper (6  pieces per gel) and nitrocellulose 
membrane (1 piece per gel) were cut to the same size as the gel and also soaked in 
transfer buffer for approximately lOmins at RT. Blotting ‘sandwiches’ were assembled 
in the blotting apparatus according to figure 2.4. The gels were transferred for 60mins 
at RT at 100V and then the nitrocellulose membrane was removed from the apparatus 
and the gels and filter paper discarded. The blots were then placed in ready-to-use 
Ponceau-S Red stain (0.1% Ponceau S (w/v) in 5% acetic acid (v/v)) (Sigma UK) for 
approximately 5mins to enable visualisation o f the proteins. This allowed some idea of 
how successful the transfer had been and acted as a check to see that lanes had been 
equally loaded and that there was sufficient consistency between the same samples run 
during different experiments. At this point, RMM marker bands were highlighted on 
the blot using a pencil. The Ponceau-S Red was then washed off the blot by rinsing 
several times in d.H^O in preparation for immuno-probing.
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2.4.6 Detection of proteins
■ PBST (see section 2.3.4 for preparation)
■ Blocking solution:
5% ECL blocking agent (Amersham Pharmacia Biotech, UK) in PBST
Blots were placed in plastic, disposable trays on an orbital shaker and blocked for 
60mins at RT in 25ml blocking solution, which was followed by two 5min washes in 
PBST. The blots were then placed in clean trays on an orbital shaker and incubated 
with appropriately diluted (in PBST) primary antibody overnight at 4°C. The following 
day, blots were removed from the primary antibody solution and washed lx l5m in  then 
3x5min in PBST.
Figure 2.4 Assembly o f ‘sandwich’ for protein transfer
-VE
electrode
Blotting paper 
(3 sheets)
Gel
N itrocellulose
Blotting paper 
(3 sheets)
+VE N 
electrode
Appropriately diluted (in PBST) HRP- conjugated secondary antibody solution was 
added to the trays and the blots incubated for a further 60mins at RT with gentle 
shaking. After the incubation, blots were washed lx l5m in  then 3x5min in PBST. 
Excess PBST was removed and blots were placed protein side up onto a piece o f cling­
film. The required volume of ECL-Plus™ detection reagent (Amersham Pharmacia 
Biotech, UK) was prepared, by adding 50jnl o f reagent B to every 2ml o f reagent A, and 
then added to each blot so that the entire surface o f the membrane was covered before 
incubating for 5mins at RT. Excess reagent was removed by holding the blot gently in
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forceps and holding the edge against a tissue. The blots were then placed protein side 
down onto a fresh piece o f cling-film, which was gently wrapped around the blot to 
form an envelope and any air bubbles were gently smoothed out. Light emission 
resulting from the substrate was visualised using a UVP imager (UVP, UK) and 
captured using Labworks software (UVP, UK).
2.4.7 Determination of protein molecular mass
The relative mobility o f each of the proteins in the RMM standard mixture was 
calculated as the distance moved down the gel as a percentage o f the total distance 
moved by the dye front, using the equation below,
% Relative mobility = Distance moved by protein standard o f interest (mm) x  100
Total distance moved by dye front (mm)
A calibration curve was formed by plotting relative mobility against Log RMM for each 
of the protein standards in the mixture using a curve-fitting programme for Windows 
(CurveExpert 1.34, Microsoft, USA). The relative mobilities of unknown proteins 
within samples were calculated in the same way and their Log RMM determined from 
the calibration curve. From these values the RMM of the unknown proteins were 
calculated.
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CHAPTER THREE
CIRCULATING GLUTEN SENSITIVITY- 
ASSOCIATED ANTIBODY LEVELS IN 
PATIENTS WITH GLUTEN ATAXIA
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3.1 Introduction
3.1.1 Anti-gliadin antibodies and anti-tissue transglutaminase 
antibodies as serological markers of gluten sensitivity
Both anti-gliadin and anti-TG2 antibodies are produced as a result o f the intestinal 
immune response against gluten. Their presence in the serum of gluten sensitive 
patients and the relatively recent availability of reliable, rapid methods o f measurement 
(by ELISA) has resulted in these tests becoming a useful adjunct to duodenal biopsy 
and HLA testing for the diagnosis o f CD. Additionally, these non-invasive tests 
facilitate the monitoring of patient response to a GFD and, together with other tests such 
as HLA testing, screening large populations for gluten sensitivity.
Previously, measurements o f ARA, AEA and anti-gliadin antibodies were made as part 
o f the diagnostic process o f CD. However, ARA have a lower specificity for the 
disease (Troncone & Ferguson, 1991), and are now rarely included in current routine 
diagnostic tests. AEA, first described in 1983, are detected by immunofluorescence 
from their specific binding pattern using either monkey oesophagus or human umbilical 
cord as substrate (Chorzelski et al., 1983, Ladinser et al., 1994). Following the 
discovery that TG2 was the primary autoantigen recognised by AEA (Dieterich et al., 
1997), many diagnostic assays for their detection in serum were developed. Anti- 
gliadin and anti-TG2 antibody assays are today widely used serological tests for the 
diagnosis of CD, the combined sensitivity reaching 93% in patients where there is 
clinical suspicion o f CD (Dahele et al, 2001).
3.1.1.1 Anti-gliadin antibody assays
Initial reports o f anti-gliadin antibodies in CD first appeared in the late 1950s and early 
1960s (Rossi & Tjota, 1995). Isotype-specific anti-gliadin antibody tests are most 
usually detected by ELISA, the first method being described in 1977, although other 
detection methods such as immunofluorescence and RIA have also been used (Maki, 
1995, Rossi & Tjota, 1995).
Production o f anti-gliadin antibodies is strictly dependent on dietary exposure to gluten 
(Sollid, 2000). The antibodies are mainly of the IgA (IgAi and IgA2) or IgG (IgGi and 
IgG4) classes (Maki, 1995; Volta et al., 1990) and are readily detected in the serum of
86
patients with CD. Generally, IgA anti-gliadin antibodies tend to have a greater 
specificity for CD and correlation with mucosal damage whereas IgG anti-gliadin 
antibodies have a greater sensitivity, although predictive values tend to vary and both 
isotypes should be tested for (Milford-Ward et al, 2001; Troncone & Ferguson, 1991) 
(table 3.1). It is believed that this variation is mostly due to patient selection within 
studies, rather than inherent properties o f the assays themselves (Maki, 1995). 
Specificity appears more satisfactory in children (Savilahti et al., 1983) than in adults 
(Maki, 1995; Uibo et al, 1993) and positivity for anti-gliadin antibodies appears to 
increase with age in normal individuals (Uibo et al, 1993). Additionally, IgG anti- 
gliadin antibodies have been reported in a small proportion of patients with other GI 
disorders such as Crohn’s disease, ulcerative colitis and cow’s milk intolerance 
(Milford-Ward et al, 2001) as well as in otherwise healthy individuals (Troncone & 
Ferguson, 1991). Even so, the IgG anti-gliadin antibodies assay remains a valuable tool 
not least as it enables detection of IgA deficient patients with CD, a condition where 
subjects have a 10-20 fold increase of CD (Cataldo et al, 1998; Korponay-Szabo et al, 
2003b).
As may be expected, anti-gliadin antibody levels tend to decrease once a GFD is 
initiated (Savilahti et al, 1983; Troncone & Ferguson, 1991) and the mucosa is allowed 
to recover, making them useful indicators o f dietary compliance. Patients on a strict 
GFD have serum levels o f IgA anti-gliadin antibodies similar to healthy controls but 
IgG anti-gliadin antibodies tend to persist at slightly higher levels for longer periods of 
time (Savilahti et al, 1983; Troncone & Ferguson, 1991). Re-introduction of gluten 
into the diet rapidly causes the reappearance of anti-gliadin antibodies but, for unknown 
reasons, they disappear again in a significant proportion o f patients during a prolonged 
period (>3years) o f a gluten-containing diet (Burgin-Wolff & Hadziselimovic, 1997).
3.1.1.2 Anti-tissue transglutaminase antibody assays
Production o f anti-endomysial and anti-TG2 antibodies is also gluten-dependent and 
levels are correlated with the degree o f enteropathy (Maki, 1995; Sollid et a l , 1997; 
Tursi et a l, 2003). Their levels fluctuate with gluten ingestion and normally disappear 
within one year on a GFD (Maki, 1995; Sollid et a l, 1997). Reintroduction o f gluten 
causes reappearance o f anti-endomysial antibodies for the duration o f a gluten- 
containing diet (Burgin-Wolff & Hadziselimovic, 1997).
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Table 3.1 Sensitivity and specificity of serum anti-gliadin antibodies in untreated
coeliac disease
IgA class IgG class
Study
number
PATIENT
GROUP
Sensitivity
(% )
Specificity
(% )
Sensitivity
(% )
Specificity
(% )
1 Children 97 92 - -
2 Adults 46 98 62 97
3 Adults 90 85 ■ 76 88
4 Adults 65 100 95 98
5 Adults 67 94 78 94
6 Children 100 100 100 100
7 Adults 100 100 57 87
8 Adults 31 87 46 89
9 Children 96 100 91 99
10 Children 90 86 94 67
The above table is a summary o f ten different studies investigating the sensitivity and 
specificity o f anti-gliadin antibodies in patients with untreated CD.
Taken from Maki, 1995
Following the discovery that the primary target of AEA is actually TG2 (Dieterich et 
al, 1997), recently developed anti-TG2 antibody ELISAs have become a more 
widespread tool in the diagnosis of CD. Immunofluorescent detection o f AEA using 
monkey oesophagus or human umbilical cord was the assay o f choice with a reported 
specificity of 96-100% and sensitivity of 90-98% (Amin et al, 1999; Baidas et al,
2000; Leon et al, 2001; Milford-Ward et al, 2001). However, good correlation 
between both assays has been shown (Amin et al, 1999; Dieterich et al, 1998; Leon et 
al, 2001; Sulkanen et al, 1998) and new TG2 ELISAs have comparable specificity (98- 
99%) and sensitivity (93-97%) (Baidas et al, 2000; Biagi et al, 1999b; Dieterich et al, 
1998; Milford-Ward et al, 2001; Sblattero et al, 2000). IgA anti-TG2 antibodies are 
normally measured for the purpose of diagnosis and monitoring o f CD. Although IgG 
assays are available they have been reported to be less effective for this purpose but are 
useful for the detection o f IgA-deficient patients with CD (Cataldo et al, 2000;
Korponay-Szabo et al, 2003b; Sblattero et al, 2000). Originally, anti-TG2 ELISAs 
utilised TG2 from guinea-pig liver, which has an approximate 80% homology with 
human TG2 and, recently, assays using a human recombinant form of the enzyme have 
been made available. There is some suggestion that human recombinant TG2 assays are 
slightly more specific, possibly because they are able to detect antibodies directed 
against specific human TG2 epitopes (Amin et al, 1999; Tonutti et al, 2003).
However, a more important factor influencing specificity appears to be the purity o f the 
TG2 and purified guinea-pig TG2 ELISAs have been reported to have similar 
specificities to human recombinant TG2 ELISAs (Sblattero et al, 2000).
3.1.2 Aims of this study
The presence and significance of anti-gliadin and anti-TG2 antibodies in the serum of 
patients with CD is well defined. In addition, both o f these antibodies have been 
reported in patients with DH (Kumar et al, 2001; Reunala & Hallstrom, 1990).
Although the presence o f serum anti-gliadin antibodies (IgG or IgA) is a diagnostic 
prerequisite o f gluten ataxia, the full profile of these antibodies in conjunction with the 
presence o f serum anti-TG2 antibodies had not been previously investigated. Finally, 
the presence o f anti-gliadin antibodies has been reported in the CSF o f a patient with 
neurological dysfunction and gluten sensitivity (Chinnery et al, 1997).
Therefore, the aims o f this study were:
o To investigate and characterise the presence of serum anti-gliadin (IgG and IgA) and 
anti-TG2 (IgA) antibodies in patients with gluten ataxia, using ELISA, 
o To compare this serological profile with that of patients with CD only, other causes 
of ataxia (both genetic and sporadic (non-gluten) idiopathic ataxia) and healthy 
controls.
o To investigate any correlation between the levels o f circulating anti-gliadin (IgG and 
IgA) and levels o f IgA anti-TG2 antibodies, 
o To investigate the presence of anti-gliadin antibodies in the CSF o f patients with 
gluten ataxia.
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3.2 Methods
3.2.1 Serum ELISAs
Initially, measurements o f serum IgG and IgA anti-gliadin antibodies were made using 
an in-house gliadin ELISA method and then repeated using commercially available 
ELISA kits for comparative purposes. Measurements o f serum IgA anti-TG2 were 
made using commercially available ELISA kits. For each kit type, serum antibody 
levels and inter and intra-assay variation were calculated according to the methods 
described in sections 2.2.6 and 2.2.7 respectively. Statistical analysis was carried out as 
described in section 2.2.8. Finally, for each patient, the corresponding levels of 
circulating antibodies were correlated using the Spearman rank order correlation as 
below:
o IgG anti-gliadin antibodies and IgA anti-gliadin antibodies 
o IgG anti-gliadin antibodies and IgA anti-TG2 antibodies 
o IgA anti-gliadin antibodies and IgA anti-TG2 antibodies
3.2.1.1 In-house anti-gliadin ELISA
This method was based on an in-house ELISA for detection o f anti-gliadin antibodies, 
which had previously been used successfully in the Immunology Department o f The 
Northern General Hospital, Sheffield. Preliminary experiments were undertaken to 
optimise the method, which included investigation o f antigen concentration for coating 
the plates, serum dilution and dilution of secondary antibody (data not shown). 
Following optimisation, a total of 9 gluten ataxia (untreated), 2 CD without neurological 
complications (untreated), 7 ataxia control and 5 healthy control serum samples were 
assayed for both IgG and IgA anti-gliadin antibodies, using the methods detailed in 
sections 2.2.2 and 2.2.3.1. Due to a lack o f appropriate calibrants and controls, the 
inter- and intra variabilities were not calculated and statistical analysis was not carried 
out on the results. Variation between the average ODs from the in-house and 
commercial kit methods for each individual sample were assessed by calculating the 
%CV (as detailed in section 2.2.6) o f the readings obtained by each method. I f  this 
value was 20% or less, the two methods were considered to have given comparable 
results. Any difference between the average OD of all samples assayed using each 
method were determined using the Mann-Whitney U test.
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3.2.1.2 Commercial anti-gliadin IgG ELISA
A total o f 33 gluten ataxia (untreated), 33 CD without neurological complications 
(untreated), 28 ataxia control (a mixture of familial and sporadic (non-gluten) idiopathic 
ataxias) and 43 healthy control serum samples were assayed according to the methods 
detailed in sections 2.2.2 and 2.2.3.2.
In addition, 4 gluten ataxia (untreated) and 1 healthy control CSF samples were assayed 
for IgG anti-gliadin antibodies according to the same methods.
3.2.1.3 Commercial anti-gliadin IgA ELISA
A total o f 32 gluten ataxia (untreated), 32 CD without neurological complications 
(untreated), 25 ataxia control (a mixture of familial and sporadic (non-gluten) idiopathic 
ataxias) and 23 healthy control samples were assayed according to the methods detailed 
in sections 2.2.2 and 2.2.3.3.
3.2.1.4 Commercial anti-tissue transglutaminase IgA ELISA
A total o f 30 gluten ataxia (untreated), 33 CD without neurological complications 
(untreated), 25 ataxia control (a mixture of familial and sporadic (non-gluten) idiopathic 
ataxias) and 42 healthy control samples were assayed according to the methods detailed 
in sections 2.2.2 and 2.2.4.
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3.3 Results
3.3.1 Inter- and Intra-assay variability
The average inter- and intra-assay variability for each commercial ELISA kit type is 
shown in table 3.2.
3.3.2 In-house anti-gliadin antibody ELISA
Data from both the IgG and IgA anti-gliadin ELISAs are summarised in figures 3.1 and
3.2 respectively using box and whisker plots. Table 3.3 shows how this data compares 
to that obtained using commercial kits to assay the same samples. In both IgG and IgA 
assays, the median values o f each group followed a similar pattern in both the in-house 
and kit ELISAs (figures 3.1 & 3.2 vs 3.4 & 3.6 respectively). The median IgG anti- 
gliadin antibody levels o f both the gluten ataxia and CD only groups (0.73 and 1.03 OD 
units respectively) were higher than either the ataxia or healthy control groups, which 
had similar median levels (0.37 and 0.39 OD units respectively) (figure 3.1). The 
patients with CD only, also had a higher median IgA anti-gliadin value than any other 
group (0.89 OD units) whereas patients with gluten ataxia had a median level similar to 
that of the ataxia controls (0.05 and 0.06 OD units respectively). The median level of 
the healthy control group (0.20 OD units) was intermediate between these two values 
and the CD only group (figure 3.2).
Considerable variation was found between the actual OD values obtained with the in- 
house ELISA and those obtained using a commercial kit in both IgG and IgA assays 
(table 3.3). Although similar ODs were obtained for several samples (highlighted in 
grey), in some cases the difference was two-fold or more. In general, greater 
discrepancy was observed between IgA measurements than IgG. Variations between 
results followed an unpredictable pattern although both IgG and IgA OD values o f all 
normal control samples and the majority of ataxia control samples were consistently 
higher when determined using the in-house ELISA method. However, the overall 
average ODs o f all samples assayed using both the in-house ELISA and commercial 
ELISA kit methods were not significantly different (IgG, p = 0.61; IgA, p = 0.59).
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Table 3.2 The inter- and intra-assay variability for each type of commercial ELISA kit
ELISA
AVERAGE (%)
Inter-assay
variability
Intra-assay
variability
17 7
IgG anti-gliadin
(n=7) (n=7)
24 10
IgA anti-gliadin
(n=6) (n=6)
IgA anti-TG2 17 13
(n=7) (n=7)
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3.3.3 Commercial IgG anti-gliadin ELISA
According to the cut-off values supplied by the kit manufacturer, 76% of gluten ataxia 
samples were either positive or borderline positive for IgG anti-gliadin antibodies as 
compared to 82% of CD only samples, 2% healthy control samples and 0% of ataxia 
control samples. This is represented in figure 3.3, which illustrates the distribution of 
sample levels o f IgG anti-gliadin antibodies between groups. Samples from both 
control groups had similar ranges whereas samples from patients with gluten ataxia had 
the largest spread and those from patients with CD only had the smallest. The lowest 
level in each o f the control groups was much lower than that o f either the gluten ataxia 
or CD only groups (O.lU/ml compared to 0.8U/ml and 2.1U/ml respectively). The 
highest levels were greater in the gluten ataxia and CD only groups (31.9U/ml and 
67.47U/ml respectively) than either the ataxia (6.41U/ml) or normal (10.9U/ml) control 
groups. Also, a greater proportion of samples from the gluten ataxia and CD only 
groups had levels close to the positive/negative cut-off value than either o f the control 
groups.
The median value and inter-quartile range of each group, is shown in figure 3.4. 
Kruskal-Wallis analysis indicated a highly significant difference between groups 
(p<0.001). Median antibody levels o f gluten ataxia patients and patients with CD only 
were found to be significantly higher than both the normal and ataxia control patients 
(pO.OOl). Antibody levels o f patients with CD only were not significantly higher than 
those o f gluten ataxia patients (p>0.05).
3.3.4 Commercial IgA anti-gliadin ELISA
Using the cut-off values provided by the kit manufacturer, 25% of gluten ataxia samples 
were either positive or borderline positive as compared to 47% o f CD only samples, 4% 
healthy controls and 0% of ataxia control samples. The distribution o f all sample levels 
is represented in figure 3.5. More than half o f the control sample levels fell below 
measurable limits, a greater proportion than in the other groups. Additionally, samples 
from both control groups were spread over a smaller range than either the gluten ataxia 
or CD only samples, which had similar ranges. The highest levels o f the gluten ataxia 
and CD only groups were much higher (16.71U/ml and lOOU/ml respectively) than the 
highest level o f either the ataxia (2.07U/ml) or normal (5.97U/ml) controls.
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Figure 3.4 Summary of serum IgG anti-gliadin antibody levels of patients with gluten ataxia, coeliac disease only and ataxia and healthy 
controls
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of gluten ataxia and CD groups nor control groups were not significantly different from each other. Median level of each group is shown next 
to the corresponding plot.
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Figure 3.6 Summary of serum IgA anti-gliadin antibody levels of patients with gluten ataxia, coeliac disease only and ataxia and healthy 
controls
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control group, "kic k = p<0.001 compared to normal control group. 44=p<0.05 compared to gluten ataxia group according to non-parametric 
multiple comparison. Median levels of gluten ataxia and control groups were not significantly different from each other. Median level of each 
group is shown next to the corresponding plot.
The median antibody concentration of patients with CD only was significantly higher 
than in both the normal (PO.OOl) and ataxia control groups (PO.OOl) as well as the 
gluten ataxia group (P<0.05). Patients with gluten ataxia did not have significantly 
higher levels than either o f the control groups (P>0.05) (figure 3.6).
3.3.5 Commercial IgA anti-tissue transglutaminase ELISA
The distribution of levels is shown in figure 3.7. 40% of gluten ataxia patients, 94% of 
CD only patients, 24% of ataxia control patients and 19% of healthy controls were 
positive. Patients with gluten ataxia had the largest range o f antibody levels whereas 
the ataxia control samples had the smallest. Patients with CD only had a similar range 
to the normal controls, which was between the gluten ataxia and ataxia control group 
ranges. The lowest sample level was similar in each o f the gluten ataxia (2.32U/ml), 
ataxia control (2.76U/ml) and normal control (1.6U/ml) groups but was slightly higher 
in the CD only group (6.63U/ml). The highest level from the ataxia and normal control 
groups 21.1U/ml and 36.3U/ml respectively) were lower than that o f both the gluten 
ataxia and CD only groups (1227U/ml and 23000U/ml respectively).
Overall, the median IgA anti-TG2 antibody level o f patients with CD was significantly 
increased compared to all other patient groups, (P<0.001), including the gluten ataxia 
group (figure 3.8). Patients with gluten ataxia had a higher median level than normal 
control samples (PO.OOl).
3.3.6 Individual serum antibody profiles of patients with gluten 
ataxia
The individual serum levels of IgG and IgA anti-gliadin antibodies and IgA anti-TG2 
antibodies of each patient with gluten ataxia are summarised in table 3.4.
3.3.7 Correlation of serum antibody levels
A significant positive correlation was observed between the presence o f IgG anti-gliadin 
antibodies and the presence of IgA anti-gliadin antibodies in both patients with gluten 
ataxia (pO .05) and patients with CD without neurological complications (p<0.01) 
(figures 3.9 and 3.10 respectively). This association was not seen in either the ataxia 
control group or the healthy control group (data not shown). The presence o f either IgG
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Figure 3.8 Summary of patient serum IgA anti-tissue transglutaminase antibody levels of patients with gluten ataxia, coeliac disease only and ataxia 
and healthy controls
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non-parametric multiple comparison. Median levels of gluten ataxia and ataxia control groups were not significantly different from each other. 
Median level of each group is shown next to the corresponding plot.
Table 3.4 Summary of the individual serum levels of IgG and IgA anti-gliadin
antibodies and IgA anti-TG2 antibodies of each patient with gluten ataxia
Patient
num ber
IgG AGA level 
(U/ml)
IgA AGA level 
(U/ml)
IgA TG2 level 
(U/ml)
1 22.7 1.1 3.7
2 2.2 ND 7.1
3 20.4 0.8 2.3
4 3.1 8.4 Not assayed
5 24.6 4.7 13.3
6 7.4 6.7 Not assayed
7 12.9 11.8 1227
8 17.1 3.8 9.2
9 12.4 ND 10.9
10 12.2 0.4 14.8
11 9.6 13.6 10.7
12 11.5 1.0 5.7
13 7.1 7.5 7
14 12.1 ND 7.7
15 12.2 5.5 408
16 3.9 ND 7.1
17 6.6 ND 7.7
18 8.5 ND 6.3
19 4.4 ND 45.6
20 12.3 ND 9.3
21 7.5 0.4 13.9
22 0.8 ND 10.1
23 31.9 1.6 21.3
24 15.4 16.7 57.9
25 5.6 ND 7.5
26 11.9 0.2 7.4
27 9.9 1.0 8.0
28 11.2 1.0 15.3
29 10.8 5.0 2.7
30 21.1 4.7 5.9
31 1.3 ND 6.6
32 9.1 1.4 6.6
33 Not assayed Not assayed
Data expressed in arbitrary units (defined by the kit manufacturers). Patient number
corresponds to that in table 2.1. ND -  non-detectable (level too low to be detected). 
Samples highlighted in red are positive or borderline positive according to the kit cut­
off values.
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or IgA anti-gliadin antibodies was not significantly associated with the presence of IgA 
anti-TG2 antibodies in patients with gluten ataxia (figure 3.11) or any control patients 
(data not shown). However, the presence of IgA anti-gliadin antibodies in patients with 
CD without neurological complications was significantly associated with the presence 
o f IgA anti-TG2 antibodies (p<0.01) (figure 3.12).
3.3.7 Presence of IgG anti-gliadin antibodies in the CSF
None of the CSF samples tested were positive according to the kit threshold value 
(figure 3.13), all had higher levels than the normal CSF sample, which fell below the 
measurable limits o f the assay (data not shown). There was no correlation between 
serum level and CSF level, although all serum levels were higher than the 
corresponding CSF level.
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Figure 3.13 Comparison of serum and CSF IgG anti-gliadin antibody levels of patients with gluten ataxia
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3.4 Discussion
It is now well-established that CD is associated with the presence o f various circulating, 
gluten-driven antibodies, which are produced during the intestinal immune response 
against gluten. The majority of patients with CD have significantly increased levels of 
circulating antibodies directed against the primary aetiological agent, gluten (anti- 
gliadin antibodies) and also autoantibodies directed against the intestinal enzyme TG2. 
Measurement o f these antibodies plays a major role in the diagnosis and monitoring of 
the condition. In addition, increased serum levels o f these antibodies have been 
reported in patients with DH (Kumar et al., 2001; Reunala & Hallstrom, 1990) but, to 
date, the presence o f these antibodies in patients with gluten ataxia has not been 
comprehensively established.
In-house vs commercial anti-gliadin antibody ELISA
A comparison of in-house and commercial kit anti-gliadin ELISA methods found that, 
overall, commercial ELISA kits gave more reliable, reproducible results and the assay 
took less time, allowing more rapid screening of samples. Reproducibility o f the in- 
house anti-gliadin ELISA may have been affected by factors such as non-uniform 
coating o f the ELISA plate or slight variations in the concentration of the coating 
solution due to difficulties encountered related to the solubility o f crude gliadin. 
Although, the average results obtained from each o f the methods did not differ 
significantly (p>0.05), individual in-house ELISA results were often discordant to those 
obtained with the kit, by quite large margins on occasion. Discrepancies were 
unpredictable although generally the in-house method reported higher levels, 
particularly of control samples. These differences may be due to factors such as the use 
of higher concentrations of secondary antibody or the longer incubation times used in 
the in-house method. The median OD of healthy control samples, determined by the 
IgA anti-gliadin in-house assay, however, was considerably higher than expected. This 
is most likely due to the observed problems of assay reliability rather than a true 
reflection of sample levels as the levels of all healthy control samples were consistently 
lower when re-assayed using a commercial ELISA kit.
Commercial ELISA kit characteristics
The average ELISA kit intra-assay variabilities of each assay type were acceptable, the 
greatest being 13% in the case of the IgA anti-TG2 kit. However, the average inter­
assay variabilities were greater, ranging from 17-24%. These greater variations were
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found to be mainly due to the effects of one or two outlying values in each assay type, 
variations ranging from 13-15% with their exclusion. These outlying values may be 
attributable to slight differences in ambient conditions, such as temperature and light, 
occurring naturally between assays or kit batches. However, in each assay, all controls 
were within the specified ranges and assay results were considered valid.
Antibody levels o f patients with coeliac disease only
As expected, the patients with CD only, examined in this thesis, had significantly 
elevated levels o f circulating anti-gliadin antibodies (both IgG and IgA) as well as IgA 
anti-TG2 antibodies compared to both ataxia control and healthy control patients 
(pO.OOl). The most sensitive assay in these patients was the IgA anti-TG2 ELISA 
with 94% testing positive, a comparable value to the range o f 81-98% quoted in similar 
studies (Dahele et al, 2001; Dieterich et al., 1998; Kumar et al., 2001; Tursi et al., 
2003). In comparison, 82% and 47% of patients with CD only were positive for IgG or 
IgA anti-gliadin antibodies respectively, giving an overall total of 84% positive for IgG 
and/or IgA anti-gliadin antibodies. The finding that 82% of patients with CD were 
positive for circulating IgG anti-gliadin antibodies is comparable to the figure of 87% 
reported in a recent study, although the number o f patients in the current study positive 
for IgA anti-gliadin antibodies appears to be relatively low compared to the equivalent 
figure o f 61% in the same study (Dahele et al., 2001). However, previous findings of 
the sensitivity o f both IgG and IgA anti-gliadin ELIS As in untreated CD show wide 
variation (as illustrated in table 3.1). These differences may, in part, be due to 
differences in the positive/negative cut-offs of different assays. Alternatively, 
differences in gliadin peptides used to coat the plates or variation in patient selection 
have both been suggested as possible causes of such variation (Maki, 1995; Rossi & 
Tjota, 1995). The lower number o f CD patients positive for IgA anti-gliadin antibodies 
is consistent with the reported greater specificity o f these antibodies and the greater 
sensitivity o f IgG anti-gliadin antibodies for CD (Milford-Ward et al, 2001; Troncone 
& Ferguson, 1991). Finally, the two patients in this group who were negative for both 
IgA anti-TG2 antibodies and anti-gliadin antibodies may be part o f the small group of 
patients with CD who are seronegative for all circulating antibodies associated with the 
disease (Rostami et al, 1998).
Antibody levels o f control patients
In the current study, 2/43 (5%) healthy control samples were positive for IgG anti-
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gliadin antibodies and 1/23 (4%) healthy control samples was borderline positive for 
IgA anti-gliadin antibodies. No ataxia control patients were positive for anti-gliadin 
antibodies, an observation not consistent with the 8-15% of familial ataxia patients 
found to be positive for anti-gliadin antibodies in a recent study (Abele et al, 2003). 
However a prevalence o f anti-gliadin antibodies in familial ataxia patients, similar to 
healthy control values, has been confirmed by other studies (Hadjivassiliou et al, 
2003a) and it is likely that the numbers of patients in the current study were too small to 
confirm these observations. Although the significance o f circulating anti-gliadin 
antibodies in otherwise healthy individuals remains uncertain, both circulating IgG and 
IgA anti-gliadin antibodies have been reported in a small proportion o f otherwise 
healthy individuals with no apparent association with underlying CD (Troncone & 
Ferguson, 1991; Uibo et al, 1993). IgG anti-gliadin antibodies may also be found in 
patients with other GI disorders (Milford-Ward et al, 2001). Alternatively, these may 
represent cases of potential gluten sensitivity where the disorder is not yet fully 
apparent. One striking observation in the current study was the unexpectedly high 
numbers of both ataxia control and healthy control samples positive for IgA anti-TG2 
antibodies (24% and 19% respectively). These values compare with reported values of 
between 1% and 7% in other similar studies (Dahele et al, 2001; Dieterich et al, 1998; 
Kumar et al, 2001). It is unclear why the current values are so high although the 
differences may partially be explained by assay differences. H alf o f the positive 
samples (4/8) in the current study had levels between 10-13 U/ml, just above the kit 
positive cut-off of 10 U/ml or above and it is possible that these samples would have 
been recorded as negative by a different assay. The other 4 positive samples however 
had individual levels well above the cut-off value. A prevalence o f IgA anti-TG2 
antibodies has been reported in up to 7% of patients with other GI diseases (including 
irritable bowel syndrome and Crohn’s disease), a finding which is thought tp reflect the 
wide distribution o f TG2 throughout the GI tract (Dahele et al, 2001). IgA, IgG or IgM 
anti-TG2 antibodies, detected by ELISA, have also been reported in rheumatoid arthritis 
patients and systemic lupus erythematosus (SLE) patients as well as healthy controls 
(11%, 22% and 3% respectively) (Feighery et al, 2003). Therefore, it is possible that 
some o f the anti-TG2 antibody positive control patients had other co-existing conditions 
causing their positive results although it is unlikely that this alone would explain the 
high prevalence observed. The lack of corresponding positivity for anti-gliadin 
antibodies implies that undiagnosed gluten sensitivity is a possible but unlikely 
explanation for the increased levels of anti-TG2 antibodies although one o f the positive
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samples was also positive for IgG anti-gliadin antibodies, suggesting that this individual 
may actually have undiagnosed gluten sensitivity.
Antibody levels o f gluten ataxia patients
Patients with gluten ataxia were found to have significantly elevated levels of 
circulating IgG anti-gliadin antibodies, (p<0.05), and IgA anti-TG2 antibodies, 
(pO.OOl), compared to both ataxia controls and healthy controls. While not 
significantly different, individual levels of these antibodies in patients with gluten ataxia 
were generally not as high as those seen in patients with CD only. The IgG anti-gliadin 
antibody ELISA was the most sensitive assay in patients with gluten ataxia, a total of 
73% of patients were positive which is a similar proportion to the number o f patients 
with CD only. However, complete positivity was expected as, previously, all o f these 
patients had tested positive for IgG anti-gliadin antibodies during the diagnostic 
process. However, these assays were carried out in a different laboratory where a 
different method was initially used and occasionally, although all not on a GFD, 
samples taken from patients at differing time-points were used. The antibody levels of 
some patients with gluten ataxia have been found to fluctuate slightly whilst on a gluten 
containing diet (unpublished observations). A combination o f different methods and 
samples is the most likely reason for the discordance seen between results. Patients 
with gluten ataxia did not have significantly elevated levels o f circulating IgA anti- 
gliadin antibodies compared to both ataxia and healthy controls. These levels were 
significantly lower (p<0.05) than levels of circulating IgA anti-gliadin antibodies in 
patients with CD only. Only 25% of patients with gluten ataxia were positive for 
circulating IgA anti-gliadin antibodies, giving an overall total o f 79% of patients with 
gluten ataxia who were positive for either IgG and/or IgA anti-gliadin antibodies. This 
value is very similar to the corresponding value of 84% of patients with CD only. 
Conversely, and of note, was the large difference observed between the numbers o f 
patients positive for circulating IgA anti-TG2 antibodies in the gluten ataxia and CD 
only groups. Only 40% of gluten ataxia patients had increased levels o f these 
antibodies compared to 94% of patients with CD only. This value is also much lower 
than that found by Kumar and co-workers where all 33 examined DH patients were 
positive for circulating IgA anti-TG2 antibodies, an even greater number than the 91% 
of patients with CD only in the same study who were found to be positive (Kumar et al., 
2001). The lower proportion o f IgA anti-gliadin and anti-TG2 antibody positive 
patients with gluten ataxia compared to those with CD only may be explained by the
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relative intestinal involvement. Several recent studies have reported the much lower 
sensitivity o f anti-gliadin and anti-TG2 assays in detecting patients with mild intestinal 
damage (Rostami et al, 2003; Tursi et al, 2001, 2003). Although numbers were small, 
Tursi and co-workers found that no patients with a Marsh I intestinal lesion were 
positive for anti-gliadin antibodies and only 8% were positive for anti-TG2 antibodies 
(Tursi et al, 2001, 2003). The majority o f patients with gluten ataxia have either Marsh 
0 or Marsh I lesions, however no correlation was observed between a positive biopsy 
suggestive o f CD associated changes (i.e. degree o f mucosal damage) and antibody 
levels in patients with gluten ataxia. In general, patients with gluten ataxia have less 
mucosal damage than patients with CD only. Therefore, it seems possible that fewer 
are likely to be classified positive for these antibodies using positive/negative thresholds 
designed to detect patients with more severe mucosal damage. This has implications for 
the detection o f patients with gluten ataxia, using such cut-off values, where anti-gliadin 
antibody screening is central to diagnosis. The ELISA kits are designed to detect 
patients with CD whose antibody titres may be up to ten times greater then those seen in 
normal individuals (Milford-Ward et al, 2001) and the cut-off values are determined 
accordingly. It cannot be assumed that this is also true o f gluten sensitive patients 
where bowel involvement is not the primary manifestation, as demonstrated by the 
findings of the current study. Closer inspection of individual antibody levels shows that 
a larger number o f IgG and IgA anti-gliadin antibody negative gluten ataxia samples 
have values that are much closer to the cut-off value than do either o f the control group 
samples which tend to lie well below the threshold. Therefore, a number o f patients 
with gluten ataxia, who have elevated disease associated antibodies compared to healthy 
controls, will be missed by the high cut-off threshold and the resulting negative status 
misleading (i.e. there is a reduced sensitivity of these assays for the diagnosis o f gluten 
ataxia). It is suggested that closer examination of relative levels is necessary in the 
detection o f patients with gluten ataxia rather than a sole reliance on positive/negative 
status assigned by kits designed for patients with CD. Further such considerations arise 
when comparing results from different laboratories and countries. The number of 
healthy individuals positive for anti-gliadin antibodies varies between populations and 
is used in the calculation o f kit thresholds, which therefore vary somewhat between 
geographical regions. Normally, this slight variation has no effect on the assay result as 
patient levels are so much higher than healthy controls. However, in the case of patients 
with gluten ataxia, where levels are generally lower, this effect will be more pronounced 
leading to more gluten ataxia patients being classified as negative in some regions and
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laboratories than others. This is likely to contribute to the varied reports o f the 
prevalence o f IgG anti-gliadin antibodies in patients with sporadic ataxia, which have 
ranged from 11.5% in Germany to 41% in the UK (Burk et al, 2001a; Hadjivassiliou et 
al, 2003a). There is, therefore, a possible risk of significant under-diagnosis o f gluten 
ataxia in these populations.
Correlation o f antibody levels
Levels of IgG and IgA anti-gliadin antibodies were positively correlated in both patients 
with CD only (p<0.01) and patients with gluten ataxia (p<0.05). The weaker correlation 
in patients with gluten ataxia may be due to the lesser intestinal involvement resulting in 
lower levels o f IgA anti-gliadin antibodies, which have been reported to be more closely 
correlated with intestinal damage (Troncone & Ferguson, 1991). In addition, in patients 
with CD only, but not patients with gluten ataxia, IgA anti-gliadin levels were positively 
correlated with IgA anti-TG2 levels (pO .Ol). This too, may be related to intestinal 
involvement as levels o f anti-TG2 antibodies are reportedly correlated with the severity 
of mucosal damage (Tursi et al, 2003).
In conclusion, the main findings of this study were that commercial anti-gliadin 
antibody ELISA kits have better reliability and reproducibility, as well as greater ease of 
use than the in-house assay. Consistent with previous reports (Hadjivassiliou et al, 
2003a), circulating IgG anti-gliadin antibodies are the most sensitive marker o f gluten 
sensitivity in patients with gluten ataxia. However, using the high cut-off values of 
commercial ELISA kits, designed for the detection o f patients with CD, may miss 
gluten sensitivity in patients with gluten ataxia who frequently have lower, although 
elevated, levels of circulating gluten sensitivity associated antibodies.
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CHAPTER FOUR
INVESTIGATION OF THE CEREBELLAR 
REACTIVITY OF CIRCULATING 
ANTIBODIES IN PATIENTS WITH GLUTEN 
ATAXIA BY IMMUNOHISTOCHEMISTRY
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4.1 Introduction
Neuropathological findings in patients with gluten ataxia have shown the cerebellum to 
be the predominantly affected area. Within the cerebellum, Purkinje cells appear to be 
particularly susceptible to damage with the result of complete loss of these cells (figure 
4.1) (Hadjivassiliou et al., 1998). Preliminary evidence suggests that this damage is 
immune-mediated (section 1.12.3.2). As described in the previous chapter, patients 
with gluten ataxia all possess circulating anti-gliadin antibodies and a large proportion 
also possess circulating anti-TG2 antibodies.
These features are reminiscent of conditions such as paraneoplastic neurological 
syndromes, which arise as the indirect result o f a malignancy. It is believed that an 
immune response, directed against tumour antigens which are normally only found in 
neurones, is mounted and the resultant cross-reactive immune response with neural 
tissue is responsible for the observed damage and clinical signs (Darnell & Posner, 
2003; Sutton & Winer, 2002). Often, the resulting neurological dysfunction results 
before the discovery o f any underlying tumour (Darnell & Posner, 2003; Sutton & 
Winer, 2002). Several o f these syndromes have antigenic targets within the cerebellum 
where the immune response gives rise to similar symptoms to those seen in gluten 
ataxia and total Purkinje cell loss is often observed. This is known as paraneoplastic 
cerebellar degeneration (PCD). Patients possess antibodies against different cerebellar 
antigens in their serum and CSF, depending on the site o f the tumour. Patients 
presenting with PCD most commonly possess antibodies against cdr 62 and 34 proteins 
(also termed Yo) (resulting from ovarian and breast carcinomas) but also against 
voltage-gated calcium channels (resulting from small cell lung cancer) and glutamate 
receptors (resulting from Hodgkins’s disease) (Mason et al, 1997; Peterson et al., 1992; 
Sillevis Smitt et al, 2000). There is some evidence to suggest that these antibodies may 
be considered pathogenic in the development of PCD (Fukunaga et al, 1983; Lang et 
al, 1983; Okano et al, 1999; Sillevis Smitt et al, 2000).
The knowledge o f pathogenic antibodies involved in conditions sharing certain 
similarities with gluten ataxia, such as PCD, suggests it is conceivable that the 
circulating gluten sensitivity-associated antibodies present in patients with gluten ataxia 
may have a similar pathogenic role. Interestingly, TG2 is expressed in the cerebellum 
(Perry et al, 1995) as well as in numerous different neural tissues including peripheral 
nerve, spinal cord and the forebrain (Hand et al, 1993). Significant TG2 reactivity
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Figure 4.1 Haematoxylin and eosin stain of a section of the cerebellar cortex o f a 
patient with gluten ataxia
Iw JlC4? >** « '*iVift J
G
A paraffin-embedded section of post-mortem cerebellar tissue from a patient with 
gluten ataxia. The loss of Purkinje cells is particularly evident (Purkinje cell layer 
indicated by arrows).
M -  molecular layer G -  granular layer 
Photograph courtesy o f Dr. M. Hadjivassiliou.
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has been reported in areas such as the cerebellum, white matter, hippocampus and the 
frontal and temporal neocortex (Gilad & Varon, 1985; Johnson et al., 1997). Recent 
research has shown that TG2 may play a role in neurodegenerative diseases such as 
Alzheimer’s and Huntington’s disease via a variety o f different means (Lesort et al, 
2000). In addition, increased levels of TG2 have been reported in both o f these diseases 
(Johnson et al, 1997; Lesort et al, 1999).
4.1.1 Aims of this study
With knowledge o f other disorders involving immune-mediated cerebellar damage, 
where pathogenic antibodies play a role in the disease process, and the knowledge that 
patients with gluten ataxia possess circulating disease-associated antibodies, the overall 
aim of this study was to investigate the cerebellar reactivity of these antibodies, using 
IHC. Particular consideration was paid to the involvement o f Purkinje cells, which 
appear the most susceptible to damage. This aim was achieved by completion of 
several separate objectives, detailed below:
o Overall assessment of cerebellar reactivity of the serum from patients with gluten
ataxia by a titration study o f patient serum samples. This had two objectives.
Firstly, to assess and compare the pattern of cerebellar staining by serum antibodies 
from different patient groups and, secondly, to investigate the serological titres of 
anti-cerebellar antibodies in each of these groups, 
o To determine whether a correlation exists between the levels of circulating anti- 
gliadin or anti-TG2 antibodies and the intensity or persistence o f serum reactivity to 
cerebellar tissue.
o Comparison of the cerebellar staining pattern by serum antibodies from patients 
with gluten ataxia with those of other cerebellar proteins o f interest (TG2 and Yo) to 
assess any similarities or differences, 
o Investigation o f the cross-reactive potential o f anti-gliadin antibodies (present in all
patients with gluten ataxia) with cerebellar tissue using a commercially available 
polyclonal antibody and pre-adsorption o f anti-gliadin antibodies from gluten ataxia 
serum samples to determine whether these antibodies are responsible for the 
cerebellar staining pattern, 
o Preliminary investigation of the cerebellar reactivity o f CSF samples from patients 
with gluten ataxia and healthy control patients.
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4.2 Methods
4.2.1 Titration study of patient serum samples
4.2.1.1 Human tissue
Staining was investigated using human cerebellar sections, using the indirect IHC 
method outlined in sections 2.3.2 and 2.3.4. The method was initially optimised in 
order to achieve good delineation of specific versus non-specific staining (data not 
shown). A total o f 5 gluten ataxia (untreated), 5 CD without neurological complications 
(untreated), 5 ataxia controls (including both familial and sporadic cases) and 5 healthy 
control serum samples were used as the primary antibody at dilutions o f 1 TOO, 1:200, 
1:400,1:800, 1:1600 and 1:3200. In each staining run, serum samples from each group 
were used in order to minimise inter-experiment variation. Sections incubated with a 
Purkinje cell specific antibody (monoclonal anti-calbindin D28K, table 4.1), diluted in 
PBST, were included as a positive control. Calbindin is a member o f the family of EF- 
hand calcium binding proteins and is believed to function as a calcium buffer 
(Schwaller et al, 2002). It is useful as a Purkinje cell marker as it is present in Purkinje 
cells at all stages of development and not present in any other cerebellar cells 
(Schwaller et al, 2002). It is also very soluble and present throughout Purkinje cells 
facilitating visualisation o f the cell shape and structure (Baimbridge et al, 1992). 
Sections incubated with PBST as a substitute for primary antibody were included as 
negative controls. Details of secondary antibodies used are given in table 4.1.
Semiquantitative evaluation o f the staining intensity was performed independently by 
three blinded observers. Weak or strong positive staining was recorded if  Purkinje cell 
staining was above background levels and negative staining was recorded if  Purkinje 
cell staining did not exceed background levels. The number o f unanimous agreements 
between observers with regards to positivity/negativity o f staining and strength of 
staining was calculated as a percentage of the total number o f observations and quoted 
as a measure o f inter-observer variability. In situations where classification was not 
unanimous, the majority classification was recorded. In the instance o f staining on a 
particular section being classified differently by each observer (eg. weak, strong, 
negative), the staining was re-evaluated. Finally, for each patient, the corresponding 
levels o f circulating anti-gliadin (IgG & IgA) and anti-TG2 (IgA) antibodies were 
correlated with the last dilution where positive staining was observed and also the last 
dilution where strong positive staining was observed to determine whether circulating
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antibodies were correlated with either of these measurements. Correlation was 
determined using the Spearman rank-order correlation.
4.2.1.2 Rat tissue
The research group o f Dr. E. Tongiorgi, at the University of Trieste in Italy, 
investigated the staining of rat cerebellar tissue by serum samples from the Sheffield 
study as part o f an ongoing collaboration. This was done to confirm the results obtained 
from the parallel study on human tissue (section 4.2.1.1). Following cervical 
dislocation, brains from adult Sprague-Dawley rats were removed and fresh-frozen on 
dry-ice, sectioned in a cryostat (Leica, Italy) and 10-pm saggital sections collected on 
gelatin-coated slides (Sigma, UK). Staining was carried out using the indirect IHC 
method outlined in section 2.3.4. A total o f 10 gluten ataxia (untreated), 19 CD without 
neurological complications (untreated), 6 ataxia control and 12 healthy control serum 
samples were used as the primary antibody at dilutions of 1:100, 1:300 and 1:600. In 
addition, 3 o f the serum samples from patients with gluten ataxia were tested at 
dilutions of 1:1200 and 1:1500. Details of secondary antibodies used are given in table 
4.1.
Semiquantitative evaluation of the staining intensity was performed independently by 
two blinded observers. Weak or strong positive staining was recorded if  Purkinje cell 
staining was above background levels and negative staining was recorded if Purkinje 
cell staining did not exceed background levels.
4.2.2 Investigation of the cerebellar staining patterns of known 
cerebellar proteins (tissue transglutaminase and Yo)
Details o f all primary and secondary antibodies used in this study are given in tables 4.2 
and 4.3. In all experiments, sections incubated with either a Purkinje cell specific 
antibody (as described in section 4.2.1.1) or PBST as a substitute for primary antibody 
were included as positive and negative controls. Again, methods were optimised 
initially in order to achieve the best results for each antibody used (data not shown).
The staining pattern o f commercially available anti-TG2 antibody against rat cerebellar 
tissue was investigated using the indirect IHC method, outlined in sections 2.3.2 and
2.3.4.
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Table 4.1 Details o f the specificity, supplier and dilution o f primary and secondary 
antibodies used in the serum titration study
Antibody
Specificity
Species
(supplier)
D ilution C orrespond ing  
Secondary antibody
Secondary
antibody
dilution
Monoclonal
anti-Calbindin
D-28K
Mouse IgGl anti- 
bovine kidney 
calbindin 
(Sigma, UK)
1:200
HRP
Conjugated goat anti-mouse 
IgG
(Jackson Immunoresearch 
Laboratories, USA  (UK  
distributor, Stratech))
1:500
Patient serum 
(Human 
tissue)
- 1:100 to 
1:3200
HRP
Conjugated goat anti-human 
IgG
(Jackson Immunoresearch 
Laboratories, U SA  (UK  
distributor, Stratech))
1:500
Patient serum 
(Rat tissue)
1:100 to 
1:1500
HRP
Conjugated goat anti-human 
IgG
(Jackson Immunoresearch 
Laboratories, USA (UK  
distributor, Stratech))
1:200
Table 4.2 Details o f reagents used in the indirect IHC study o f antibodies directed 
against known cerebellar proteins
Antibody
Specificity
Species
(supplier)
D ilution C orrespond ing  
Secondary antibody
Secondary
antibody
dilution
Monoclonal
anti-TG2 Mouse IgG anti­
guinea pig TG2 
(Labvision, USA)
1:50, 
1:100,1:500 (rat 
tissue)
HRP
Conjugated goat anti­
mouse IgG 
(Jackson Immunoresearch 
Laboratories, USA (UK  
distributor, Stratech))
1:500
Yo positive 
serum 2
Obtained from the 
Neurology 
Department, The 
Royal Hallamshire 
Hospital, Sheffield, 
UK
1:400,1:800  
(rat tissue)
HRP
Conjugated goat anti­
human IgG 
(Jackson Immunoresearch 
Laboratories, U SA (UK  
distributor, Stratech))
1:500
Table 4.3 Details o f reagents used in the avidin-biotin peroxidase IHC study of 
antibodies directed against known cerebellar proteins
Antibody
Specificity
Species
(supplier)
D ilution C orrespond ing  
blocking agent
C orrespond ing  
secondary antibody
Yo positive 
serum 1
Kindly donated 
by Dr N  
Gregson, GKT 
London, UK
1:150000 
(rat & human 
tissue)
Goat serum 
3:200 
(Vector Laboratories, 
UK)
Biotinylated goat anti­
human IgG 1:200 
(Vector Laboratories, 
UK)
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The staining patterns of two, anti-Yo antibody positive serum samples, from patients 
with PCD, against rat cerebellar tissue were investigated. Additionally, the reactivity of 
PCD serum sample 1 against human cerebellar tissue was also investigated using the 
avidin-biotin amplified IHC method described in sections 2.3.2 and 2.3.3. PCD serum 
sample 2 was investigated using the indirect IHC method described in sections 2.3.2 and
2.3.4.
4.2.3 Investigation of the cerebellar staining pattern of commercial 
anti-gliadin antibody with/without pre-adsorption with crude 
gliadin
Rabbit polyclonal horseradish peroxidase-conjugated anti-gliadin antibody (Sigma, UK) 
was used at dilutions of 1:100,1:200,1:400, 1:800,1:1600,1:3200,1:64000,1:128000 
and 1:256 000 on human cerebellar tissue and at dilutions o f 1:100, 1:200, 1:400 ,1:800, 
1:1600 and 1:3200 on rat cerebellar tissue. The antibody was diluted in PBST or a 
saturated crude gliadin (Sigma, UK) solution (~20mg/ml) made up in PBST. The crude 
gliadin solution was prepared by crushing crude gliadin into a fine powder using a 
pestle and mortar before adding the required weight to the correct amount of PBST.
The resulting solution was stirred on a magnetic stirrer whilst being heated gently for 
approximately 15mins. It was ensured that the temperature o f the solution did not rise 
above 60°C to avoid denaturation o f the gliadin. Once diluted with either PBST or 
crude gliadin solution, the commercial anti-gliadin antibody was left for lhour at RT to 
allow adsorption of anti-gliadin antibodies in the sample. Following adsorption, 
indirect IHC staining was performed, using the methods described in sections 2.3.2 and
2.3.4 but with omission of the secondary antibody incubation step as the anti-gliadin 
antibody was peroxidase-conjugated. Sections incubated with either a Purkinje cell 
specific antibody diluted in PBST (as described in section 4.2.1.1) or PBST as a 
substitute for primary antibody were included as positive and negative controls.
Sections incubated with crude gliadin solution only were included as an additional 
negative control.
The effectiveness of adsorption of anti-gliadin antibodies was confirmed using 
commercial IgG and IgA anti-gliadin antibody ELISAs, carried out according to the 
methods described in sections 2.2.2, 2.2.3.2 and 2.2.3.3. Anti-gliadin antibody was 
diluted 1:800 in PBST or crude gliadin solution (~20mg/ml, prepared as detailed in
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section 4.2.3) and incubated for 60mins at RT to allow adsorption of antibodies. 
Samples were then assayed and the results compared.
4.2.4 Investigation of the cerebellar staining pattern of patient serum 
with/without pre-adsorption with crude gliadin
A total of 4 gluten ataxia (untreated), 3 CD without neurological complications 
(untreated) and 2  healthy control serum samples were used at dilutions o f 1:200  and 
1:800 on human cerebellar tissue. An additional 2 gluten ataxia (untreated), 2 CD 
without, neurological complications (untreated), 2  ataxia controls and 2  healthy control 
serum samples were used at a dilution o f 1:400 on rat cerebellar tissue. Serum samples 
were diluted to the appropriate dilution in PBST or a saturated crude gliadin (Sigma, 
UK) solution (~20mg/ml) made up in PBST. The crude gliadin solution was prepared 
as in section 4.2.3. Once diluted with either PBST or crude gliadin solution, serum 
samples were left for lhour at RT to allow adsorption o f anti-gliadin antibodies in the 
sample. Following adsorption, indirect IHC staining was performed, using the methods 
described in sections 2.3.2 and 2.3.4. HRP-conjugated goat anti-human IgG (Jackson 
Immunoresearch Laboratories, USA (UK distributor, Stratech), diluted 1:500 in PBST 
was used as the secondary antibody. Sections incubated with either a Purkinje cell 
specific antibody diluted in PBST (as described in section 4.2.1.1) or PBST as a 
substitute for primary antibody were included as positive and negative controls.
Sections incubated with crude gliadin solution only were included as an additional 
negative control.
The effectiveness o f adsorption of serum anti-gliadin antibodies was confirmed using 
commercial IgG and IgA anti-gliadin antibody ELISAs, using 2 serum samples from 
each group, carried out according to the methods described in sections 2.2.2, 2.2.3.2 and 
2.2.3.3. Samples were diluted in PBST or crude gliadin solution (~20mg/ml, prepared 
as detailed in section 4.2.3) and incubated for 60mins at RT. Following incubation, 
samples were assayed and the results compared.
4.2.5 Investigation of the cerebellar staining pattern of patient CSF
A preliminary investigation of the staining pattern o f CSF samples from 2 patients with 
gluten ataxia and 1 healthy control patient, on human cerebellar tissue, was performed 
using the indirect IHC methods described in sections 2.3.2 and 2.3.4. CSF samples 
were diluted in PBST and used at dilutions of 1:50, 1:100, 1:200 and 1:400. HRP-
126
conjugated goat anti-human IgG (Jackson Immunoresearch Laboratories, USA (UK 
distributor, Stratech), diluted 1:500 in PBST was used as the secondary antibody. 
Sections incubated with either a Purkinje cell specific antibody diluted in PBST (as 
described in section 4.2.1.1) or PBST as a substitute for primary antibody were included 
as positive and negative controls.
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4.3 Results
4.3.1 Titration study of serum samples on human cerebellar tissue
4.3.1.1 Inter-observer variability
Complete agreement between all 3 independent observers with respect to whether 
staining was negative or positive was overall 59%. Complete agreement with regards to 
whether positive staining was weak or strong was overall 78%.
4.3.1.2 Study controls
Consistently strong staining o f Purkinje cells was seen using anti-calbindin D28k 
(figure 4.2a) as a positive control. Sections incubated with PBST, in the absence o f 
primary antibody, showed consistently negative Purkinje cell staining (figure 4.2b).
4.3.1.3 Serum reactivity
Typical staining patterns, at all dilutions, o f sera from patients with untreated gluten 
ataxia are shown in figures 4.3 and 4.4. In 4 o f 5 sera (80%) from patients with 
untreated gluten ataxia, positive staining o f Purkinje cells was seen at all dilutions up to 
1:800. At dilutions o f 1:800 positive Purkinje cell staining was seen in only 40% of 
sera from patients with CD only and 20% of sera from each o f the ataxia and healthy 
control groups. In 4 o f the 5 gluten ataxia sera, staining was classified as strong at some 
dilution. Strong staining was seen in 1 o f the 4 sera up to a dilution o f 1:100, in 2 o f the 
4 sera up to a dilution o f 1:400 (figure 4.4) and up to a dilution o f 1:800 in the last o f 
the 4 sera (figure 4.3). The remaining serum sample showed positive staining at all 
dilutions up to 1:400 but at no dilution was the staining classified as strong. Positive 
staining did not persist in any sera from patients with untreated gluten ataxia above a 
dilution o f 1:800.
Typical staining patterns, at all dilutions, o f sera from patients with untreated CD 
without neurological complications are shown in figures 4.5 and 4.6. Sera from all 5 
patients in this group showed positive staining at a dilution o f 1:100. Staining was 
classified as strong in 4 o f 5 sera at this dilution. In 3 o f 5 sera, positive staining was 
not observed above 1:100 (figure 4.6). In one patient strong staining persisted to a 
dilution o f 1:400 (figure 4.5) and in another weak staining persisted to a dilution of 
1:800.
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Figure 4.2 Immunohistochemical staining of positive and negative control
sections from the titration study of serum samples on human cerebellar 
tissue
a. Positive control
' :•<••• ■ j >• yy; wj' ; . •
■ . • • ••-•-. _ ■ Q'£ :______-__ ;__ ' • - ___ ' L
b. Negative control
The Purkinje-cell specific anti-calbindin D28K antibody was used as a positive control 
(a.) at a dilution of 1:200. PBST, as a substitute for primary antibody, was used as a 
negative control (b.). G - granular layer; P - Purkinje cell layer; M - molecular layer. 
Purkinje cells are indicated by arrows. Scale bar = 100pm
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Figures 4.5 and 4.6 show the typical staining pattern, on human cerebellar tissue, by sera from patients with coeliac disease only. Serum was used at
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Figure 4.5 Reactivity, at increasing dilutions, of sera from a patient with coeliac disease only on control human cerebellum
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Typical staining patterns, at all dilutions, o f sera from ataxia control patients are shown 
in figures 4.7 and 4.8. Positive Purkinje cell staining was seen in all 5 sera from ataxia 
control patients at a dilution o f 1:100  but was only classified as strong in two of these 
samples (figure 4.8). Staining persisted in 2 patients to a dilution o f 1:400 (figure 4.8), 
remaining strong until 1:200  in one, and to a dilution o f 1:200  in another.
Typical staining patterns, at all dilutions, o f sera from healthy control patients are 
shown in figures 4.9 and 4.10. Sera from 4 o f 5 healthy control patients showed 
positive Purkinje cell staining at a dilution o f 1:100 (figures 4.9 & 4.10). In two sera, 
this staining persisted to a dilution o f 1:200 (figures 4.9 & 4.10) and persisted to 1:400 
and 1:800 in the remaining 2 samples. At no dilution was any staining classified as 
strong. The remaining serum sample showed no positive Purkinje cell staining at any 
dilution.
The reactivity and intensity o f staining of all serum samples tested is summarised in 
tables 4.4 and 4.5.
4.3.1.4 Correlation between human cerebellar staining and circulating levels of 
gluten sensitivity associated antibodies
No correlation was observed (p>0.05), in any patient group, between persistence o f 
Purkinje cell staining and the titres o f either circulating anti-gliadin antibodies (IgG or 
IgA) or IgA anti-TG2 antibodies (data not shown).
No correlation was observed (p>0.05), in any o f the groups, between the strength o f 
Purkinje cell staining and the titres of either circulating anti-gliadin antibodies (IgG or 
IgA) or IgA anti-TG2 antibodies (data not shown).
4.3.2 Titration study of serum samples on rat cerebellar tissue
Sera from 9 o f 10 patients with untreated gluten ataxia showed strong staining of 
Purkinje cells at 1:100,1:300 and 1:600 dilutions. None o f the subset of sera from 3 
patients with untreated gluten ataxia showed any recognisable staining at a dilution o f 
1:1200. Sera from 4 o f 12 healthy control subjects showed weak staining at a dilution 
o f 1:100 with no further staining detected at higher dilutions. No staining was seen 
using serum from 6 control patients with ataxia. The sera from 5 o f 19 patients with CD 
without neurological complications showed strong staining o f Purkinje cells at dilutions 
o f 1:100 and 1:300 but this became weak staining at 1:600.
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Table 4.4 Summary o f individual staining patterns at all dilutions, on human cerebellar 
tissue, by sera used in the serum titration study
Serum dilution — 1:100 1:200 1:400 1:800 1:1600 1:3200
Patient group 
(Patient n o ).^
”;•*/*'*'•
GA (17) S S s w N N
GA (34) s w w w N N
GA (1) s s s s N N
GA (15) s s s w N N
GA (8) w w w N N N
CD w N N N N N
CD s s s N N N
CD s N N N N N
CD s W W W N N
CD s N N N N N
AC w W N N N N
AC s N N N N N
AC s W W N N N
AC w N N N N N
AC s S ‘ W N N N
HC w W N N N N
HC N N N N N N
HC w W W W N N
HC w W W N N N
HC w w N N N N
KEY to staining:
S - Strong, positive Purkinje cell staining 
(shaded)
W - Weak, positive Purkinje cell staining 
N - Negative Purkinje cell staining
KEY to groups:
GA -  Gluten ataxia, untreated 
CD -  Coeliac disease without 
neurological complications 
AC -  Ataxia controls 
HC -Healthy controls
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Table 4.5 Summary o f positive and strong positive staining patterns, on human 
cerebellar tissue, by sera used in the serum titration study
A. Summary o f positive Purkinje cell staining
G roup sera (n=5)
D ilutions and percentage o f  positive Purkinje cell stain ing
1:100 1:200 1:400 1:800 1:1600 1:3200
Gluten ataxia, untreated 100% 100% 100% 80% 0% 0%
Coeliac disease, no neurology 100% 40% 40% 20% 0% 0%
Ataxia controls 100% 60% 40% 0% 0% 0%
Healthy controls 80% 80% 40% 20% 0% 0%
B. Summary of strong positive Purkinje cell staining
D ilutions and percentage o f  strong positive Purkinje cell stain ing
G roup sera (n=5) 1:100 1:200 1:400 1:800 1:1600 1:3200
Gluten ataxia, untreated 60% 60% 60% 20% 0% 0%
Coeliac disease, no neurology 80% 20% 20% 0% 0% 0%
Ataxia controls 60% 20% 0% 0% 0% 0%
Healthy control subjects 0% 0% 0% 0% 0% 0%
n = number o f serum samples assessed
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Weak staining was seen in 9 patients at all dilutions and no staining was seen in the 
remainder. These results are summarised in table 4.6. (Data provided by Dr. E. 
Tongiorgi).
Table 4.6 Summary o f positive and strong positive staining patterns, on rat 
cerebellar tissue, by sera used in the serum titration study
A. Summary o f positive Purkinje cell staining
Dilutions and percen tage o f  positive Purkinje cell stain ing
Group sera (n) 1:100 1:300 1:600
Gluten ataxia, untreated (10) 90% 90% 90%
Coeliac disease, no neurology (19) 68% 68% 68%
Ataxia controls (6) 0% 0% 0%
Healthy controls (12) 33% 0% 0%
B. Summaiy o f strong positive Purkinje cell staining
Dilutions and percen tage o f positive Purkinje cell stain ing
Group sera (n) 1:100 1:300 1:600
Gluten ataxia, untreated (10) 90% 90% 90%
Coeliac disease, no neurology (19) 26% 26% 0%
Ataxia controls (6) 0% 0% 0%
Healthy controls (12) 0% 0% 0%
n = number o f serum samples assessed
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4.3.3 Staining patterns of anti-tissue transglutaminase and anti-Yo 
antibodies on rat and human cerebellar tissue
The first serum sample from one o f two patients with PCD, positive for anti-Yo 
antibodies, was used on both rat and human cerebellar tissue and the staining pattern 
was found not to differ. The staining pattern o f the sample on human cerebellum is 
shown in figure 4.1 la. Even at a dilution o f 1:150,000, strong, specific, grainy 
cytoplasmic staining o f Purkinje cells is evident. No other area appears stained. The 
second sample, only used on rat cerebellar tissue, differed slightly in its staining pattern. 
At both dilutions o f 1:400 and 1:800 used, approximately 50% of Purkinje cells were 
uniformly, cytoplasmically stained in a pattern similar to that o f the previous anti-Yo 
positive serum sample tested. However, the remainder o f Purkinje cell staining was 
primarily membranous with varying degrees o f cytoplasmic staining (figure 4.1 lb).
The staining pattern o f commercial, monoclonal anti-TG2 antibody was investigated on 
both rat and human cerebellum. Staining patterns were similar on both tissues but 
positive staining was only seen at a dilution o f 1:50. Figure 4.1 lc  shows the staining on 
human cerebellum at an antibody concentration o f 1:50. In contrast to the other 
antibodies investigated, anti-TG2 antibodies appeared not to specifically stain Purkinje 
cells but instead a weak, diffuse staining pattern was present throughout the tissue.
4.3.4 Reactivity of commercial anti-gliadin antibody with cerebellar 
tissue with/without pre-adsorption with crude gliadin
The staining pattern o f commercial anti-gliadin antibody, at all dilutions used, differed 
slightly between rat and human cerebellar tissue. The main difference was that, on rat 
tissue the antibody positively stained the majority o f Purkinje cells with uniform 
intensity throughout the cytoplasm and membrane o f the cell. Although most Purkinje 
cells within human tissue were also stained with a similar pattern, a few exhibited 
stronger membranous or peri-nuclear staining.
Commercial polyclonal anti-gliadin antibody was found to stain rat cerebellar tissue at 
all dilutions up to, and including, 1:1600. Staining was not observed using the antibody 
at a dilution o f 1:3200. Staining was present throughout the tissue but particularly 
within the granular layer and Purkinje cells. The antibody positively stained the
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Figure 4.11 Staining patterns of anti-Yo and anti-tissue transglutaminase antibodies on 
control cerebellum
Typical staining patterns of serum from an anti-Yo antibody positive patient with PCD, 
diluted to 1:150000, (a, human control cerebellum); serum from a second anti-Yo 
antibody positive patient with PCD, diluted to 1:800, (b, rat control cerebellum) and 
commercial anti-TG2 antibody, diluted to 1:50, (c, human control cerebellum).
Purkinje cells are indicated by arrows. Scale bar = 100pm.
M -  molecular layer G -  granular layer.
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majority o f Purkinje cells with uniform intensity throughout the cytoplasm and 
membrane o f the cell (figure 4.12). This staining was most intense at lower dilutions 
and lessened in intensity as the antibody was used at higher dilutions. The antibody was 
found to stain rat cerebellar tissue at an optimal dilution o f 1:800 (figure 4.12f).
Staining with commercial anti-gliadin antibody at a dilution o f 1:400 and 1:800 was 
abolished following adsorption o f the antibody for lh r with crude gliadin (figures 4.12d 
& 4.12h respectively). At dilutions o f up to 1:400, staining was progressively 
decreased, but not completely eliminated, following adsorption of the antibody with 
crude gliadin.
Commercial anti-gliadin antibody was found to stain human cerebellar tissue in a 
similar manner to rat cerebellum. Positive staining o f the tissue was observed in all 
dilutions tested up to, and including, 1:3200. No staining was seen when the antibody 
was used at a dilution o f 1:6400 or above. Although some staining o f molecular and 
granular layers by the antibody was seen, this was less intense than that produced by an 
equivalent dilution o f the antibody on rat tissue and Purkinje cells were more strongly 
stained in comparison to the rest o f the tissue.
The Purkinje cell staining was mostly uniformly cytoplasmic and membranous (figure 
4.13), similar to that seen on rat tissue. As with rat tissue, the antibody was found to 
stain human cerebellar tissue at an optimal dilution o f 1:800 (figure 4.13c). In contrast 
to rat tissue, staining o f commercial anti-gliadin antibody at a dilution o f 1:400 was not 
abolished following adsorption o f the antibody for lh r with crude gliadin (figure 4.13d). 
At a dilution o f 1:800, staining was virtually eliminated following pre-adsorption o f the 
antibody with crude gliadin (figure 4.13e) but was completely abolished following pre­
adsorption at a dilution o f 1:1600 (figure 4.13j).
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Figure 4.12 Reactivity of commercial anti- gliadin antibody with/without pre­
adsorption with crude gliadin on control rat cerebellum
1:400 Non-adsorbed 1:400 Pre-adsorbed
GM
d
Immunohistochemistry using rat cerebellum to investigate the cross-reactivity of 
commercial anti-gliadin antibodies with cerebellar proteins. A typical negative control 
section (absence of primary antibody) is shown (a). Widespread staining using the 
commercial anti-gliadin antibody was observed, including positive Purkinje cell 
staining, at a dilution of 1:400 (b & c). Cerebellar staining was completely abolished 
following pre-adsorption of antibodies using crude gliadin (d & e). Purkinje cells are 
indicated by arrows. G -  Granular layer M -  Molecular layer. Scale bar = 100pm.
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Figure 4.12 cont’d Reactivity of commercial anti- gliadin antibody with/without pre­
adsorption with crude gliadin on control rat cerebellum
1:800 Non-adsorbed 1:800 Pre-adsorbed
Immunohistochemistry using rat cerebellum to investigate the cross-reactivity of 
commercial anti-gliadin antibodies with cerebellar proteins. Widespread staining using 
the commercial anti-gliadin antibody was also observed, including positive Purkinje cell 
staining, at a dilution of 1:800 (f & g). Cerebellar staining was completely abolished 
following pre-adsorption of antibodies using crude gliadin (h & i). Purkinje cells are 
indicated by arrows. G -  Granular layer M -  Molecular layer. Scale bar = 100pm.
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Figure 4.13 Reactivity of commercial anti- gliadin antibody with/without pre­
adsorption with crude gliadin on control human cerebellum
1:400 Non-adsorbed 1:400 Pre-adsorbed
1:800 Non-adsorbed 1:800 Pre-adsorbed
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Immunocytochemistry using control human cerebellum to investigate the cross­
reactivity of commercial anti-gliadin antibodies with cerebellar proteins. A typical 
negative control section (absence of primary antibody) is shown (a). Widespread 
staining of the commercial anti-gliadin antibody was observed, including positive 
Purkinje cell staining, at dilutions of 1:400 (b) and 1:800 (c & f). Cerebellar staining 
was reduced, but not abolished, following pre-adsorption of anti-gliadin antibodies with 
crude gliadin at a dilution of 1:400 (d). At a dilution of 1:800, staining was virtually 
abolished following pre-adsorption of antibodies (e & i). Purkinje cells are indicated by 
arrows. G -  Granular layer M -  Molecular layer. Scale bar = 100pm.
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Figure 4.13 cont’d Reactivity of commercial anti-gliadin antibody with/without pre­
adsorption with crude gliadin on human control cerebellum
1:1600 Non-adsorbed 1:1600 Pre-adsorbed
Widespread staining of the commercial anti-gliadin antibody was also observed, 
including positive Purkinje cell staining, at a dilution of 1:1600 (g & h). This staining 
was abolished, following pre-adsorption of anti-gliadin antibodies with crude gliadin (j 
& k). Purkinje cells are indicated by arrows. G -  Granular layer M -  Molecular layer. 
Scale bar = 100pm.
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4.3.5 Reactivity of patient sera with rat cerebellar tissue with/without 
pre-adsorption with crude gliadin
The staining o f both normal control sera tested was not affected by pre-adsorption with 
crude gliadin (figure 4.14h & 4.14i). Pre-adsorption o f anti-gliadin antibodies also did 
not affect the staining o f the two sera samples tested from patients with sporadic 
idiopathic ataxia (figure 4.14f & 4.14g). O f two serum samples from patients with CD 
without neurological complications, Purkinje cell staining was eliminated in one, 
following pre-adsorption with crude gliadin. However, staining was unchanged in the 
other following pre-adsorption o f anti-gliadin antibodies (figure 4.14d & 4.14e).
Finally, staining o f both gluten ataxia sera was slightly decreased in intensity, but not 
completely abolished, following pre-adsorption with crude gliadin (figure 4.14b & 
4.14c). In this series o f patients, as previously observed, Purkinje cell staining was 
characterised by staining both membranous and cytoplasmic structures. However, it 
was noted that both sera from patients with sporadic idiopathic ataxia and serum from 
one patient with CD without neurological complications showed a different pattern o f 
Purkinje cell staining. In these cases, in approximately half o f the Purkinje cells 
stained, the staining was mainly membranous with no cytoplasmic staining (figure 
4.14d & 4.14f).
4.3.6 Reactivity of patient sera with human cerebellar tissue 
with/without pre-adsorption with crude gliadin
Sera were found to stain human cerebellar tissue in a similar manner to rat cerebellum. 
The crude gliadin solution, used to pre-adsorb serum samples, when used in place o f the 
primary antibody was similar to the negative control (PBST as primaiy antibody)
(figure 4.15b). In these experiments, a dilution o f 1:200, as opposed to 1:800, was 
optimal to investigate the effect o f pre-adsorption o f anti-gliadin antibodies between 
groups on staining o f human cerebellum. Similar to rat cerebellar staining, the staining 
of both normal control sera, at both 1:200  and 1:800 dilution, was not affected by pre­
adsorption with crude gliadin. Staining o f 3 serum samples from patients with CD 
without neurological complications was virtually eliminated in 2/3 and completely 
eliminated in the other at a dilution o f 1:200  following pre-adsorption o f anti-gliadin 
antibodies (figure 4.15e & 4.15f). At a dilution o f 1:800, serum staining o f all 3 CD 
serum samples was completely abolished following pre-adsorption o f antibodies with 
crude gliadin. Finally, staining o f 4/4 serum samples from patients with gluten ataxia
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Figure 4.14 Reactivity of sera from patients with gluten ataxia and coeliac disease only
with/without pre-adsorption with crude gliadin on control rat cerebellum
1:400 Non-adsorbed 1 :400  Pre-adsorbed
: ’ ■
A typical negative control section (absence of primary antibody) is shown (a). Sera 
from both gluten ataxia patients and patients with CD only, diluted 1:400, positively 
stained Purkinje cells (b & d respectively). Pre-adsorption of both gluten ataxia patient 
sera and CD only sera, with crude gliadin, did not alter staining (c & e respectively). 
Scale bar = 100 pm. Purkinje cells are indicated by arrows. G -  Granular layer 
M -  Molecular layer.
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Figure 4.14 cont’d Reactivity of sera from ataxia controls and healthy controls
with/without pre-adsorption with crude gliadin on control rat
cerebellum
1:400 Non-adsorbed 1:400 Pre-adsorbed
. -
.
Sera from patients with idiopathic sporadic ataxia, diluted 1:400, positively stained 
Purkinje cells (f). Pre-adsorption, with crude gliadin, did not eliminate this staining (g). 
Similarly, pre-adsorption with crude gliadin (i) did not alter staining observed using 
healthy control serum, diluted 1:400 (h). Scale bar = 100pm.
Purkinje cells are indicated by arrows. G -  Granular layer M -  Molecular layer.
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Figure 4.15 Reactivity of sera from patients with gluten ataxia and coeliac disease only
with/without pre-adsorption with crude gliadin on control rat cerebellum
1:200 Non-adsorbed
G M
■ ■ -."v ! v  -v:-- .AT
- ~• V * • - •' ^W • , f * ■>'* ’ v‘ " V--
HrC
G
M
1:200 Pre-adsorbed
b
Typical negative control sections (absence of primary antibody and crude gliadin in 
place of primary antibody) are shown (a & b respectively). Sera from both gluten 
ataxia patients and patients with CD without neurological complications, diluted 1:200, 
positively stained Purkinje cells (c & e respectively). Pre-adsorption, with crude 
gliadin, of sera from patients with CD without neurological complications resulted in 
elimination of staining (f). However, pre-adsorption, with crude gliadin, of sera from 
patients with gluten ataxia resulted in a decrease in intensity but not elimination of 
Purkinje cell staining (d). Scale bar = 100pm. Purkinje cells are indicated by arrows.
G -  Granular layer M -  Molecular layer.
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was decreased in intensity, but not eliminated following pre-adsorption o f anti-gliadin 
antibodies at dilutions of both 1:200 and 1:800 (figure 4.15c & 4.15d).
4.3.7 Confirmation of adsorption of anti-gliadin antibodies using 
crude gliadin, determined by ELISA
ELISA confirmed the successful adsorption o f anti-gliadin antibodies with crude gliadin 
using a crude gliadin solution o f a similar concentration to that used in the experiments 
described above. Following adsorption o f anti-gliadin antibodies with crude gliadin, the 
commercial anti-gliadin antibody and all sera tested were negative for IgG anti-gliadin 
antibodies on ELISA (figure 4.16). All, except one serum sample from a patient with 
CD without neurological complications, were also negative for IgA anti-gliadin 
antibodies on ELISA (figure 4.17).
4.3.8 Reactivity of CSF with human cerebellar tissue
No CSF sample showed reactivity with human cerebellar tissue at any o f the dilutions 
used (data not shown).
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Figure 4.16 Confirmation by ELISA of adsorption of IgG anti-gliadin antibodies, following incubation with crude gliadin, in commercial anti-gliadin 
antibody and sera from patients with gluten ataxia, coeliac disease only, ataxia controls and healthy controls
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SA - sporadic ataxia, FA - familial ataxia, HC - healthy control, AGA - commercial anti-gliadin antibody.
Figure 4.17 Confirmation by ELISA of adsorption of IgA anti-gliadin antibodies, following incubation with crude gliadin, in commercial anti-gliadin 
antibody and sera from patients with gluten ataxia, coeliac disease only, ataxia controls and healthy controls
(|iu/f)) |3A3| /{poqijuB uipeiiS-ijue ySf unuas
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SA - sporadic ataxia, FA - familial ataxia, HC - healthy control, AGA - commercial anti-gliadin antibody.
4.4 Discussion
The results of these studies show that patients with gluten ataxia possess circulating IgG 
anti-cerebellar antibodies. IgG anti-gliadin antibodies are the most sensitive marker for 
gluten sensitivity in patients with gluten ataxia (see previous chapter) and in conditions, 
such as PCD, only IgG anti-cerebellar antibodies are considered clinically relevant 
(Bradwell et al., 1997). In both rat and human tissue, serum from patients with gluten 
ataxia reacted most strongly with Purkinje cells, a result consistent with the 
neuropathological feature o f Purkinje cell loss and the notion that these cells are most 
susceptible to damage in these patients (Hadjivassiliou et al., 1998).
Although Purkinje cell staining was also seen using sera from other patient groups (CD 
without neurological complications, familial ataxia, sporadic ataxia (non-gluten)) and 
healthy control subjects it was only seen at high antibody concentrations, suggesting 
that it is relatively non-specific. Purkinje cell staining by control sera at dilutions of up 
to 1:100 has been reported previously and is considered non-specific (Jaeckle et al., 
1985).
At all increasing dilutions staining persisted in the majority o f patients with gluten 
ataxia but only in a minority of patients from other groups. By a dilution o f 1:800, 
positive Purkinje cell staining was evident in 4 of 5 patients with gluten ataxia 
compared to 1 o f 5 patients with CD only, lo f  5 healthy control subjects and no ataxia 
control patients.
Marked differences were also seen between groups in the strength o f Purkinje cell 
staining. The majority o f sera, from all patient groups, stained strongly with Purkinje 
cells at the lowest dilution but only in patients with gluten ataxia did strong staining 
persist in the majority of sera (3/5) at higher dilutions. At these dilutions strong staining 
was only seen in 1/5 patients with CD only and 1/5 ataxia control patients. Overall, 
strong and persistent staining of Purkinje cells by sera was only seen in the majority of 
patients with gluten ataxia and the lack of a similar staining pattern in ataxia control 
patients implies that this is not a general feature o f Purkinje cell loss. These staining 
patterns were confirmed by experiments carried out by the group o f Dr. Tongiorgi, 
using rat cerebellum. Both o f these results from studies on rat and human tissue are in 
apparent disagreement with a recent report by Wiendl and co-workers who found no 
binding to either cell-surface or intracellular Purkinje cell antigens by gluten ataxia sera,
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quantified by flow cytometry (Wiendl et al, 2003). However, importantly, the neuronal 
cell lines used in this study may not have included Purkinje cells, the target of 
antibodies in gluten ataxia. In addition, the study did not include use o f sera containing 
antibodies against Purkinje cell epitopes, such as anti-Yo antibodies, as a positive 
control, without which it is not possible to conclude the absence o f Purkinje cell 
binding.
Experiments using anti-Yo positive sera, in the current study, showed granular staining 
of the Purkinje cell cytoplasm, consistent with the established staining pattern o f this 
antibody (Bradwell et al., 1997; Okano et al, 1999). Sera from all patient groups 
stained Purkinje cells in a uniform diffuse manner. Most frequently, the cell bodies 
were most strongly stained although weaker dendritic staining was seen on occasion. 
Staining of the cell bodies appeared predominantly cytoplasmic although lacking the 
granular appearance o f anti-Yo cytoplasmic staining. These experiments did not 
provide evidence of any distinguishing staining features, which could be reliably used in 
the differential diagnosis o f gluten ataxia.
It is possible that this staining may be due to cross-reactivity o f circulating gluten 
sensitivity associated antibodies (anti-gliadin or anti-TG2 antibodies) with shared 
epitopes on Purkinje cells. Several factors are suggestive o f a limited role for 
circulating anti-TG2 antibodies in this respect. Firstly, the diffuse, non-specific staining 
pattern observed using a commercial anti-TG2 antibody does not correlate with the 
observed staining pattern o f Purkinje cells by sera. In addition, although measured 
circulating anti-TG2 antibodies are of the IgA type, staining is not correlated with the 
presence or level o f these antibodies in patients. For example, staining was observed in 
all patients with gluten ataxia yet antibodies are only positive in 40% of patients. 
Conversely, nearly all patients with CD only possess circulating anti-TG2 antibodies 
(94%), often at high levels, yet the same degree of Purkinje cell staining as that of 
patients with gluten ataxia was not generally seen. In contrast, the IHC results 
demonstrate the ability of commercial anti-gliadin antibody to cross-react with Purkinje 
cells, suggesting the existence of common epitopes. Cross-reactivity o f anti-gliadin 
antibodies with the calcium-binding protein, calreticulin, and enterocytes has previously 
been demonstrated and a recent genome screen using gliadin cDNA as a probe showed 
partial homology with several genes (Krupickova et al, 1999; Kumar et al, 2000). 
Anti-gliadin antibodies are a common feature o f almost all patients with gluten
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sensitivity. This cross-reactivity may account for the Purkinje cell staining by sera from 
patients with CD only without neurological complications observed in the current study. 
One important consideration of this hypothesis is that, if  Purkinje cell staining by sera is 
considered to be completely, or at least partially, due to the cross-reactivity of 
circulating anti-gliadin antibodies then the degree o f staining may be expected to 
depend on the levels o f these antibodies in the serum. It is therefore o f note that levels 
of circulating IgG anti-gliadin antibodies were not correlated with either the persistence 
or strength of staining of sera from any patient group. Although, this correlation was 
assessed using a visual, semi-quantitative evaluation o f staining and, it may be the case 
that a more subtle correlation would have been apparent with use of a more sensitive 
and precise measurement of Purkinje cell staining such as quantitive image analysis 
involving measurements of staining density.
In addition, the results o f the adsorption experiments suggest that, in patients with 
gluten ataxia at least, anti-gliadin antibodies are not solely responsible for the observed 
staining of Purkinje cells. Adsorption with crude gliadin was sufficient to eliminate 
anti-gliadin antibodies, as shown by the ELISA results, yet Purkinje cell staining by sera 
from patients with gluten ataxia was not completely abolished. These findings suggest 
that patients with gluten ataxia exclusively possess additional antibodies against 
Purkinje cells, which are distinct from anti-gliadin antibodies.
In summary, the main findings of this study are that, sera from patients with gluten 
ataxia stain cerebellar Purkinje cells more strongly and persistently than sera from 
patients in other groups and therefore have higher titres o f circulating IgG anti-Purkinje 
cell antibodies. Gluten sensitivity associated, circulating anti-TG2 antibodies are 
unlikely to contribute significantly to this staining but gluten-driven circulating anti- 
gliadin antibodies have been shown to cross-react with Purkinje cells, suggesting that 
gliadin and Purkinje cells share common epitopes. However, circulating levels o f both 
antibodies show no correlation with the strength or persistence of Purkinje cell staining. 
Finally, adsorption experiments have suggested that patients with gluten ataxia possess 
circulating anti-Purkinje cell antibodies, which are distinct from anti-gliadin antibodies 
and are not found in patients from other groups. These antibodies may explain the 
observed cerebellar staining characteristics of patients with gluten ataxia.
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CHAPTER FIVE
INVESTIGATION OF THE CEREBELLAR 
SPECIFICITY OF CIRCULATING 
ANTIBODIES IN PATIENTS WITH GLUTEN 
ATAXIA BY WESTERN BLOTTING
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5.1 Introduction
Patients with gluten ataxia possess circulating anti-gliadin antibodies, which have been 
shown to cross-react with cerebellar Purkinje cells, and, to a lesser extent, antibodies 
against TG2, a ubiquitous protein also found in the cerebellum. In addition, patients 
with gluten ataxia possess specific circulating anti-Purkinje cell antibodies, which are 
distinct from anti-gliadin antibodies and which do not appear to be present in patients 
with CD only or in individuals with non-gluten ataxia (see previous chapter for details). 
However, the Purkinje cell antigen to which these antibodies are directed is unknown. 
Analysis of antibody binding by western blotting in such situations, in order to gain 
additional information on the target protein, is commonly employed. In addition, 
western blotting is also widely used to confirm antibody binding to known proteins 
detected by IHC. For example, the specificity of PCD associated antibodies is 
confirmed by western blot analysis against cerebellar extracts or recombinant proteins 
(Bradwell ^  a/., 1997).
5.1.1 Aims of this study
The overall aim o f this study was to continue the study o f the humoral immune response 
in the cerebellum of patients with gluten ataxia by investigating the specificity of 
circulating antibodies from patients with gluten ataxia within the cerebellum, using 
SDS-PAGE and western blotting. This was achieved by several means:
o Confirmation of the cross-reactivity of anti-gliadin antibodies with cerebellar 
proteins and the presence of TG2 in the cerebellum by western blotting 
o Screening of sera from patients with gluten ataxia for specificity to cerebellar 
proteins on a western blot and determination of the RMM of immunoreactive 
proteins.
o Comparison of this antigenic specificity of gluten ataxia sera with that o f patients 
with CD without neurological involvement, patients with sporadic idiopathic ataxia 
or familial ataxia and normal healthy controls, 
o Assessment o f the contribution o f circulating anti-gliadin or anti-TG2 antibodies to 
staining and determination of any reactivity to these proteins specific to patients 
with gluten ataxia.
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5.2 Methods
5.2.1 Optimisation of protein extraction
Adult, female Wistar rats were used as the source o f cerebellar tissue for SDS-PAGE. 
The objective o f the method was to extract sufficient amounts o f protein for adequate 
detection on a western blot. A total o f four different extraction protocols were tried, 
including a commercial protein extraction kit (Bio-Rad, UK). Protein extractions were 
performed an average of 3 times for each protocol. Once the optimal method had been 
selected (section 2.4.2), this was used for all subsequent protein extractions.
The amount o f protein in each extract (mg/ml) was calculated using the BCA protein 
assay, described in section 2.4.3, to enable the same amount o f protein to be loaded into 
each lane of the polyacrylamide gel and allow comparison of results between 
experiments.
5.2.2 Optimisation of SDS-PAGE and western blotting
The separation o f cerebellar proteins on polyacrylamide gels and their transfer onto 
nitrocellulose membrane was first optimised in order to facilitate subsequent detection 
o f proteins of interest. This process included consideration o f the factors detailed 
below:
5.2.2.1 Equipm ent
Optimisation of the SDS-PAGE method was carried out using a mini-protean III 
vertical electrophoresis system (Bio-Rad, UK). Subsequently, and throughout all the 
studies included in this thesis, a Hoefer mighty small SE250 vertical mini-gel system 
was used (Amersham Pharmacia Biotech, UK). Initially, transfer o f proteins was 
carried out using the blotting module o f the mini-protean III system (Bio-Rad, UK). 
Subsequently, and throughout all the studies included in this thesis, a Hoefer semi-dry 
blotting system was used (Amersham Pharmacia Biotech, UK), the major advantage 
being the use of 80% less transfer buffer in its operation with comparable results to the 
Bio-Rad system.
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5.2.2.2 Percentage of polyacrylamide gels
A 5% stacking gel was used in all experiments. Resolving gels of 8%, 10%, 12% and 
12.5% were used to compare separation of cerebellar proteins. Protein separation was 
assessed by staining the gel in Coomassie blue stain to visualise the proteins. Briefly, 
gels were placed in Coomassie blue stain (45.5% v/v methanol, 0.9% v/v acetic acid, 
1.5mM Coomassie blue (Sigma, UK) in d.P^O) overnight at RT with gentle shaking. 
Gels were then removed into destain (45.5% v/v methanol, 0.9% v/v acetic acid in 
d.H2 0 ) at RT with gentle shaking. The destain was changed as many times as necessary 
until all background staining of the gel had disappeared and the protein staining was 
clearly visible.
5.2.2.3 Amount of protein loaded onto gel
As the cerebellar antigen o f interest was unknown, and may be present at low levels 
within the tissue, the amount of protein loaded in each lane influenced its subsequent 
detection. The objective was to find the amount o f protein that was optimal for 
detection but that also avoided the detrimental effects on separation that can occur with 
too high quantities of protein. Quantities of 5pg, 10pg, 20pg, 32.5pg and 36pg of 
protein per lane were loaded to see which was optimal.
5.2.2.4 Time of protein transfer
Transfer times o f 45mins, 60mins and 75mins, all at 100V, were used to assess optimal 
transfer conditions.
5.2.3 Optimisation of protein detection
In order to produce optimal detection of proteins o f interest whilst minimising 
background and non-specific staining o f nitrocellulose blots, the technique was first 
optimised as detailed below.
5.2.3.1 Blocking of nitrocellulose membrane
Nitrocellulose membranes were blocked in solutions o f 15% milk powder in TBS (pH 
8), 5% milk powder in PBS, 5% milk powder in PBST or a 5% solution o f ECL 
blocking agent (Amersham Pharmacia Biotech, UK) in PBST. Blocking times of 
60mins at RT or overnight at 4°C were used in order to determine the optimal 
incubation time.
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5.2.3.2 Primary antibody dilutions and incubation periods
Monoclonal anti-calbindin D28K (Sigma, UK), anti-TG2 (Labvisions, USA) and anti- 
GAD antibodies (Affmiti Research, UK) were incubated with nitrocellulose membranes 
at dilutions ranging from 1:200 to 1:10 000. Serum samples were incubated with 
membranes at dilutions ranging from 1:100 to 1:1000. All primary antibodies were 
diluted in either PBS, ‘Blotto’ (5% milk powder in TBST (0.05% Tween20 in TBS, pH 
8)) or PBST.
Primary antibodies were incubated with membranes for periods o f either 60 or 120mins 
at RT or overnight at 4°C.
5.2.3.3 Secondary antibody dilutions and incubation periods
Horseradish peroxidase-conjugated anti-human IgG or anti-mouse IgG (as appropriate) 
secondary antibodies from Sigma, UK, Vector Laboratories, UK or Jackson 
Immunoresearch, USA were used. Dilutions ranged from 1:100 to 1:50 000.
All secondary antibodies were also diluted in either PBS, ‘Blotto’ (5% milk powder in 
TBST (0.05% Tween20 in TBS, pH 8)) or PBST.
An incubation period o f 60mins at RT was used in all experiments.
5.2.3.4 Washing of membranes
Membranes were either washed in TBST or PBST with washing times varied from 2 x 
5mins to 3 x 30mins.
5.2.3.5 Substrates and detection of antibody binding
Initially, chromogenic substrates including 0.2mg/ml solution o f DAB (Sigma, UK) or 
opti-4CN (opti-4CN western blotting staining kit, Bio-Rad, UK) were used with 
development times of between 5-20mins.
A more sensitive chemiluminescent detection system was also used. Two different 
chemiluminescent substrates were compared, the femtolucent ECL detection kit 
(Chemicon, USA) and the ECL-plus™ detection kit (Amersham Pharmacia Biotech, 
UK). Kits were used according to the manufacturer’s instruction. Initially, light 
emission resulting from addition o f substrate was recorded using autoradiography film 
and developed manually using Kodak™ developer and fixer (Sigma, UK). The film
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was placed in Kodak™ developer (Sigma, UK) for approximately 15secs, rinsed briefly 
in d.H2 0 , placed in Kodak™ fixer (Sigma, UK) for approximately 30secs and then 
finally rinsed in d.IUO before drying. Kodak™ (Sigma, UK) and hyperfilm™ ECL 
(Amersham Pharmacia Biotech, UK) films were compared. Blots were exposed to the 
film for periods o f 15secs to 3mins. However, light emission was subsequently 
recorded using a UVP imager (UVP, UK) and Labworks, software (UVP, UK).
5.2.4 Detection of known cerebellar proteins (calbindin and tissue 
transglutaminase)
Detection of the cerebellar proteins, calbindin and TG2, was performed by probing an 
extract of rat cerebellum, separated on a 10% polyacrylamide gel, with appropriate 
commercial monoclonal antibodies. The same rat cerebellar extract (#9, section 5.3.1) 
was used in all experiments in order to minimise inter-experimental variation.
36pg/lane o f rat cerebellar extract was loaded onto a 10% polyacrylamide gel, prepared 
as detailed in section 2.4.4. The first lane of each gel was loaded with lOpl coloured 
pre-stained molecular weight marker (Sigma, UK). SDS-PAGE and Western blotting 
was then performed using the optimised method, as detailed in sections 2.4.4 and 2.4.5 
respectively. Proteins of interest were detected according to the optimised method 
detailed in section 2.4.6. Details of the primary and secondary antibodies used are 
given in table 5.1. Finally, the RMM of the protein bands were determined according to 
the method detailed in section 2.4.7. Blots were probed with anti-calbindin D28K 
antibody in 8 different experiments and with anti-TG2 antibody in 4 different 
experiments. In each case, the average RMM of resultant protein bands was calculated.
5.2.5 Detection of gliadin proteins and investigation of the cross­
reactive potential of commercial anti-gliadin antibody with 
cerebellar proteins
A 5mg/ml gliadin solution was prepared by mixing crushed crude gliadin (Sigma, UK) 
with the appropriate volume of PBST. The resulting solution was heated gently 
overnight in a water-bath at 30°C and then mixed in a ratio o f 1:1 v/v with 2x sample 
buffer (section 2.4.4). lOpl/lane (25pg) of the solution was loaded onto a 10% 
polyacrylamide gel, prepared as detailed in section 2.4.4. The first lane o f each gel was 
loaded with lOpl coloured pre-stained molecular weight marker (Sigma, UK). SDS-
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Table 5.1 Details of reagents used in the detection of calbindin and tissue 
transglutaminase within rat cerebellar extract on a western blot
Antibody
Specificity
Species
(supplier)
D ilution C orrespond ing  
secondary antibody
Secondary
antibody
dilution
Monoclonal
anti-TG2
Mouse IgG anti­
guinea pig TG2 
(Lab vision, USA)
1:1000
HRP
conjugated goat anti­
mouse IgG
Monoclonal
anti-
Calbindin
D-28K
Mouse IgGl anti- 
bovine kidney 
calbindin 
(Sigma, UK)
1:1000
(Jackson Immunoresearch 
Laboratories, U SA (UK  
distributor, Stratech))
1:10 000
PAGE and western blotting was then performed using the optimised method, as detailed 
in sections 2.4.4 and 2.4.5 respectively. Blots were blocked for 25mins in a 5% solution 
of ‘quick-block’/PBST (Chemicon, USA) at RT with gentle shaking. Following 
3x5min washes in PBST, blots were incubated with a peroxidase-conjugated, polyclonal 
rabbit anti-gliadin antibody (Sigma, UK), diluted to 1:10 000 in PBST overnight at 4°C 
with gentle shaking. Blots were then washed 4xl0mins in PBST and incubated in ECL- 
detection reagent (Chemicon, USA) for 3mins at RT with gentle shaking. The UVP 
imaging system detailed in section 2.4.6 was not yet available and so blots were 
visualised using autoradiography film. Binding was visualised by exposure o f the blot 
to hyperfilm™ ECL (Amersham Pharmacia Biotech, UK) autoradiography film for 
60secs and manual development using Kodak™ developer and fixer (Sigma, UK), as 
described in section 5.2.3.5. The RMM of the protein bands were determined according 
to the method detailed in section 2.4.7. Binding o f anti-gliadin antibodies to gliadin 
proteins was performed in two separate experiments and the mean RMM of resultant 
protein bands was calculated.
In order to investigate cross-reactivity of anti-gliadin antibodies with cerebellar proteins 
on a western blot, 36pg/lane of rat cerebellar extract (#9, section 5.3.1) was loaded onto 
a 10% polyacrylamide gel, prepared as detailed in section 2.4.4. The same rat cerebellar 
extract was used in all experiments in order to minimise inter-experimental variation.
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The first lane o f each gel was loaded with lOfil coloured pre-stained molecular weight 
marker (Sigma, UK). SDS-PAGE and western blotting was then performed using the 
optimised method, as detailed in sections 2.4.4 and 2.4.5 respectively. A peroxidase- 
conjugated, polyclonal rabbit anti-gliadin antibody (Sigma, UK), diluted to 1:1000 in 
PBST, was used to probe the blot and proteins of interest were detected according to the 
optimised method detailed in section 2.4.6 with the omission o f the secondary antibody 
step. The. RMM of the protein bands were determined according to the method detailed 
in section 2.4.7. Investigation of the cross-reactivity o f anti-gliadin antibodies with 
cerebellar proteins was performed on three separate occasions and the mean RMM of 
resultant protein bands was calculated.
5.2.6 Investigation of the specificity of patient serum antibody binding 
to cerebellar proteins
Sera from different patient groups were screened for reactivity against rat cerebellar 
proteins separated on a 10% polyacrylamide gel. The same rat cerebellar extract (#9, 
section 5.3.1) was used in all experiments in order to minimise inter-experimental 
variation.
Samples from patients with untreated gluten ataxia, patients with CD without 
neurological complications, patients with familial ataxia, patients with idiopathic 
sporadic ataxia (non-gluten) and healthy controls were compared (table 5.2). lOpl/lane 
(36pg) o f rat cerebellar extract was loaded onto a 10% polyacrylamide gel, prepared as 
detailed in section 2.4.4. The first lane of each gel was loaded with lOfil coloured pre- 
stained RMM marker (Sigma, UK). SDS-PAGE and western blotting was then 
performed according to the optimised method detailed in sections 2.4.4 and 2.4.5 
respectively. As described in section 2.4.5, Ponceau-S red stain (Sigma, UK) was used 
to temporarily stain the protein in the blot to assess the transfer success and allow the 
protein bands of the RMM marker to be indicated with pencil before destaining. At this 
stage, blots were cut into single lane strips. Strip orientation was enabled by the 
removal of the bottom left-hand comer of the strip. Reactivity of serum samples was 
assessed according to the optimised method detailed in section 2.4.6, using serum as 
primary antibody. Each strip was probed with a different primary antibody. One strip 
from each blot was probed with a monoclonal anti-GAD65/67 antibody to allow an 
estimate o f inter-experimental variation. Further details o f the samples screened and
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secondary antibodies used are given in table 5.2. Staining was visualised using the 
UVP imaging system detailed in section 2.4.6. The RMM of the protein bands were 
determined according to the method detailed in section 2.4.7. The RMM of GAD was 
calculated for each blot and used to determine the inter-experimental variation (%CV).
The average RMM and the standard deviation of the values were calculated and used to
calculate %CV as below,
%CV = (SD/Mean reading) xlOO
In order to determine which bands may be due to binding o f IgG anti-gliadin or anti- 
TG2 antibodies within positive serum samples, the mean RMM (as reported in sections
5.3.4 and 5.3.5) of the respective gliadin or TG2 protein band was used. Any bands at 
the calculated RMM ± inter-experimental variability were considered likely to be 
produced by binding o f these specific antibodies. The percentage o f the total number of 
patients whose serum was positive for anti-gliadin antibodies on ELISA and that also 
produced a band suggestive of binding of anti-gliadin antibodies, was calculated. This 
was repeated for patients whose serum was positive for anti-TG2 antibodies.
Table 5.2 Summary o f sera and detection antibodies used in screening studies of 
sera reactivity against rat cerebellar proteins on a western blot
Patient Group n Serum
dilution
Corresponding 
secondary antibody
Secondary
antibody
dilution
Gluten Ataxia (untreated)
14 HRP
conjugated goat anti­
human IgGCD without neurological complications (untreated)
10
Familial ataxia 7 1 :1 0 0 0 (Jackson 
Immunoresearch 
Laboratories, USA 
(UK distributor, 
Stratech))
Sporadic idiopathic ataxia 
(non-gluten)
2 1 :1 0  0 0 0
Healthy controls 11
Stiff-person syndrome 1
n= number of patients in each group
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5.3 Results
5.3.1 Optimisation of protein extraction
Table 5.3 shows the protein yields obtained for each extraction carried out using each of 
the four extraction methods. Method 4 was selected as optimal and used in all protein 
extractions thereafter.
Table 5.3 A comparison of the results obtained from four different protein extraction 
methods
Extraction
#
M ethod
used
Tissue used W eight of 
tissue used 
(g)
Protein yield
(mg/ml)
Pellet
fraction
Supernatant
fraction
1 1 Rat cerebellum 2.9 0.6 ■ -
2 1 Rat cerebellum 0.6 <0.1 -
3 1 Human cerebellum 0.016 <0.1 -
4 2 Rat cerebellum 3.62 6.5 -
5 2 Rat cerebellum 1.7 2.3 -
6 2 Rat cerebellum 2.92 2.0 4.0
7 3 Rat cerebellum 0.15 - 4.7
8 4 Rat cerebellum 0.365 5.5 7.0
9 4 Rat cerebellum 0.616 5.49 7.33
- = Indicates fraction not tested
A typical BSA standard curve (from extraction #9), used in the BCA assay to calculate 
protein yield following the extraction procedure, is shown in Figure 5.1. Data is 
expressed as Mean ± standard error of the mean (SEM).
5.3.2 Optimisation of SDS-PAGE and western blotting
A 10% resolving gel was found to give the best overall separation over a wide range of 
RMMs, important as the cerebellar antigen o f interest was unknown, and was used in all 
subsequent experiments. It was found that, generally, the greater the amount o f protein 
loaded in each lane, the better the protein detection.
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Figure 5.1 A typical BSA standard curve used to determine the protein concentration 
of tissue extracts
IOin
O  0 .6 -
0 .4  -
0.2 -
P ro te in  c o n c e n tr a t io n ,  m g /m l
BSA solutions ranging in concentration from 0.1-20mg/ml were prepared and used in 
the BCA protein assay as standards (in duplicate). Protein concentration is plotted 
against the corresponding blank-corrected, average OD to produce a standard curve. 
The unknown protein concentration of tissue extracts is determined using this curve by 
using the blank-corrected, average OD reading o f the sample to determine the 
corresponding protein concentration. Data is expressed as MEAN ± SEM.
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Initially, protein amount was limited due to poor protein yields from extractions from 
tissue. In addition, higher amounts o f protein were problematic to load because the 
resultant increase in volume necessaiy to load the specified amount o f protein caused 
sample wells to overflow. As the protein extraction method was improved, higher 
amounts o f protein contained within lesser volumes were able to be loaded. The 
maximum, 36pg per well was found to produce the best results and was used in all 
subsequent experiments. Typical separation o f rat cerebellar proteins (extraction #9), 
36pg/lane, on a 10% polyacrylamide gel, visualised by Coomassie blue staining, is 
shown in figure 5.2.
A transfer time o f 60mins at 100 V was optimal for transfer o f proteins from the 
polyacrylamide gel onto nitrocellulose membrane.
5.3.3 Optimisation of protein detection
Once transfer o f proteins onto nitrocellulose membrane had been completed, blocking 
solutions o f 5% milk powder in PBST and 5% ECL blocking agent in PBST were found 
to be equally as effective at minimising non-specific background staining o f proteins. 
However, a 5% solution o f ECL blocking agent in PBST was used in all experiments 
included in this thesis due to the standardised formulation o f a commercially available 
blocking-agent, minimising variation between experiments. Incubation o f membranes 
in blocking solution overnight at 4°C or 60mins at RT were equally as effective. An 
incubation period o f 60mins at RT was selected due to its convenience.
Adequate washing o f the membrane between incubation steps was critical to the success 
o f detection o f antibody binding with minimal non-specific background binding. PBST 
was the most efficient washing solution and washes o f lxl5m ins followed by 3x5mins 
between each step resulted in the best outcome.
Dilution o f primary and secondary antibodies (from Jackson Immunoresearch) in PBST 
with incubation periods o f overnight at 4°C and 60mins at RT, respectively, gave the 
best results. Optimal dilutions o f primary and secondary antibodies were found to vary 
according to the detection and imaging systems used. Generally, lower dilutions were 
required for chromogenic detection than for the more sensitive chemiluminescent 
detection system. Optimal dilutions also varied according to whether the
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Figure 5.2 Typical separation of rat cerebellar proteins on a 10% polyacrylamide gel, 
visualised by Coomassie blue stain
116 kDa
66  kDa 
45 kDa
29 kDa
Lane 1 2  3 4
A 10% polyacrylamide gel was loaded as follows,
Lane 1 1 Opl coloured pre-stained RMM marker (Sigma, UK)
Lanes 2-4 1 Opl/lane (36pg protein) rat cerebellar protein extract (supernatant,
extraction #9)
Proteins were separated by SDS-PAGE for 60mins at 150V. Following separation, 
proteins were visualised by Coomassie blue stain.
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chemiluminescent signal was detected using manual development o f autoradiography 
film or using the UVP imager (table 5.4).
Table 5.4 Optimal dilutions of primary and secondary antibodies for the detection of 
proteins using both chromogenic and chemiluminescent detection systems
ANTIBODY
DILUTION
CHROMOGENIC CHEMILUMI1VESCENT
DAB Opti-4CN Manual
Development
UVP
imager
Anti-calbindin D28K ND 1:500 1:5000 1:1000
Anti-TG2 ND ND 1:5000 1:1000
Anti-GAD ND ND - 1:10 000
Anti-gliadin - - 1:10 000 1:1000
Patient sera ND ND 1:5000 1:1000
Secondary antibody 
(peroxidase-conjugated anti­
mouse or anti-human IgG)
1:5000 1:50 000(mAb) 
1:10 OOO(serum)
1:10 000
ND -  Not detectable mAb -  monoclonal antibodies
Binding of monoclonal calbindin D28k was detected following exposure to opti-4CN 
chromogenic substrate for 5mins. Overall, chemiluminescent detection o f monoclonal 
antibody binding produced superior results with the added advantage o f the permanency 
of autoradiography film or direct computer-stored images. Binding o f serum antibodies 
could not be detected using chromogenic detection systems, only by chemiluminescent 
detection. Chemiluminescent detection was best achieved using the ECL-plus™ 
reagent. Manual imaging of the signal was most successful when hyperfilm™ECL 
autoradiography film was used with a 15secs (serum) or 30secs (monoclonal antibodies) 
exposure time to the membrane. However, once available, the UVP imager was found 
to have greater ease of use and efficiency whilst producing comparable results.
Optimisation o f the chromogenic detection o f monoclonal calbindin D28K antibody is 
shown in figure 5.3 and the resultant optimal primary and secondary antibody dilutions 
for this system are summarised in table 5.4.
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Figure 5.3 Determination of the optimal dilution of monoclonal calbindin D28k for 
detection of antibody binding to rat cerebellar extract using a chromogenic 
detection system
66  k D a ---------- ►
45 k D a ---------- ►
29 k D a ---------->
14 k D a  ►
Lane 1 2 3 4 5
A 10% polyacrylamide gel was loaded as follows,
Lane 1 1 Opl coloured pre-stained molecular weight marker (Sigma, UK)
Lanes 2-5 1 Opl/lane (35pg protein) rat cerebellar protein extract (extraction #8)
Following separation and transfer, optimal detection of binding of monoclonal anti- 
calbindin D28k was established using the following antibody dilutions,
Lane 2 3 4 5
Primary antibody 
dilution
1 :200 1:500 1 :1 0 0 0 1 :2 0 0 0
Horseradish-peroxidase conjugated anti-mouse IgG secondary antibody was used at a 
dilution of 1:5000. Visualisation was attained by exposure to Opti-4CN substrate for 
5mins. The optimal anti-calbindin D28k and secondary antibody dilutions for this 
system were 1:500 and 1:5000, respectively.
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The optimisation of chemiluminescent detection o f monoclonal calbindin D28K 
antibody and serum antibody binding using the manual chemiluminescent imaging 
method is shown in figures 5.4 and 5.5 respectively. The resultant optimal dilutions of 
primary and secondary antibodies for the detection of these proteins are summarised in 
table 5.4.
5.3.4 Detection of known cerebellar proteins (calbindin and tissue 
transglutaminase)
Typical staining o f the cerebellar proteins, calbindin and TG2, within a rat cerebellar 
extract on a western blot, using monoclonal antibodies, is shown in figure 5.6. 
Immunodetection of calbindin using a monoclonal anti-calbindin D28k antibody 
resulted in a single band o f an average RMM of 26.4kDa (range 23-30kDa). Detection 
of TG2 using a monoclonal anti-TG2 antibody resulted in two visible bands, the upper 
having an average RMM of 69.6kDa (range 61- 79kDa) and the lower having an 
average RMM of 48.2kDa (range 44-57kDa).
5.3.5 Detection of gliadin proteins and investigation of the cross­
reactive potential of commercial anti-gliadin antibody with 
cerebellar proteins
Probing of separated gliadin proteins on a western blot using a polyclonal anti-gliadin 
antibody resulted in the visualisation o f two bands. The upper band was found to have 
an average RMM of 48.5kDa (weights 48 and 49kDa) and the lower band was found to 
have an average RMM of 39.5kDa (weights 41 and 38kDa) (figure 5.7a).
Probing of separated cerebellar proteins on a western blot using a polyclonal anti- 
gliadin antibody demonstrated the presence o f several bands. Two bands appeared 
consistently with average RMMs of 43.2kDa (range 41-45kDa) and 32.8kDa (range 30- 
37kDa) (figure 5.7b).
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Figure 5.4 Determination of the optimal secondary antibody dilution for
detection of monoclonal calbindin D28k antibody binding to rat cerebellar
extract using a chemiluminescent detection system
205 k D a _______ ►
116 k D a  ----------- ►
66  k D a  ----------- ►
45 k D a  ----------- ►
29 k D a  -----------►
20.1 k D a ----------►
14.2 k D a ---------- ►
Lane 1 2  3 4
A 10% polyacrylamide gel was loaded as follows,
Lanes 1-4 lOpl/lane (35pg protein) rat cerebellar protein extract (extraction #8)
Following separation and transfer, optimal detection o f binding o f monoclonal anti- 
calbindin D28k at a dilution o f 1:5000 was established using horseradish-peroxidase 
conjugated anti-mouse IgG secondary antibody at the following dilutions,
Lane 1 2 3 4
Secondary 
antibody dilution
1:5000 1:10 000 1:50 000 1:100  000
Visualisation was attained by exposure to ECL substrate (Chemicon, USA) followed by 
exposure to autoradiography film for 30secs and manual development of film. The 
optimal anti-calbindin D28k and secondary antibody dilutions for this system were 
1:5000 and 1:50 000, respectively.
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A 10% polyacrylamide gel was loaded as follows,
All lanes 10pl/lane (3 5 jig protein) rat cerebellar protein extract (extraction #8)
Following separation and transfer, optimal detection of binding of serum antibodies was 
established using serum and horseradish-peroxidase conjugated anti-human IgG 
secondary antibody at the following dilutions,
LANE Primary antibody 
(serum) dilution
Secondary antibody 
dilution
1 1:100 1:5000
2 1:100 1:10  000
3 1:100 1:50 000
4 1:500 1:5000
5 1:500 1:10  000
6 1:500 1:50 000
7 1:1000 1:5000
8 1:1000 1:10  000
9 1:1000 1:50 000
Visualisation was attained by exposure to ECL substrate (Chemicon, USA) followed by 
exposure to autoradiography film for (a) 15secs, (b) 30secs or (c) 60secs and manual 
development of film.
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Figure 5.5 Determination of the optimal conditions for detection o f serum antibody
binding to rat cerebellar extract using a chemiluminescent detection system
Lane 1 3 4 5 6 8
205 k D a *►
116 k D a  
66  k D a
>
45 k D a
29 k D a
20.1 kDa
15 secs
205 k D a  .
116 kD a- 
66  k D a  -
45 kDa_
29 k D a  ►
20.1 kDa ------ ►
Lane 1
30 secs
Lane 1
205 kD a
116 k D a 
66  k D a
45 k D a ■
29 kD a 
20.1 kDa
60 secs
181
Figure 5.6 Typical binding to known cerebellar proteins (calbindin and TG2) 
using commercial monoclonal antibodies detected by use o f a 
chemiluminescent detection system
116 kDa
6 6  kDa
45 kDa
29 kDa
20.1 kDa
b.a.
Lane 1 2  3 4
A 10% polyacrylamide gel was loaded as follows,
Lanes 1-4 1 Opl/lane (36pg protein) rat cerebellar protein extract (extraction #9)
Following separation and transfer, the blot was probed with (a), monoclonal anti- 
calbindin D28k antibody, 1:1000 (b). monoclonal anti-TG2 antibody, 1:1000. Binding 
was visualised using horseradish-peroxidase conjugated anti-mouse IgG secondary 
antibody at a dilution of 1:10 000. The blot was then incubated with ECL-plus™ 
reagent and imaged using a UVP imager.
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Figure 5.7 Binding of a polyclonal anti-gliadin antibody to gliadin proteins and rat 
cerebellar proteins detected using a chemiluminescent detection system
a. b.
A 10% polyacrylamide gel was loaded with either (a). lOpl/lane (25pg protein) crude 
gliadin solution or (b). lOpl/lane (36pg protein) rat cerebellar protein extract (extraction 
#9).
Following separation and transfer, the blot was probed with horseradish-peroxidase 
conjugated anti-gliadin antibody at a dilution o f either (a). 1:10 000 or (b). 1:1000. The 
blot was then incubated with either (a). ECL substrate (Chemicon, USA) followed by 
exposure to autoradiography film for 60secs and imaged by manual development o f film 
or (b). ECL-plus™ reagent and imaged using a UVP imager.
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5.3.6 Specificity of patient serum antibody binding to cerebellar 
proteins
Inter-experimental variation of the positive control (anti-GAD65/67 antibody) was 8%. 
The reactivity and RMM of protein bands for all sera tested are shown in figure 5.8(a- 
g). These results are summarised in table 5.5. Bands possibly due to binding of serum 
anti-gliadin or anti-TG2 antibodies, among antibody positive patients, are highlighted in 
table 5.5. Bands at 69.6 ± 8% kDa (64-75kDa) or 48.2 ± 8% kDa (44-52kDa) were 
considered to be possibly due to binding of anti-TG2 antibodies and bands at 43.2 ± 8% 
kDa (40-47kDa) or 32.8 ± 8% kDa (30-35kDa) were considered to be possibly due to 
binding of anti-gliadin antibodies. Using these criteria, overall, 65% of sera positive for 
anti-TG2 antibodies on ELISA also exhibited a band on a blot possibly due to binding 
of anti-TG2 antibodies. The corresponding value for anti-gliadin antibodies was 58%. 
However, 62% and 55% of sera negative for anti-gliadin and anti-TG2 antibodies 
respectively also exhibited bands at these RMMs.
Bands at wide ranges of RMMs were seen in sera from all groups. No band appeared 
specific to patients with gluten ataxia (table 5.5). However, bands within certain RMM 
ranges were observed more frequently in certain groups. For example, sera from 
patients with gluten ataxia and from patients with CD without neurological 
complications showed high RMM bands (100-101kDa) more frequently than other 
groups (2 1 % and 2 0 % respectively compared to no reactivity in other groups apart from 
9% of healthy control sera). Bands with a RMM of 77 or 78kDa were observed in 2/14 
(14%) sera from patients with gluten ataxia and 1 of 2 sera from patients with sporadic 
ataxia (non-gluten) but not with any other sera. RMM bands between 80-83kDa were 
observed in 3/14 (21%) sera from patients with gluten ataxia and in 2/7 (29%) sera from 
patients with familial ataxia but only 1/10 (10%) sera from patients with CD without 
neurological complications and 1/11 (9%) sera from healthy controls. Interestingly, 
RMM bands between 24-28kDa were seen in 6/14 (43%) sera from patients with gluten 
ataxia and 1 o f 2 sera from patients with sporadic ataxia (non-gluten). These bands 
were also seen with sera from other groups but not at a frequency of more than 18%. 
Similarly, RMM bands between 56-59kDa were seen in 7/14 (50%) sera from patients 
with gluten ataxia and 1 o f 2  sera from patients with sporadic ataxia (non-gluten) but at 
a frequency of not more than 36% in sera from other groups. In addition, bands 
between 56-59kDa were more likely to be strong in the gluten ataxia group (57%) than 
in other groups.
184
Figure 5.8 Binding of antibodies within patient sera samples to rat cerebellar
proteins, separated by SDS-PAGE and western blotting, detected using
chemiluminescence
A 10% polyacrylamide gel was loaded with 10pl/lane (36p,g protein) rat cerebellar 
protein extract (extraction #9). Following separation, the blot was cut into strips (1 
lane/strip) and each strip was probed with patient sera at a dilution of 1:1000. A total 
of, 14 sera from patients with gluten ataxia, 10 sera from patients with CD without 
neurological complications, 7 sera from patients with familial ataxia, 2 sera from 
patients with sporadic ataxia (non-gluten), 1 serum from a patient with stiff-person 
syndrome and 11 sera from healthy control patients were tested. One strip from each 
blot was probed with anti-GAD65/67 antibody (1:10 000 dilution) as a positive control. 
Binding was visualised by incubation with horseradish-peroxidase conjugated-anti 
human IgG (1:10 000 dilution) and development in ECL-plus™ substrate. Finally, blots 
were imaged using a UVP imager.
GA -gluten ataxia (patient number corresponding to table 2.1 is shown in brackets), FA 
-  familial ataxia, SA -  sporadic ataxia (non-gluten), CD -  CD without neurological 
complications, SPS -  stiff-person syndrome, HC -  healthy control. RMMs of visible 
bands were calculated as detailed in section 2.4.7. Weights of intense bands are in bold. 
The serological antibody status of anti-gliadin (AGA) and anti-tissue transglutaminase 
(TG2) antibodies for each patient is provided for reference. Previous experiments 
indicated expected bands for AGA at approximately 33 and 43kDa and for anti-TG2 
antibodies at approximately 48 and 70kDa. The inter-experimental variation of the 
positive control (anti-GAD65/67 antibody) was 8%. Therefore, bands at 69.6 ± 8% kDa 
(64-75kDa) or 48.2 ± 8% kDa (44-52kDa) were considered to be possibly due to 
binding of anti-TG2 antibodies and bands at 43.2 ± 8% kDa (40-47kDa) or 32.8 ± 8% 
kDa (30-35kDa) were considered to be possibly due to binding of anti-gliadin 
antibodies.
NA -  not applicable
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Figure 5.8a Binding of antibodies within patient serum samples to rat cerebellar
proteins, detected using chemiluminescence
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Figure 5.8b Binding of antibodies within patient serum samples to rat cerebellar
proteins, detected using chemiluminescence
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Figure 5.8c Binding of antibodies within patient serum samples to rat cerebellar
proteins, detected using chemiluminescence
RM M
(kDa)
220 j.  ^ 1 '
100 ;
v:«t, •»
60 _  ^ ;v -m  :
45 ■ : r ; -
&
30 >
20
12
8 f
Lane 1 2 3 4 5 6
LANE 1 ; ; 2 3 4 5 6
GROUP  
(patient num ber)
GAD  
+ control
CD FA FA GA
(28)
HC
AG A NA + - - + -
TG2 NA + + - + -
M AJOR  
VISIBLE BANDS (kDa)
70
67
59
56
46
56
188
Figure 5.8d Binding of antibodies within patient serum samples to rat cerebellar
proteins, detected using chemiluminescence
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Figure 5.8e Binding of antibodies within patient serum samples to rat cerebellar
proteins, detected using chemiluminescence
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Figure 5.8f Binding of antibodies within patient serum samples to rat cerebellar
proteins, detected using chemiluminescence
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Figure 5.8g Binding of antibodies within patient serum samples to rat cerebellar
proteins, detected using chemiluminescence
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Table 5.5 Summary of reactivity of sera from patients with gluten ataxia, coeliac disease only, familial ataxia, sporadic
ataxia (non-gluten), stiff-person syndrome and healthy controls with rat cerebellar proteins separated on a western blot, detected using 
chemiluminescence
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Table 5.5 cont’d Summary of reactivity of sera from patients with gluten ataxia, coeliac disease only, familial ataxia,
sporadic ataxia (non-gluten), stiff-person syndrome and healthy controls with rat cerebellar proteins separated on a western blot, 
detected using chemiluminescence
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Table 5.5 cont’d Summary of reactivity of sera from patients with gluten ataxia, coeliac disease only, familial ataxia,
sporadic ataxia (non-gluten), stiff person syndrome and healthy controls with rat cerebellar proteins separated on a western blot, 
detected using chemiluminescence
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5.4 Discussion
The antigen to which the circulating anti-Purkinje cell antibodies associated with gluten 
ataxia are directed remains unknown. Screening o f sera using cerebellar proteins on a 
Western blot failed to identify a specific target protein associated with gluten ataxia. In 
sera from all groups multiple immunoreactive bands were observed. The failure to 
identify the autoantigen associated with gluten ataxia using western blotting may be due 
to sub-optimal extraction of the protein or because it is present in too low amounts in 
the whole cerebellar extract used to be adequately detected. Alternatively, denaturation 
of the protein prior to electrophoresis may prohibit recognition by the autoantibodies. 
However, bands with a RMM of 56-59kDa were observed more frequently when sera 
from patients with gluten ataxia was used (50% samples) than sera from other groups 
(22% ataxia control, 20% CD only, 36% healthy control samples). In the same way, 
43% sera from patients with gluten ataxia exhibited a band with a RMM of 24-28kDa 
compared to 22% ataxia control, 10% CD only and 18% healthy control samples. It is 
possible that the proteins represented by these bands are important in the pathogenesis 
of the condition and possible candidate proteins within the cerebellum remain to be 
identified. Bands at a RMM of 77-78kDa were only seen in patients with gluten ataxia 
or sporadic ataxia (non-gluten) (19% of total samples). Bands at a RMM of 80-83kDa 
were seen in a total of 24% of samples from patients with gluten ataxia or familial 
ataxia but only 9% and 10% of healthy control and CD only samples respectively.
Bands with higher RMMs of 100-101kDa were seen in a total of 21% of samples from 
gluten sensitive individuals (gluten ataxia and CD only) but in no samples from other 
groups apart from one healthy control sample.
Subsequent western blot analysis to assess and/or confirm the possible contribution of 
binding of anti-gliadin and anti-TG2 antibodies to cerebellar staining by sera was 
limited by the high numbers of antibody negative sera also exhibiting bands in the 
expected RMM range. This analysis is also of limited use due to the inability to 
positively identify the immunoreactive protein without sequencing. However, 58% and 
65% of all anti-gliadin and anti-TG2 antibody positive samples, respectively, showed 
corresponding bands on a western blot, which may possibly may be attributable to the 
binding of these antibodies. Comparison of bands before and after pre-adsorption of 
antibodies with the appropriate protein will help to clarify the relative involvement of 
these antibodies to staining.
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Finally, the cross-reactivity of commercial anti-gliadin antibody with cerebellar proteins 
was confirmed by western blotting. Commercial anti-gliadin antibody bound to two 
cerebellar proteins with RMMs of approximately 33 and 43kDa, which remain 
unidentified. It is likely, although not certain, that these are the Purkinje cell proteins 
stained in the IHC experiments. Interestingly calreticulin, the protein with which anti- 
gliadin antibodies have been shown to cross-react with, is reported to be present in 
cerebellar Purkinje cells (Perrin et al, 1991). Autoantibodies to calreticulin have also 
been reported in a proportion of patients with other autoimmune diseases, such as SLE 
(Sanchez et al, 2000). However, the protein has an apparent RMM on western blot of 
~60kDa, which is not consistent with the RMMs of the bands detected by commercial 
anti-gliadin antibody but may account for some of the bands close to this RMM 
produced by sera from anti-gliadin antibody positive patients (Sanchez et al, 2000; 
Tuckova et al, 1997). Reactivity to proteins of RMMs of -33  and 43kDa was not 
apparent in all anti-gliadin antibody positive sera from patients with gluten ataxia or CD 
only, which may suggest that commercial and serum anti-gliadin antibodies have 
varying specificities.
In summary, the main findings of this study were that sera, from all groups, were found 
to react with numerous cerebellar proteins, detected by western blotting. None were 
specific to patients with gluten ataxia. Bands with a RMM of between 24-28kDa and 
56-59kDa were observed more frequently when sera from patients with gluten ataxia 
was used than sera from other groups. The proteins represented by these bands may be 
associated with gluten ataxia. 58% and 65% of anti-gliadin and anti-TG2 antibody 
positive samples respectively showed corresponding bands on a western blot that 
possibly may be attributable to the binding of these antibodies although analysis of this 
type has limitations. Finally, the cross-reactivity of commercial anti-gliadin antibodies 
with cerebellar proteins was confirmed. The antibody bound to proteins with RMMs of 
-  43kDa and 33kDa.
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CHAPTER SIX
INVESTIGATION OF A POSSIBLE 
RELATIONSHIP BETWEEN GLUTEN 
ATAXIA AND CIRCULATING ANTI- 
GLUTAMIC ACID DECARBOXYLASE
ANTIBODIES
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6.1 Introduction
6.1.1 Glutamic acid decarboxylase
GAD is an intracellular enzyme involved in the synthesis of the inhibitory 
neurotransmitter GAB A (figure 6.1).
Figure 6.1 Synthesis of y-aminobutyric acid from glutamic acid
GABA Shunt O
H2N i l 'OH
y-Amino-butyric acid Glutamic acid
•qji Succinic seirMdeltyi: 
dehydrogenase q  II ‘OHSuccinic
OH
GAD catalyses the removal o f the carboxyl group adjacent to the a-amino group from 
glutamic acid to produce GABA and carbon dioxide. GABA is broken down by 
GABA-transaminase to form succinic semialdehyde.
Taken from www.neurosci.pharm.utoledo.edu/MBC3320/GABA.htm
Like GABA, GAD is ubiquitously present in a variety o f cells and tissues as well as 
plants and various unicellular organisms. In particular, GABA and GAD are found in 
both the peripheral and central (especially hippocampal, striatal and cerebellar 
neurones) nervous systems and the pancreas (islet cells). GABA is the neurotransmitter 
used by cerebellar Purkinje cells and is also present in the enteric nervous system.
GAD exists as two isoforms, GAD65 with a RMM of 65kDa which is encoded by the 
GAD2 gene on chromosome 10 and GAD67 with a RMM of 67kDa encoded by the
2 0 0
GAD1 gene on chromosome 2. However, there is evidence for a common ancestral 
gene and the two isoforms have an overall 65% homology at the amino acid level 
(Lemmark, 1996). The GAD isoforms are extremely well conserved between species, 
for example porcine GAD65 and GAD67 are 96% and 95% identical to human and rat 
isoforms respectively (Suzuki et al, 1995). Evidence suggests that constitutive levels of 
GABA are provided by GAD67 and GAD65 provides reserve levels according to 
localised demand (Ji et al., 1999). Both isoforms are usually found together in tissues 
although some tissue-specific differences in the relative amounts of each isoform are 
apparent (table 6.1).
Cellular distribution also differs between isoforms. For example within neurones, 
GAD67 is distributed throughout the neurone whilst GAD65 is primarily found in nerve 
terminals (Soghomonian & Martin, 1998). GABA is released from nerve terminals via 
synaptic vesicles. GAD may be associated with these vesicles, where it plays a role in 
the accumulation of GABA into the vesicle, or present in a soluble cytosolic pool. The 
relative ratio of GAD65 to GAD67 associated with vesicles varies between cells, 
depending on the overall expression of the two isoforms. Overall, the amount of 
vesicle-bound GAD65 is higher than the amount of vesicle-bound GAD67. It has been 
shown that only GAD65 contains the correct information for vesicular binding, which is 
associated with amino acids 24-31 within the N-terminal although the protein(s) to 
which it binds are still unknown (Lemmark, 1996; Soghomonian & Martin, 1998).
GAD67 tends to be at greater concentrations within the soluble pool although it may also 
be vesicle-bound by a heterodimeric interaction with GAD65 (Soghomonian & Martin,
1998).
GAD exists either as an active holoenzyme containing bound co-factor (pyridoxal 5’- 
phosphate) or as an inactive apoenzyme lacking the co-factor. GAD67, responsible for 
constitutive GABA levels, tends to be found as the holo-GAD form whilst GAD65, 
responsible for reserve GABA levels, tends to be found as apo-GAD. However, little is 
known about the regulation of levels of apo- and holo-GAD and its importance in 
maintaining GABA levels (Lemmark, 1996).
2 0 1
Table 6.1 Human glutamic acid decarboxylase isoforms
g a d 65 GAD67
Gene GAD2 GAD1
Chromosome 10 2
mRNA (kb) 5.6 3.7
Protein (RMM x lO3) 65 67
Brain ++ +
Testis + ±
Islets + + ±
Human beta cells ++ -
Human non beta cells ± +
Taken from Lemmark, 1996
6.1.2 Glutamic acid decarboxylase and disease
GAD65 is a shared autoantigen in IDDM, SPS and polyendocrine autoimmune 
syndrome. The responses, involving both humoral and cellular mechanisms, are mainly 
directed against GAD65, but to a lesser extent, also GAD67. This may be due to the 
higher tissue concentration of GAD65, but more likely is the fact that immunological 
tolerance to GAD67 is established due to the early expression o f the GAD67 gene, before 
the GAD65 gene in development (Lemmark, 1996). The trigger for autoimmunity to 
GAD is not fully known. It has been speculated that the sequence similarity o f GAD to 
various vimses, particularly the Coxsackie B4 virus (Kaufman et al, 1992) which allows 
an immune response to be mounted against GAD following infection due to molecular 
mimicry. However, this notion is not consistent (Cainelli et al, 2000; Lemmark, 1996) 
and it seems likely that a combination of genetic and environmental factors are 
necessary for overt autoimmunity to GAD and the development of diseases such as 
IDDM, SPS and autoimmune polyendocrine syndrome. In addition, the nature o f the 
immune response to GAD seems to define, to some degree, which clinical manifestation 
will develop.
2 0 2
All of these diseases are associated with the expression of certain HLA class II 
molecules: primarily HLA DQ2, HLA DQ8 and HLA DR3 and DR4 (Abraham et al, 
2001), thus sharing the same genetic susceptibility as gluten sensitive individuals. 
Spontaneous T-cell reactivity to GAD has been shown in mice expressing these genes 
and, interestingly, expression of DQ6 or DR2 appeared to confer resistance or neutrality 
(Abraham et al, 2001). However, the presence of susceptible HLA genes alone does not 
induce IDDM in mice (Abraham et al, 2001), supporting the theory that, as in the case 
of gluten sensitivity, multiple genetic and environmental factors promote development 
of these diseases. Finally, 1-2% of healthy individuals have circulating anti-GAD65 
antibodies (Hao et al, 1999) yet only 10-20% of these will go on to develop IDDM 
(Lemmark, 1996) suggesting that differences in the type o f immune response may also 
influence disease development.
6 .1.2.1 Insulin dependent diabetes mellitus
IDDM is an autoimmune disease associated with an immune response against various 
pancreatic antigens and consequent destmction of insulin-producing beta-cells 
necessitating regular administration of synthetic insulin. GAD65 has been shown to be a 
major autoantigen in the disease and approximately 60-80% of newly diagnosed 
sufferers have circulating GAD65 antibodies (Rharbaoui et al, 1998; Schloot et al,
1999). Anti-GAD67 antibodies, when present, are exclusively associated with the 
presence of anti-GAD65 antibodies and competitively bind to epitopes on GAD65 
(Lemmark, 1996). Anti-GAD antibodies tend to be present for long periods o f time 
before clinical onset of the disease and anti-GAD antibody assays have proved useful in 
identifying at-risk patients.
IDDM associated anti-GAD65 antibodies recognise several conformational epitopes 
located within the middle and C-terminus portions of the GAD65 protein (Lemmark, 
1996; Powers et al, 1999; Rharbaoui et al, 1998; Schloot et al, 1999). The immune 
response to GAD in IDDM is of a Thl type, mediated primarily by CD4+ T-cells 
(Dalakas & Floeter, 1999; Lemmark, 1996), although a mixed Thl/Th2 response has 
been reported in mice (Abraham et al, 2001). Petersen and co-workers (1999) 
suggested that progression to clinical onset of IDDM is associated with a decrease in 
Th2 response to GAD and that dominance of a Th2 response is associated with non­
development of IDDM, possibly explaining why many anti-GAD65 positive people do
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not develop IDDM. Functionally, anti-GAD65 antibodies associated with IDDM do not 
inhibit the enzymatic activity of GAD65 (Powers et al, 1999).
6.1.2.2 Stiff-person syndrome
SPS is a rare neurological disorder characterised by progressive muscle rigidity and 
stiffness together with episodic spasms primarily involving axial and limb muscles. The 
disease is thought to have an autoimmune pathogenesis and also has an association with 
expression of certain HLA class II molecules. .GAD, is a major autoantigen and 
approximately 60% of patients have circulating anti-GAD65 antibodies. Interestingly, 
anti-GAD65 antibody titres tend to be 10-100 fold higher than in IDDM patients 
(Lemmark, 1996; Schloot et al, 1999). This may be due to the relatively late-onset of 
SPS, which allows titres to gradually increase prior to clinical manifestation. 
Alternatively, in contrast to IDDM, SPS is associated with a Th2 type immune response 
(Dalakas & Floeter, 1999; Lemmark, 1996; Schloot et al, 1999), which may also 
explain the higher titres. Additionally, several differences exist between IDDM- 
associated and SPS associated anti-GAD65 antibodies themselves. SPS associated 
antibodies also target conformational epitopes located in the C-terminus and middle 
sections but additionally target a linear epitope located in the N-terminus of the protein 
and are also able to inhibit the enzymatic activity of GAD65 (Lemmark, 1996; Powers et 
al, 1999; Schloot et al, 1999). Approximately 30% of SPS patients also have IDDM 
(Schloot et al, 1999). This may be due to the fact that IDDM requires a dominant Thl 
response for clinical onset or due to the difference in target epitopes. Powers and co­
workers (1999) observed that SPS patients who subsequently developed IDDM were 
more likely to express HLA DQ2-DR3 markers leading to the hypothesis that subtle 
differences in HLA class II molecules may differentiate between disease manifestation.
6.1.2.3 Autoimmune polyendocrine syndrome
Autoimmune polyendocrine syndrome patients also tend to have higher titres o f anti- 
GAD65 antibodies than are found in IDDM patients (Klemetti et al, 2000).
Autoimmune polyendocrine syndrome is also associated with a Th2 dominant immune 
response and the antibodies also inhibit GAD enzymatic activity. In common with 
IDDM-associated anti-GAD65 antibodies, epitopes within the middle and C-terminus 
(different to that recognised in IDDM) regions are targeted (Powers et al., 1999). 
Klemetti and co-workers (2000) found that 12% of patients also had IDDM but that 
anti-GAD antibodies were present in 41% of patients without clinical IDDM.
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Interestingly, the authors also found a dissociation of cellular and humoral immune 
responses. Increased antibody titres and T-cell proliferative responses to GAD rarely 
occurred within the same patient. This provides further evidence for differences in the 
immune response, which may influence manifestation of the different diseases.
6.1.2.4 Ataxia
The presence of anti-GAD antibodies in association with sporadic idiopathic ataxia was 
first reported in 1988 (Solimena et al, 1988). This has since been confirmed by a 
number of case-reports and a larger study of 14 patients with anti-GAD antibodies and 
ataxia (Honnorat et al., 2001). It has been suggested that the mechanism of ataxia 
associated with anti-GAD antibodies is also immune-mediated. There is convincing in 
vitro evidence to suggest that anti-GAD antibodies, present in the CSF o f such patients 
with ataxia, interfere with inhibitory GABAergic synaptic transmission in the 
cerebellum by acting presynaptically to decrease GABA synthesis and release (Dinkel 
et al, 1998; Ishida et al, 1999; Mitoma et al, 2000, 2003; Takenoshita et al, 2001).
6.1.3 Aims of this study
Conditions associated with anti-GAD antibodies share the same genetic susceptibility as 
patients with gluten sensitivity. Humoral reactivity to GAD has also been reported in 
patients with sporadic ataxia. Furthermore, it was noted that 4/5 SPS patients attending 
the neurology clinic in Sheffield had circulating anti-gliadin antibodies and expressed 
the HLA DQ2 allele. This prompted the investigation of whether, conversely, patients 
with gluten ataxia, with circulating anti-gliadin antibodies, may also have raised levels 
of circulating anti-GAD antibodies.
Therefore, the overall aim of this study was to investigate the potential relationship 
between gluten sensitivity, ataxia and anti-GAD antibodies. This was achieved by 
several means:
o To investigate the presence of serum anti-GAD (IgG) antibodies in patients with 
gluten ataxia, using ELISA, 
o To compare these levels with patients with CD only, patients with other causes of 
ataxia (both genetic and sporadic (non-gluten) idiopathic ataxia), SPS and healthy 
controls.
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o To investigate any correlation between the levels of circulating anti-GAD (IgG)
antibodies and anti-gliadin (IgG and IgA) or IgA anti-TG2 antibodies, 
o Comparison of the cerebellar staining pattern by serum from patients with gluten
ataxia with that of GAD, using IHC, to assess any similarities or differences, 
o Assessment of the contribution of circulating anti-GAD (IgG) antibodies to serum
staining with cerebellar proteins on a western blot.
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6.2 Methods
6.2.1 Investigation of circulating IgG anti-glutamic acid 
decarboxylase antibodies using ELISA
A total o f 29 gluten ataxia (untreated), 32 CD without neurological complications 
(untreated), 25 sporadic ataxia (non-gluten), 16 familial ataxia, 41 healthy control and 3 
SPS serum samples were assayed according to the methods detailed in sections 2.2.2 
and 2.2.5. Antibody levels and inter- and intra-assay variabilities were calculated 
according to the methods described in sections 2.2.6 and 2.2.7 respectively. In addition, 
a further 39 gluten ataxia (untreated), 32 CD without neurological complications 
(untreated), 65 sporadic ataxia (non-gluten) and 22 familial ataxia serum samples were 
assayed using the same commercial assay by the Immunology Department of The 
Northern General Hospital, Sheffield. Results were pooled and statistical analysis 
performed according to the method described in section 2.2.8. Finally, for each patient 
(not including those assayed at The Northern General Hospital), the corresponding 
levels of circulating antibodies were correlated using the Spearman rank order 
correlation as below:
o IgG anti-gliadin antibodies and IgG anti-GAD antibodies 
o IgA anti-gliadin antibodies and IgG anti-GAD antibodies 
o IgA anti-TG2 antibodies and IgG anti-GAD antibodies
6.2.2 Investigation of the cross-reactivity of anti-gliadin and anti­
tissue transglutaminase antibodies with glutamic acid 
decarboxylase using ELISA
Commercial polyclonal peroxidase-conjugated rabbit anti-gliadin antibody (Sigma, UK) 
or monoclonal mouse anti-guinea pig TG2 antibody (Labvision, USA) were assayed at 
dilutions o f 1:100 and 1:500 using a commercial anti-GAD IgG ELISA according to the 
methods detailed in sections 2.2.2 and 2.2.5.
These antibodies, as well as 4 gluten ataxia (untreated), 1 CD without neurological 
complications (untreated), 1 ataxia control and 2 healthy control serum samples were 
also assayed at a dilution of 1:100 both before and after adsorption of anti-gliadin 
antibodies by crude gliadin. Samples were diluted 1 TOO in PBST or crude gliadin 
solution (~20mg/ml, prepared as detailed in section 4.2.3) and incubated for 60mins at
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RT to allow adsorption of antibodies. Samples were then assayed according to the 
methods detailed in sections 2.2.2 and 2.2.5.
6.2.3 Investigation of the cerebellar staining pattern of commercial 
glutamic acid decarboxylase antibody
The staining pattern of a commercially available monoclonal, mouse anti-GAD 
antibody (Affiniti Research, UK) against rat cerebellar tissue were investigated using 
the indirect IHC method, outlined in sections 2.3.1 and 2.3.3. The antibody was used at 
a dilution of 1:500 or 1:1000 in PBST and binding was detected using a HRP- 
conjugated, goat anti-mouse IgG antibody (Jackson Immunoresearch Laboratories, USA 
(UK distributor, Stratech)) at a dilution of 1:500 in PBST.
In all experiments, sections incubated with either a Purkinje-cell specific antibody 
(section 4.2.1) or PBST as a substitute for primary antibody were included as positive 
and negative controls.
6.2.4 Detection of glutamic acid decarboxylase within rat cerebellar 
extract by western blotting
Detection of GAD was performed by probing an extract o f rat cerebellum, separated on 
a 10% polyacrylamide gel, with a commercial monoclonal antibody. The same rat 
cerebellar extract (#9, section 5.3.1) was used in all experiments in order to minimise 
inter-experimental variation.
36pg/lane of rat cerebellar extract was loaded onto a 10% polyacrylamide gel, prepared 
as detailed in section 2.4.4. The first lane of each gel was loaded with lOpl coloured 
pre-stained molecular weight marker (Sigma, UK). SDS-PAGE and western blotting 
was then performed using the optimised method, as detailed in sections 2.4.4 and 2.4.5 
respectively. GAD was detected according to the optimised method detailed in section
2.4.6. Details of the primary and secondary antibodies used are given in table 6.2. The 
RMM of the protein band was determined according to the method detailed in section
2.4.7. Blots were probed with monoclonal anti-GAD antibody in 10 different 
experiments. The average RMM of resultant protein bands was calculated.
208
Table 6.2 Details of reagents used in the detection of glutamic acid decarboxylase 
within a cerebellar extract on a western blot
Antibody
Specificity
Species
(supplier)
Dilution Corresponding 
secondary antibody
Secondary
antibody
dilution
Monoclonal
anti-
GAD65/67
Mouse IgG 
(Affmiti 
Research, UK)
1:1 0  0 0 0
Horseradish Peroxidase- 
conjugated goat anti-mouse 
IgG
(Jackson Immunoresearch 
Laboratories, USA (UK  
distributor, Stratech))
1 :10  0 0 0
6.2.5 Investigation of the specificity of patient serum antibody 
binding to glutamic acid decarboxylase by western blotting
The results of the sera screening experiment described in section 5.3.6 were re-assessed 
to determine which bands may be due to binding of IgG anti-GAD antibodies 
within positive serum samples. The average RMM of the positive control GAD protein 
band from this study was used. Any bands at the calculated RMM ± inter-experimental 
variability were considered likely to be produced by binding of anti-GAD antibodies. 
The percentage of the total number of patients whose serum was positive for IgG anti- 
GAD antibodies on ELISA and that also produced a band suggestive of binding of anti- 
GAD antibodies, was calculated.
The persistence of commercial and serological anti-GAD antibody reactivity was 
assessed and compared using commercial anti-GAD antibody or serum from a patient 
with untreated gluten ataxia, previously found to have GAD reactivity on western blot 
in the sera screening experiment. lOpl/lane (3 6 jLXg) of rat cerebellar extract was loaded 
onto a 10% polyacrylamide gel, prepared as detailed in section 2.4.4. The first lane of 
each gel was loaded with lOpl coloured pre-stained molecular weight marker (Sigma, 
UK). SDS-PAGE and western blotting was then performed according to the optimised 
method detailed in sections 2.4.4 and 2.4.5 respectively. The blot was probed with 
either commercial monoclonal anti-GAD65/67 antibody (Afflniti Research, UK) at 
dilutions of 1:10 000, 1 TOO 000 or 1:500 000 in PBST or patient serum at dilutions of
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dilutions of 1:10 000, 1:100 000 or 1:500 000 in PBST or patient serum at dilutions of 
1:5000, 1:50 000 or 1:100 000 in PBST according to the optimised method detailed in 
section 2.4.6. Peroxidase-conjugated, goat anti-human or anti-mouse IgG (Jackson 
Immunoresearch Laboratories, USA (UK distributor, Stratech)) diluted 1:10 000 in 
PBST was used as the appropriate secondary antibody. Staining was visualised using 
the UVP imaging system detailed in section 2.4.6.
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6.3 Results
6.3.1 Inter- and Intra-assay variability
The average inter- and intra-assay variability of the commercial anti-GAD IgG ELISA 
kit was 5.2 and 4.7% respectively (n=4).
6.3.2 Presence of circulating IgG anti-glutamic acid decarboxylase 
antibodies in patients with gluten ataxia
According to the cut-off values supplied by the kit manufacturer, 56% o f gluten ataxia 
samples and 59% of CD only samples were positive for IgG anti-GAD antibodies as 
compared to 29% sporadic (non-gluten) ataxia, 13% familial ataxia and 12% of healthy 
control samples. This is represented in figure 6.2, which illustrates the distribution of 
IgG anti-GAD antibody levels between groups. The median value and inter-quartile 
range of each group is shown in figure 6.3. Kruskal-Wallis analysis indicated a highly 
significant difference between groups (PO.OOl). The median antibody levels o f gluten 
ataxia patients and patients with CD without neurological complications, which were 
not significantly different (p>0.05), were significantly higher than those o f patients with 
sporadic (non-gluten) ataxia, familial ataxia and healthy controls (all p<0 .0 0 1 ). 
Although more patients with sporadic (non-gluten) ataxia than patients with familial 
ataxia were positive for circulating IgG anti-GAD antibodies, the median levels of these 
two groups were not significantly different (p>0.05). The median level o f each o f these 
groups also did not differ significantly from the median level of healthy control patients 
(p>0.05).
6.3.3 Correlation of circulating levels of gluten sensitivity associated 
antibodies and IgG anti-glutamic acid decarboxylase antibodies
Levels o f circulating IgG anti-GAD antibodies in patients with untreated gluten ataxia 
were not significantly correlated with levels of either IgG anti-gliadin antibodies or IgA 
anti-TG2 antibodies (p>0.05) (data not shown). However, levels of circulating IgG 
anti-GAD antibodies were weakly correlated with levels of IgA anti-gliadin antibodies 
in these patients (p<0.05) (figure 6.4).
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Figure 6.4 Correlation between circulating IgG anti-GAD and IgA anti-gliadin antibodies in patients with gluten ataxia
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A positive correlation was observed between circulating IgG anti-GAD and IgA anti-gliadin antibodies in patients with gluten ataxia (p<0.05).
6.3.4 Individual anti-glutamic acid decarboxylase antibody profiles of 
patients with gluten ataxia
The individual serological levels of IgG anti-GAD antibodies of each patient with 
gluten ataxia are summarised in table 6.3.
6.3.5 Cross-reactivity of anti-gliadin and anti-tissue transglutaminase 
antibodies with glutamic acid decarboxylase and the effects of 
pre-adsorption of sera with crude gliadin on IgG anti-glutamic 
acid decarboxylase antibody levels
Commercial anti-gliadin and anti-TG2 antibodies showed no cross-reactivity with GAD 
on the IgG anti-GAD ELISA. Pre-adsorption of patient serum anti-gliadin antibodies 
using crude gliadin did not affect the IgG anti-GAD levels of any sample tested, 
determined by IgG anti-GAD ELISA (figure 6.5).
6.3.6 Staining pattern of commercial anti-GAD antibody on rat 
cerebellar tissue
Commercial anti-GAD antibody, used at dilutions of 1:500 and 1:1000, weakly stained 
rat cerebellum. Purkinje cells were particularly stained with both cytoplasmic and, 
stronger, membranous staining evident (figure 6 .6).
6.3.7 Detection of GAD protein within rat cerebellar extract
Detection of GAD using a monoclonal anti-GAD65/67 antibody produced a doublet 
(although usually appearing as a single thick band) at an average RMM of 65.3kDa 
(range 60-7lkDa) (figure 6.7).
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Table 6.3 Summary of the individual levels of IgG anti- glutamic acid decarboxylase 
antibodies in patients with gluten ataxia
Patient
num ber
IgG anti-GAD level 
(U/ml)
Patient num ber IgG anti-GAD level 
(U/ml)
1 Not assayed 18 0.52
2 2.05 19 0.9
3 0.8 20 0.72
4 Not assayed 21 3.01
5 0.54 22 1.2
6 Not assayed 23 6.09
7 0.83 24 0.63
8 0.52 25 0.68
9 0.34 26 0.41
10 0.67 27 1.00
11 0.99 28 2.1
12 1.76 29 3.36
13 1.09 30 3.78
14 0.66 31 0.67
15 1.9 32 0.91
16 0.45 33 Not assayed
17 0.43 34 Not assayed
Data expressed in arbitrary units (defined by the kit manufacturers). Patient number 
corresponds to that in table 2.1. Samples defined as positive according to the kit 
manufacturers are shown in red.
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Figure 6.6 Staining pattern of commercial anti-glutamic acid decarboxylase antibody
on control rat cerebellum, as determined by IHC
Typical staining pattern of commercial anti-GAD antibody, diluted to 1:500, on rat 
control cerebellum. Purkinje cells are indicated by arrows. M -  molecular layer 
G -  granular layer. Scale bar = 100 pm.
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Figure 6.7 Binding to glutamic acid decarboxylase within rat cerebellar extract of a
commercial monoclonal antibody, detected by chemiluminescence
116 k D a---- ►
66 kD a---- ►n r
45 kD a---- ►
29 kD a---- ►
20.1 k D a ---- ►
Lane 1 2
A 10% polyacrylamide gel was loaded as follows,
Lanes 1-2 10jul/lane (36pg protein) rat cerebellar protein extract (extraction #9)
Following separation and transfer, the blot was probed with monoclonal anti-GAD65/67 
antibody, 1:10 000. Binding was visualised using horseradish-peroxidase conjugated 
anti-mouse IgG secondary antibody at a dilution of 1:10 000. The blot was then 
incubated with ECL-plus™ reagent and imaged using a UVP imager.
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6.3.8 Specificity of patient serum antibody binding to GAD
The inter-experimental variability of the sera screening experiment was 8%. Therefore, 
for antibody positive serum, bands at 65.3 ± 8% kDa (60-71 kDa) were considered 
possibly due to binding o f anti-GAD antibodies. These bands are highlighted in table 
6.4. Using these criteria, overall, 60% of sera positive for anti-GAD antibodies on 
ELISA also exhibited a band on a blot likely to be due to binding of IgG anti-GAD 
antibodies.
Reactivity of both commercial anti-GAD antibody and the sera from a patient with 
untreated gluten ataxia against GAD protein within rat cerebellar extract on a western 
blot decreased in intensity but persisted up to the highest dilutions tested (1:500 000 and 
1:100 000 respectively) (figure 6.8).
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Table 6.4 Summary of reactivity of sera from patients with gluten ataxia, coeliac 
disease only, familial ataxia, sporadic ataxia (non-gluten), stiff-person 
syndrome and healthy controls likely to be against glutamic acid 
decarboxylase within rat cerebellar extract on a western blot, detected by 
chemiluminescence
RMM (kDa)
— ►
PATIENT (no.)
60-69 70-79
GA (15) 65 -
GA (30) - -
GA (25) 65 -
GA (27) - -
GA (24) - -
GA (28) - -
GA (23) 67 -
GA (29) - -
GA (13) - -
GA (21) - -
GA (11) - -
GA (16) - 78
GA (22) 65 llS||ll§70
GA (32) 63 -
RMM (kDa)
p a t i e n t ” *
60-69 70-79
SA - -
SA - 77
SPS 65 -
FA 62 -
FA - -
FA - -
FA - -
FA 62 -
FA - -
FA 63 -
CD - wmnm.
CD - -
CD - -
GA -  gluten ataxia (patient number corresponding to table 2.1 shown in brackets), SA -  
sporadic ataxia (non-gluten), SPS -  stiff-person syndrome, FA -  familial ataxia, CD -  
CD only without neurological complications. Bands likely to be due to binding o f anti- 
GAD (RMM within 8% of known protein RMM) (60-71 kDa) antibodies within 
antibody positive serum are shaded 8  . Intense bands are shown in bold.
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Table 6.4 cont’d Summary of reactivity of sera from patients with gluten ataxia, coeliac 
disease only, familial ataxia, sporadic ataxia (non-gluten), stiff-person 
syndrome and healthy controls likely to be against glutamic acid 
decarboxylase within rat cerebellar extract on a western blot, detected 
by chemiluminescence
RM M  (kDa)
— ► 
PATIENT
60-69 70-79
CD - -
CD 67 -
CD - -
CD - -
CD - -
CD - -
CD - -
HC 63 -
HC - -
HC - -
HC - -
HC - -
HC - -
HC - -
H C - 76
HC - -
HC - -
HC - -
CD -  CD only without neurological complications, HC -  healthy controls. Bands likely 
to be due to binding of anti-GAD (RMM within 8% of known protein RMM) (60-
71 kDa) antibodies within antibody positive serum are shaded \M. Intense bands are 
shown in bold.
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Figure 6.8 Persistence of the reactivity of commercial and serological anti-glutamic
acid decarboxylase antibodies to glutamic acid decarboxylase protein within 
rat cerebellar extract, detected by chemiluminescence
Lane 1 2 3 4 5 6
A 10% polyacrylamide gel was loaded as follows,
Lanes 1-6 lOpl/lane (36pg protein) rat cerebellar protein extract (supernatant, 
extraction #9)
Following separation and transfer, the blot was probed with monoclonal anti-GAD65/67 
antibody at dilutions of 1:10 000 (lane 1), 1:100 000 (lane 2) or 1:500 000 (lane 3) or 
serum from a patient with untreated gluten ataxia (number 15 corresponding to table 
2.1) at dilutions of 1:5000 (lane 4), 1:50 000 (lane 5) or 1:100 000 (lane 6). Binding 
was visualised using horseradish-peroxidase conjugated anti-mouse IgG secondary 
antibody at a dilution of 1:10 000. The blot was then incubated with ECL-plus™ 
reagent and imaged using a UVP imager.
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6.4 Discussion
Investigation of the relationship between gluten sensitivity, ataxia and anti-GAD 
antibodies has provided an additional target area for further research related to the 
humoral immune response in gluten ataxia. The results of these demonstrate that 
patients with gluten ataxia and CD only have increased levels of circulating IgG anti- 
GAD antibodies compared to other groups (p<0.001), which are not explained by an 
increased prevalence of co-existing diseases associated with these antibodies such as 
IDDM compared to control groups. These findings are in contrast to a recent study by 
Uibo and co-workers who found no relationship between immune reactivity to GAD 
and gliadin (Uibo et al., 2001). These differences may be due to the different study 
populations examined. Uibo and co-workers examined a randomly selected adult 
population whilst the patients in the current study may be considered at an increased 
likelihood for GAD reactivity due to the presence of a co-existing autoimmune 
condition with a shared genetic susceptibility to other GAD-associated autoimmune 
disorders. Therefore, such an association may be more difficult to detect in a general 
population and may only become evident if  a greater number than the 200 individuals 
investigated by Uibo is considered.
The prevalence of anti-GAD antibodies in patients with gluten ataxia and CD only was 
similar (56% and 59% respectively) suggesting that the presence of these antibodies 
may be associated with gluten sensitivity in general. ELISA studies have shown that 
the observed reactivity of serum on the anti-GAD antibody ELISA is not due to cross­
reactivity of circulating anti-gliadin or anti-TG2 antibodies with GAD. Levels of 
circulating IgG anti-GAD antibodies in patients with gluten ataxia were not correlated 
with levels of circulating IgG anti-gliadin or IgA anti-TG2 antibodies but appear to be 
weakly correlated with IgA anti-gliadin antibodies (p<0.05). In addition, although it is 
not possible to positively identify the immunoreactive protein without sequencing o f the 
band, further analysis of western blots showed that 60% of sera from patients with 
gluten ataxia, positive for anti-GAD antibodies on ELISA, also exhibited a band 
possibly due to the binding of IgG anti-GAD antibodies.
GAD is present in the enteric nervous system and it seems possible that exposure of the 
enzyme to immune cells during the immune response against gluten may result in the 
production of anti-GAD antibodies. This may explain the observed correlation of these 
antibodies with circulating IgA anti-gliadin antibodies. Patients with more severe
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mucosal damage (for example patients with CD only) may then be expected to have 
. higher levels of antibodies, in a similar manner to the way in which levels of anti- 
gliadin and anti-TG2 antibodies are reportedly associated with the degree o f mucosal 
damage (Rostami et al, 2003; Tursi et al., 2001, 2003). However, this is not the case. 
It has been suggested that anti-GAD antibodies may arise via cross-linking by TG2 and 
presentation to the appropriate immune cells, a suggestion supported by the fact that 
IgG anti-TG2 antibodies have been reported in up to 42% of patients with IDDM (Kim 
et al, 2002). This notion is also supported by the high prevalence of IgA anti-TG2 
antibodies in patients with CD and gluten ataxia although no correlation between 
circulating levels of the two antibodies was observed in the current study.
Alternatively, immunoreactivity to GAD may be the result o f epitope spreading of 
gluten sensitivity associated antibodies or a reflection of a general increased propensity 
to autoimmunity as a result of immune hyper-responsivity in these patients. Patients 
with CD only have been shown to be at an increased risk of developing autoimmune 
diseases, such as IDDM (Sategna Guidetti et al, 2001; Ventura et al, 1999), which 
shares a genetic susceptibility with gluten sensitivity of the presence of HLA DQ2 or 
DQ8 (Abraham et al, 2001). Using anti-GAD antibodies as a marker of current or pre- 
clinical diabetes, the incidence of anti-GAD antibodies in gluten ataxia patients is much 
higher than would be expected due to the previously reported association between these 
conditions. This suggests an interesting possible link between these disorders, which 
may be more extensive than previously appreciated and requiring further investigation.
Anti-GAD antibodies have previously been reported in association with cases of 
cerebellar ataxia, most frequently in the presence of other autoimmune diseases (anti- 
GAD associated ataxia) (Abele et al, 1999; Honnorat et al, 2001; Saiz et al, 1997). 
The presence of anti-GAD antibodies has been suggested as an indicator that these 
individuals represent a subgroup o f patients with sporadic idiopathic ataxia with an 
autoimmune origin and an immune-mediated pathogenesis (Honnorat et al, 2001). 
Although the presence of anti-GAD antibodies in these patients may be attributed to the 
association with co-existing IDDM or polyendocrine autoimmunity, similarly elevated 
anti-GAD antibodies have been reported in patients with anti-GAD associated ataxia 
without these disorders (Honnorat et al, 2001). In addition, the anti-GAD levels o f 
these patients have been found to be significantly higher than the corresponding levels 
in patients with IDDM only and similar to the levels seen in patients with SPS
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(Honnorat et al, 2001; Saiz et al, 1997). In the current study, samples from patients 
with IDDM were not available to screen for comparative purposes although levels of 
anti-GAD antibodies in gluten ataxia patients were similar to those o f two sera from 
anti-GAD antibody positive patients with SPS.
Several similarities between ataxia associated with anti-GAD antibodies and gluten 
ataxia are apparent although the significance o f these observations is unclear. Both 
conditions are associated with a progressive ataxia of gait and the presence of 
oligoclonal bands (10/14 patients with anti-GAD associated ataxia and 12/28 patients 
with gluten ataxia) although the majority of patients with anti-GAD associated ataxia 
have been reported to be female whereas this is not the case in patients with gluten 
ataxia (Honnorat et al, 2001; Saiz et al, 1997). In one study, two patients with anti- 
GAD associated ataxia also had IgA anti-gliadin antibodies although this was reported 
as a probable coincidental finding by the authors (Honnorat et al, 2001). The presence 
o f IgG anti-gliadin antibodies, a more sensitive marker of gluten ataxia, was not 
reported. Although not a significant difference compared to controls, the finding that 
29% of patients with sporadic idiopathic ataxia, in the absence of any other indicators of 
gluten sensitivity, have increased circulating levels of anti-GAD antibodies is also 
interesting in this regard. It is possible that these patients represent a subgroup with 
anti-GAD associated ataxia although it is not known whether these patients have co­
existing autoimmune diseases, which may increase the likelihood of anti-GAD 
antibodies. In addition, all were found to express either DQ2 or DQ1, susceptibility 
genes associated with autoimmune conditions and found in at least 98% of patients with 
gluten ataxia. However, antibody levels of positive patients were generally not as high 
as those o f patients with CD only or gluten ataxia and the median level o f this group 
was not statistically different to those of other control groups. The significance of this 
group o f patients with regard to the possible relationship between anti-GAD associated 
ataxia and gluten ataxia remains unclear. It is unlikely that these entities are identical as 
these patients are not gluten sensitive although it seems possible that these disorders 
represent a more general group of patients with ataxia associated with anti-GAD 
antibodies related to HLA DQ2/DQ8 susceptible autoimmune conditions in general.
The finding that patients with familial ataxia did not have significantly increased levels 
of anti-GAD antibodies compared to controls is consistent with previous reports of their 
absence in patients with ataxia and no evidence of autoimmune disorders (Saiz et al,
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1997) and suggests that these antibodies too, are specific and not merely an 
epiphenomenom of Purkinje cell loss.
Finally, the observed prevalence of anti-GAD antibodies in healthy control patients 
(12%) is higher than previously reported in other studies (Honnorat et al, 2001; 
Tuomilehto et al., 1994). This difference may be due to factors such as the use o f 
different detection methods (ELISA vs RIA) or a population variation in the incidence 
of clinical and pre-clinical IDDM.
In summary, the main findings of this study were that patients with gluten sensitivity 
(gluten ataxia and CD only) have significantly increased levels of circulating IgG anti- 
GAD antibodies. These antibodies, detected by ELISA, are directed against GAD and 
not a result o f cross-reactivity of circulating anti-TG2 or anti-gliadin antibodies in 
gluten sensitive individuals. Although of limited use, western blot analysis showed that 
60% of sera from patients with gluten ataxia, positive for anti-GAD antibodies on 
ELISA, also exhibited a band on a blot possibly due to the binding o f IgG anti-GAD 
antibodies. Levels of circulating IgG anti-GAD antibodies in patients with gluten ataxia 
were not correlated with levels of circulating IgG anti-gliadin or IgA anti-TG2 
antibodies but appear to be weakly correlated with IgA anti-gliadin antibodies. A 
smaller proportion of patients with sporadic idiopathic ataxia also have increased levels 
o f IgG anti-GAD antibodies compared to healthy controls and patients with familial 
ataxia, although this difference was not significant. These patients may represent a 
subgroup o f patients with ataxia associated with anti-GAD antibodies similar to that 
which has been previously described by other authors.
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CHAPTER SEVEN
GENERAL DISCUSSION
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7.1 Discussion of results
Gluten ataxia is part of the spectrum of gluten sensitivity, ataxia being the primary 
presentation followed by the subsequent detection of previously undiagnosed gluten 
sensitivity. The cerebellum is the primary target organ in a manner analogous to the 
skin in DH or the small intestine in CD. The strong association with the HLA 
haplotypes found in CD, presence of associated circulating antibodies and oligoclonal 
bands, neuropathological findings and the clinical response to a GFD are all convincing 
evidence for the inclusion of gluten ataxia within the spectrum of gluten sensitivity and 
also the hypothesised immune-mediated pathogenesis of the condition; It is suggested 
that this immune response results in damage to the cerebellum and the associated 
clinical symptoms. The studies contained within this thesis have aimed to elucidate the 
involvement o f the humoral immune response in the pathogenesis of gluten ataxia.
The results included in this thesis demonstrate that, in common with patients with other 
manifestations of gluten sensitivity (CD and DH), patients with gluten ataxia have 
elevated levels of circulating anti-gliadin and anti-TG2 antibodies. In addition, the 
majority o f patients with gluten ataxia have elevated levels of circulating antibodies 
directed against GAD. IHC studies have shown that patients with gluten ataxia also 
possess high titres of antibodies capable of reacting with cerebellar Purkinje cell 
proteins, providing evidence for the existence of a humoral immune response, although 
the target antigen remains unidentified. Interestingly, the ability of anti-gliadin 
antibodies to cross-react with cerebellar Purkinje cell proteins has been confirmed by 
both IHC and western blotting studies, suggesting the existence of common epitopes. 
However, adsorption experiments indicate that patients with gluten ataxia also possess 
additional anti-Purkinje cell antibodies, which are distinct from anti-gliadin antibodies. 
It is hypothesised that these, as yet unidentified antibodies, may be responsible for the 
Purkinje cell damage observed in gluten ataxia.
It is logical to first consider whether these anti-Purkinje cell antibodies are related to the 
anti-gliadin, anti-TG2 or anti-GAD antibodies, which have already been identified in 
these patients. In order for an antibody to play a causal role in disease pathogenesis it 
must be present in all patients. In addition, the infrequency o f histologically evident 
mucosal damage in patients with gluten ataxia suggests that any neuropathic antibodies 
are not dependent on the presence of severe mucosal damage for their production.
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By these criteria, gluten-associated anti-TG2 antibodies are unlikely to be a requirement 
for neuronal damage as they are found in less than half of patients with gluten ataxia. 
The dissimilarity of cerebellar staining patterns of sera from patients with gluten ataxia 
and monoclonal anti-TG2 antibody is also consistent with the idea that cerebellar 
antibody reactivity is, at least primarily, mediated by antibodies other than those 
directed against TG2. In contrast, all patients with gluten ataxia possess anti-gliadin 
antibodies, which are capable o f cross-reacting with cerebellar Purkinje cells. Also, in 
contrast to anti-TG2 antibodies, production of anti-gliadin antibodies, directed against 
the universal exogenous aetiological factor o f gluten sensitivity, is not dependent on the 
presence o f histological mucosal damage. It seems possible that circulating anti-gliadin 
antibodies may somehow be involved in the humoral pathogenesis o f gluten ataxia.
However, one major consideration of this hypothesis must be that the majority of 
patients with CD only and DH also have high circulating levels of both of these 
antibodies yet don’t develop neurological complications. Some, as yet unknown, 
differentiating factor must determine whether a neurological immune response is 
initiated or established and elucidation of this factor will provide further knowledge of 
the pathogenesis of gluten ataxia.
Although patients with gluten ataxia share the same genetic HLA susceptibility as other 
gluten sensitive individuals, the expression of additional, as yet unidentified, genes may 
result in a tendency for a predominantly neurological manifestation as opposed to other 
target organs. Alternatively, it is clear that patients with gluten ataxia generally suffer 
less intestinal mucosal damage than do patients with CD. It is likely that both groups 
consume similar levels of gluten and, often, the diagnosis o f gluten ataxia at a late age 
means that these patients have been consuming gluten for a longer period yet the 
intestine appears less susceptible to immunological damage. It seems possible therefore 
that, here too, genetics or some other subtle difference in the intestinal immune response 
to gluten may be responsible for this difference. For example, IDDM, SPS and 
autoimmune polyendocrine disorder are all associated with the presence o f anti-GAD 
antibodies and it has been suggested that slight differences in the immune response to 
GAD determines the clinical manifestation (Lemmark, 1996). One such difference is 
the dominance of a Thl versus a Th2 immune response. Progression to clinical onset of 
IDDM has been reported to be associated with a decrease in the Th2 response to GAD 
(Petersen et al, 1999) whilst SPS is associated with a dominance of the Th2 response,
230
along with additional differences in the properties of anti-GAD antibodies which also 
distinguish the two disorders (Schloot et al, 1999). Analagous to this situation, onset of 
different manifestations of gluten sensitivity may be related to the relative balance 
between a Thl and Th2 response to gluten. A Thl response is responsible for most of 
the intestinal damage associated with CD and it may be that, in patients with gluten 
ataxia, this response is somehow shifted towards a Th2 response due to differences in 
the immune recognition of gluten, thereby avoiding much of the Thl-mediated 
intestinal damage but still resulting in disease associated antibody production. 
Interestingly, intestinal T-cells from patients with DH have been shown to produce 
more IL-4, a cytokine involved in antibody production, than T-cells from patients with 
CD only (Hall et al, 2000). It may be the case that a similar process occurs in patients 
with gluten ataxia. The selection of Thl/Th2 immunity may be affected by many 
factors including alterations in the sequence of the T-cell epitope, antigen dose and 
route and relative affinity to the T-cell receptor (Murray, 1998). Differences in the 
intestinal immune response to gluten may also explain the presence of anti-Purkinje cell 
antibodies in patients with gluten ataxia. The gluten T-cell epitopes that have been 
identified to date in patients with CD may not be as immunodominant in patients with 
gluten ataxia. Although anti-gliadin antibodies from both patients with CD and gluten 
ataxia cross-react with Purkinje cell epitopes, additional gluten epitopes may be more 
predominant in patients with gluten ataxia. Again, this may be in an analagous manner 
to anti-GAD antibody associated conditions where manifestation o f a particular disorder 
is partly dependent on the target epitope o f GAD recognised by antibodies (Lemmark, 
1996; Powers et al, 1999). Anti-gliadin antibodies in patients with gluten ataxia 
directed against different gluten epitopes may have a greater avidity or cross-reactive 
potential for Purkinje cell epitopes. In addition, with time these epitopes may be more 
likely to undergo epitope spreading than epitopes recognised by anti-gliadin antibodies 
in patients with CD without neurological complications. Epitope spreading refers to the 
process by which antibody recognition o f new epitopes occurs, on the same or different 
proteins to the primary disease-inducing epitope. This process has been implicated in 
the pathogenesis of other autoimmune diseases, including IDDM and multiple sclerosis 
(MS), and has also been suggested as the mechanism responsible for the increased risk 
of autoimmune diseases associated with CD (Martucci & Corazza, 2002). It is 
conceivable then, that some process of epitope spreading may occur in patients with 
gluten ataxia, but not CD only, resulting in the observed anti-Purkinje cell antibodies 
that are not adsorbed by crude gliadin in these patients. Alternatively, antigenic
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neoepitopes may be produced by the cross-linking of gliadin and TG2 in the intestine, 
which, in some cases, may produce antibodies distinct from anti-gliadin antibodies that 
cross-react with Purkinje cell epitopes resulting in an immune response targeting these 
cells.
Although initial evidence has suggested that anti-TG2 antibodies are unlikely to play a 
direct role in neurological damage, differences in the affinity of circulating antibodies to 
different transglutaminases may also play a role in the formation of anti-Purkinje cell 
antibodies. For example, patients with DH have recently been shown to have a 
serological profile suggesting a higher affinity for epidermal transglutaminase (TG3) 
than TG2. In addition, these patients possess an antibody population specific for TG3, 
which is not found in patients with CD only (Sardy et al., 2002). It is possible 
therefore, that a similar situation exists in patients with gluten ataxia, who may have a 
serological profile suggestive of a higher affinity towards a neural transglutaminase, or 
a subgroup of antibodies directed against this enzyme, not seen in patients with other 
manifestations of gluten sensitivity. This hypothesis is intriguing in light o f the recent 
discovery of a novel transglutaminase (TG6), which is primarily expressed in the brain 
including Purkinje cells (Grenard et al., 2001).
The full significance of the finding that both patients with CD and gluten ataxia have 
elevated levels of circulating anti-GAD antibodies is still not known. The fact that anti- 
GAD antibodies are present in just over half of patients with gluten ataxia suggests that 
these antibodies are unlikely to play a causative role in the pathogenesis o f gluten 
ataxia. However, these antibodies have been shown to be pathogenic mediating 
suppression o f GABA release from cerebellar neurones (Dinkel et al, 1998; Ishida et 
al., 1999; Mitoma et al., 2000, 2003; Takenoshita et al., 2001). It has been 
hypothesised that a cerebellar GAD dysfunction could lead to pathological changes and 
neuronal cell death (Honnorat et al., 1995). It seems possible therefore, that anti-GAD 
antibodies, when present, may have some additional or modulatory effect on the disease 
process.
Alternatively, the anti-Purkinje cell antibodies present in patients with gluten ataxia 
may be unrelated to any other previously described circulating disease associated 
antibody. Determination of the target antigen will shed more light on the nature of 
these antibodies. IHC studies suggest that the antigen may be cytoplasmic. Although
232
antibodies directed against cytoplasmic antigens are often thought to be non-pathogenic, 
this does not preclude the possibility that these antibodies are neurotoxic. Purkinje cells 
have previously been shown to be capable of taking up large molecules from the CSF, 
including immunoglobulins, which may provide a mechanism for pathogenic antibodies 
directed against cytoplasmic components (Borges et al, 1985). In addition, antibodies 
have been shown to penetrate living cells, including neurones (Alarcon-Segovia et al., 
1996; Wenthold et al, 1984). In this way, antibodies could theoretically be internalised 
by Purkinje cells and cause pathological effects in this manner.
In order for a neuronal immune response to occur, immune cells must gain access to the 
cerebellum. Even under normal circumstances, it has been shown that activated T- and 
B-cells as well as small amounts of IgG can enter the CNS across an intact blood-brain 
barrier (BBB) (Hickey, 2001). IgG antibodies are able to pass the BBB by passive 
diffusion and enter the CSF at a fraction of approximately 1/500 of the serum 
concentration (Wurster, 2003). This diffusion may therefore be quite significant in 
situations where the serum antibody concentration is high. This mechanism is likely to 
explain the observations in the case study by Chinnery and co-workers, which suggested 
that anti-gliadin antibodies may be able to cross the BBB (Chinnery et al, 1997). In 
other neurological inflammatory diseases, such as MS, the BBB is initially impaired 
thus allowing access of immune cells to the brain (Markovic-Plese & McFarland, 2001). 
Impairment of the BBB by factors such as inflammation caused by infection or some 
abnormality in proteins regulating permeability may occur in patients with gluten ataxia 
but not in gluten sensitive patients without neurological complications. A novel 
modulator of intestinal permeability, zonulin, a human analogue to the zonula occludins 
toxin (ZOT) found in Vibrio cholerae, has been shown to be upregulated in CD (Fasano 
et al, 2000). Related zonula occludens proteins are also present in the BBB (Pachter et 
al, 2003) and it is possible that these may be affected in a similar manner in gluten 
ataxia. However, dysfunction of these proteins still doesn’t yet fully explain why only 
some gluten sensitive patients are affected and not others.
In other conditions such as PCD and SPS, the presence of antibodies in the CSF has 
been established as well as confirmation of intrathecal synthesis in some cases (Dalakas 
et al, 2001; Darnell & Posner, 2003). The preliminary studies contained within this 
thesis failed to detect the presence of anti-gliadin antibodies in the CSF of gluten ataxia 
patients or any reactivity of CSF with Purkinje cells by IHC. This suggests that
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intrathecal anti-gliadin antibody production is unlikely in gluten ataxia patients, which 
is consistent with a report by Burk and co-workers of no anti-gliadin antibodies or any 
other abnormal values in the CSF of twelve patients with gluten ataxia (Burk et al, 
2001). However, further studies are needed to clarify this situation with regard to both 
anti-gliadin and other antibodies in the CSF of these patients.
Finally, a primary role for the humoral response in the pathogenesis o f gluten ataxia 
cannot be assumed. The involvement of a, possibly primary, T-cell response in PCD 
has been described (Albert et al., 1998; Tanaka et al, 1999) in addition to the 
established antibodies directed against onconeural antigens. There is also strong 
evidence for the involvement of a T-cell response in the pathogenesis o f gluten ataxia. 
Marked lymphocytic infiltration of the cerebellum, consisting mainly o f T-cells (CD4 
and CD8) has been observed in patients with gluten ataxia at post-mortem 
(Hadjivassiliou et al, 1998) and there is upregulation of IP-10, a T-cell chemoattractant, 
in the CSF of patients with gluten ataxia (Hadjivassiliou et al, 2003b). The relative 
contributions of both the humoral and the cellular immune responses to the 
pathogenesis of gluten ataxia have yet to be described. Access of T-cells to the 
cerebellum and initiation of a cell-mediated immune response may be the differentiating 
factor for development of gluten ataxia and it remains to be seen whether antibodies 
play a causative role in the cerebellar damage or are merely produced secondary to a 
primary T-cell mediated response.
7.2 Future work
The work contained within this thesis has raised many further questions related to the 
immune pathogenesis of gluten ataxia, which need to be answered and provide 
opportunities for further work.
These questions include:
o What is the antigen recognised by the circulating anti-Purkinje cell antibodies 
identified in patients with gluten ataxia?
This question is currently being addressed by ongoing work. To date, protein 
sequencing of two immunoreactive bands from a 1-D SDS-PAGE gel has been 
completed and ongoing work is concentrated on the preparation of.gel digests of 
target proteins for identification using MALDI-TOF and ion spray analysis, 
although this method may be complicated by the complex nature o f the proteins
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within the band (i.e. the presence of several proteins at each position). This problem 
may be overcome by the use of 2-D electrophoresis, where proteins undergo a 
second separation based on their isoelectric point, thus allowing sequencing o f 
single proteins. Further purification and concentration of the target protein prior to 
electrophoresis may also aid its identification. Initial attempts to purify and isolate 
the antigenic protein from serum using immunoprecipitation have, to date, been 
unsuccessful although positive control proteins (calbindin and GAD) have been 
precipitated onto a gel successfully using this method. Isolation of antibody from 
the serum using protein-A affinity chromatography may also be an alternative 
approach.
o What is the in vitro effect o f these antibodies on Purkinje cell function?
Purkinje cells have previously been isolated from rat embryos and cultured 
following published techniques (Furuya et al, 1998) with some success although the 
method remains to be optimised. Once established, Purkinje cell cultures may be 
used in a variety of in vitro techniques designed to answer this question including 
ion-channel assays and electrophysiology.
o What is the role o f the T-cell mediated neurological response in gluten ataxia?
It is important to investigate the potential role of the T-cell immune response in 
gluten ataxia, as well as the humoral response. Isolation of T-cells from the 
intestine o f patients with gluten ataxia and comparison with patients with CD only 
may provide information as to whether the T-cell response may be different in 
different manifestations o f gluten sensitivity. Comparative experiments may 
include assays to determine the effects on T-cells of stimulation with various 
disease-related peptides such as various transglutaminases, GAD and gluten and 
analysis of the cytokine profiles of these cells through cellular assays or flow 
cytometry.
o What are the distinguishing features between development o f gluten ataxia and 
other manifestations o f gluten sensitivity?
This is a broad question encompassing many different areas, which will provide 
valuable insights into the pathogenesis and identification of gluten sensitive patients 
who may develop gluten ataxia. Studies may include: analysis o f genotypes in 
patients with gluten ataxia and comparison with other gluten sensitive individuals;
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investigation of any impairment or abnormality of the BBB in gluten ataxia that may 
account for entry of immune cells to the CNS; further analysis of CSF samples from 
patients with gluten ataxia for the presence of specific antibodies or T-cells and 
evidence of any intrathecal antibody synthesis; further analysis of the roles of 
specific circulating antibodies in gluten ataxia, including identification o f target B- 
cell epitopes and comparison with patients with CD only as well as investigation of 
the presence of antibodies directed against specific transglutaminases that may be 
specific to patients with gluten ataxia.
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CME The humoral response in the 
pathogenesis of gluten ataxia
M. H a d jiv a ssilio u , M D; S. B oscolo , M Sc; G .A .B . D a v ie s -J o n e s , MD; R.A. G run ew ald , D P hil; T. N o t, M D; 
D .S . S a n d er s , M RCP; J .E . S im p son , PhD ; E . T ongiorgi, P hD ; C.A. W illia m so n , BSc; and
N .M . W oodroofe, P hD
A b stra ct—Objective: To characterize humoral response to cerebellum in patients w ith gluten ataxia. Background: Gluten 
ataxia is a common neurologic m an ifestation of gluten sensitivity. Methods: The authors assessed the reactivity o f sera 
from patients w ith gluten ataxia (13), new ly diagnosed patients w ith celiac disease w ithout neurologic dysfunction (24), 
patients w ith other causes o f cerebellar degeneration (11), and healthy control subjects (17) using indirect immunocyto- 
chem istry on hum an cerebellar and rat CNS tissue. Cross-reactivity of a commercial IgG antigliadin antibody w ith hum an  
cerebellar tissue also was studied. Results: Sera from 12 of 13 patients w ith gluten ataxia stained Purkinje cells strongly. 
Less in tense stain ing was seen in some but not all sera from patients w ith newly diagnosed celiac disease w ithout 
neurologic dysfunction. At high dilutions (1:800) stain ing w as seen only w ith sera from patients w ith gluten ataxia but not 
in control subjects. Sera from patients w ith  gluten ataxia also stained some brainstem and cortical neurons in rat CNS 
tissue. Commercial anti-gliadin antibody stained hum an Purkinje cells in a sim ilar manner. Adsorption of the antigliadin  
antibodies using crude gliadin abolished the stain ing in patients w ith celiac disease w ithout neurologic dysfunction, but 
not in those w ith gluten ataxia. Conclusions: Patien ts w ith gluten ataxia have antibodies against Purkinje cells. A ntiglia­
din antibodies cross-react w ith  epitopes on Purkinje cells.
NEUROLOGY 2002;58:1221-1226
G lu ten  se n s it iv ity  is  an  im m u n e-m e d ia te d  d ise a se  
tr iggered  b y  th e  in g e s t io n  o f  g lu te n  in  g e n e t ic a lly  
su sc e p t ib le  in d iv id u a ls .1 G e n e tic  s u s c e p t ib ility  in  
g lu ten  se n s it iv ity  is  a p p a ren t  b y th e  fact th a t  up to  
90% o f p a tie n ts  w ith  ce liac  d ise a se  (CD ) ex p re ss  th e  
H L A  c la ss  II m o lecu les  D Q 2. T h e re m a in in g  10%  
exp ress  H L A  D Q 8.
G astro in testin al sym ptom s b ecau se o f  in vo lvem en t  
f  th e sm all bow el (CD or g lu ten  sen s itiv e  en teropathy) 
re a com m on p resen tin g  feature. H ow ever clin ica l 
Lanifestations can be d iverse, for exam p le , th e  pru- 
't ic  v e s ic u la r  r a s h  o f  d e r m a t it is  h e r p e t ifo r m is .2 
eu rologic m a n ife s ta tio n s  w ere  f ir st  rep or ted  in  16  
a tie n ts  w ith  e s ta b lish e d  CD w ho h a d  g a it  a ta x ia , 
ith  in v o lv em e n t  o f  o th er  a rea s  o f  th e  cen tra l an d  
er ip h e ra l n erv o u s s y s te m s .3 W e h a v e  su g g e s te d  
h a t  g lu te n  se n s it iv ity  ca n  be p re sen te d  so le ly  w ith  
eu rologic d ysfu n c tion ,4 w ith  a ta x ia  (g lu ten  a ta x ia )  
e in g  th e  m o st freq u en t  p re se n ta t io n .5 U p  to 90% o f  
a tie n ts  w ith  d erm a tit is  h erp e tifo rm is an d  33% o f  
a tie n ts  p r e sen tin g  w ith  n eu ro log ic  d ysfu n c tion  a s-  
ocia ted  w ith  g lu te n  s e n s it iv ity  a lso  h a v e  C D .4 T h e  
em a in in g  p a tie n ts  h a v e  no h is to lo g ic  ev id en ce  o f  
nail b ow el in v o lv em en t  b u t h a v e  sero log ic  m ark ers  
erum  a n ti-g lia d in  a n tib o d ies) an d  g en e t ic  su sce p t i-  
i l i ty  (H L A  D Q 2) c o n s is te n t  w ith  g lu te n  se n s it iv ity .
B a se d  on  a la r g e  ep id em io lo g ic  s tu d y  ( > 2 0 0  p a ­
t ie n ts ) , g lu te n  a ta x ia  w a s  foun d  to  accou n t for 40%  o f  
ca se s  w ith  id iop ath ic  sporad ic cereb e llar  d eg en er a ­
t io n .6 T h is  figu re w a s  low er in  tw o  sm a lle r  s tu d ie s .7,8 
A n o th er  s tu d y 9 foun d  sim ila r ly  h ig h  p rev a len ce , b u t  
in  b o th  sp orad ic an d  fa m ilia l a ta x ia s . T h e n u m b e r  o f  
p a tie n ts  (2 6  sp orad ic an d  2 4  fa m ilia l)  w a s  too  sm a ll 
to  d er ive a n y  m ea n in g fu l con clu sion s ab ou t th e  p rev ­
a len ce  o f  g lu te n  a ta x ia  am on g  fa m ilia l a ta x ia s . A  
la rg er  s tu d y  (117  sporad ic an d  55  fa m ilia l)6 fou n d  
th e  p rev a len ce  o f  g lu te n  se n s it iv ity  a m o n g  fa m ilia l 
a ta x ia s  to  be th e  sa m e  as h e a lth y  con tro l su b jec ts . 
P o ssib le  rea so n s  for th e se  d ifferen ces in clu d e  th a t  
th e  p rev a len ce  o f  a n tig lia d in  a n tib o d ies  in  th e  p op u ­
la t io n  v a r ie s  d ep en d in g  on th e  a n tig lia d in  a ssa y s  
u sed  (5%8 to  13%6) an d  th a t  th e re  is  a  p o ss ib le  g eo ­
grap h ic v a r ia b ility  in  th e  p rev a len ce  o f  g lu te n  a ta x ia  
as th e re  is  in  th e  p reva len ce  o f  CD.
N eu rop ath o log ic  fin d in gs foun d  in  p a tie n ts  w ith  
g lu te n  a ta x ia  w h e n  a u to p sied  sh o w ed  p er iv a scu la r  
cu ffin g  w ith  in flam m atory  cells , p red o m in a n tly  af­
fec tin g  th e  cereb ellu m , and r e su lt in g  in  lo s s  o f  P u r ­
k in je ce lls im p ly in g  th a t  th e  n eu ro log ic  in su lt  m a y  be  
im m u n e m ed ia ted . It is  y e t  u n k n ow n  w h e th e r  su ch  
im m u n e-m ed ia ted  d am age is  p r im a rily  c e llu la r  or 
an tib od y  d riven . T h is  artic le p re sen ts  a  s tu d y  o f  th e
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T able Summary of immunocytochemistry results using human and rat cerebellum
Dilutions and percentage of strong positive staining
Tissue substrate Group sera (n) 1:200 1:400 1:800 1:100 1:300 1:600
Human cerebellum Gluten ataxia (5) 100% 100% 60%
Celiac disease no neurology (5) 40% 40% 0%
Other ataxias (5) 20% 0% 0 %
Healthy control subjects (5) 20% 0% 0%
Rat cerebellum Gluten ataxia (10) 90% 90% 90%
Celiac disease no neurology (19) 26% 26% 0%
Other ataxias (6) 0% 0% 0%
Normal control subjects (12) 0% 0% 0%
hu m oral re sp o n se  th a t  m a y  be im p lica ted  in  su ch  
dam age.
M e thod s. Patient and control sera. This was a dual 
center study carried out in Sheffield, UK, and Trieste, 
Italy. Sera from gluten ataxia and ataxia control patients 
were collected in Sheffield and used by both groups. Sera 
from healthy control subjects and patients w ith CD w ith­
out neurologic dysfunction were collected at each center 
after informed consent was obtained. The South Sheffield  
Research Ethics Committee approved the study protocol. 
Sera were collected from 13 patients upon diagnosis w ith  
gluten ataxia (defined by the presence of IgG antigliadin  
antibodies and the absence of any other cause of ataxia  
including paraneoplastic cerebellar degeneration) attend­
ing the gluten sensitivity/neurology clinic at the Depart­
m ent of Clin ical Neurology, The Royal H allam shire  
ospital, Sheffield. Sera from 24 patients w ith newly d iag -. 
osed CD but no evidence of neurologic dysfunction and l i  
atients with other causes of cerebellar degeneration (2 
riedreich ataxia, 5 autosomal dominant ataxia, 3 sporadic 
taxia, 1 ataxia postcerebellitis) were used as disease con- 
ol patients. Finally, samples from 17 healthy individuals 
ere used as healthy control subjects. All samples were 
tored at - 7 0  °C im mediately after collection.
CNS tissue. Immunocytochem istry using hum an cere- 
ellum was performed in Sheffield, UK. Immunocytochem- 
stry using rat cerebellum was performed in Trieste, Italy, 
uman cerebellar tissue from a patient w ith motor neuron  
'sease was obtained at autopsy after consent from rela- 
*ves. The tissue was snap-frozen in liquid nitrogen and 
tored in an airtight container at - 7 0  °C. It was then  
ectioned in a cryostat (Bright Instrum ents, UK), and 10- 
m-thick sections were collected on Polysine-coated slides 
BDH, UK).
Rat CNS tissu e was obtained from adult Sprague- 
awley rats. Procedures involving an im als and their hus- 
andry were performed in accordance w ith  European  
ommunity directives. Rat brains were fresh-frozen on dry 
ce, sectioned in a cryostat (Leica), and 10-fxm sagittal 
ections were collected on gelatin-coated slides (Sigma, 
Q. The slides were dried overnight at room temperature 
d stored at - 8 0  °C until required.
Immunocytochemistry on rat and human CNS tissue. 
n human CNS tissue, sera from 5 patients from each 
oup were used at dilutions of 1:100, 1:200, 1:400, 1:800,
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1:1,600, and 1:3,200. Anti-calbindin D28k antibody (Sig­
ma) diluted 1:200 w ith  phosphate buffered saline/0.05%  
Tween 20 (PBST) was used as a positive control for Pur­
kinje cell staining; negative controls included sections in­
cubated w ithout either serum or antihum an IgG secondary 
antibody.
On rat CNS tissue, sera from 11 patients w ith gluten  
ataxia, 19 patients w ith CD but no neurologic illness, 6 
patients w ith other causes o f ataxia, and 12 healthy con­
trol subjects were analyzed. All sera were used at dilutions 
of 1:100, 1:300, and 1:600. In addition, a subset of 3 sera 
from patients w ith gluten ataxia also was tested at 1:1,200 
and 1:1,500.
CNS sections were warmed to room tem perature and 
then washed in  PBST for 10 m inutes at room temperature. 
Sections were incubated for 1 hour at room tem perature 
w ith  either patient or healthy control sera. After incuba­
tion w ith sera, sections were washed in PBST and incubated 
for 30 m inutes at room temperature w ith a horseradish 
peroxidase-conjugated goat anti-human IgG antibody (Jack­
son Immunoresearch Laboratories) diluted 1:200 (for rat tis­
sue) or 1:500 (for human tissue) w ith PBST. After a second 
wash in PBST, sections were developed for 20 m inutes at 
room temperature using a peroxidase substrate solution of 
0.4 mg/mL 3,3'-diaminobenzidine tetrahydrochloride (DAB) 
with 0.0135% hydrogen peroxide (Sigma). Sections were de­
hydrated in methanol, cleared in methanol/xylene (1:1) fol­
lowed by xylene, and then mounted.
Sem iquantitative evaluation of the signal in tensity  of 
the rat and hum an CNS sections w as performed indepen­
dently by two blinded observers. W eak or strong positive 
stain ing was recorded i f  Purkinje cell stain ing w en t above 
background levels, and negative stain ing was recorded if  
Purkinje cell stain ing did not exceed background levels. 
Patient and control samples w ere run sim ultaneously with  
a concordance rate of 75% between the observers.
Based on the optimal serum dilution for rat CNS tissue, 
1:600, reactivity w ith other rat brain structures u sing sera 
from 10 patients w ith gluten ataxia (and also 6 patients  
with CD but no neurologic dysfunction and 12 healthy  
control subjects) was investigated using the above method.
Immunocytochemistry on human CNS tissue using anti­
gliadin antibody and patient sera before and after adsorp­
tion with crude gliadin. Sera (four patien ts w ith gluten  
ataxia, three patients w ith CD without neurologic dysfunc­
tion, and two healthy control subjects) were d iluted to
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Figure 1. Immunohistochemical stain­
ing of human cerebellar Purkinje cells 
using anti-calbindin D28K  antibody (A, 
positive control), anti-human IgG only 
(B, negative control), and sera at differ­
ent dilutions from a patient with gluten  
ataxia (C-E), a healthy blood donor (F- 
H), and a patient with celiac disease 
without neurologic dysfunction (I-K). 
Dilutions used were 1:200 (C,F,I), 1:400 
(D,G,J) and 1:800 (E,H,K). Calibration  
bar = 65 pm. g  = granular layer; p  = 
Purkinje cell layer; m  =  molecular 
layer.
:200 and 1:800 in PBST or in a saturated crude gliadin  
igma) solution (-2 0  mg/mL) made up in PBST. Commer- 
'al rabbit polyclonal peroxidase-conjugated predom inantly 
G anti-gliadin antibody (Sigma) was diluted from 1:100 
1:256,000 in either PBST or a saturated crude gliadin  
igma) solution (-2 0  mg/mL) in PBST. Once diluted, sera  
d commercial anti-gliadin antibody were incubated for 1 
our at room temperature to allow adsorption of anti- 
'adin antibodies by the crude gliadin. The effectiveness 
blocking of antigliadin antibodies was tested by an anti- 
'adin ELISA assay on the sera after adsorption. Immu- 
cytochem istry was performed as above w ith adsorbed 
d nonadsorbed samples.
su its . Characteristics of patients with gluten ataxia. 
e mean age of the 13 patients w ith gluten ataxia was 61 
ars (range 46-79). The m ean duration of the ataxia was 
years (range 3-25). Ten patients had the HLA DQ2, one 
d DQ8, and two had DQ1. All patients were by definition 
sitive for IgG antigliadin antibodies; four also had IgA 
tig liad in antibodies. Screen ing for antiendom ysium  
A) immunoreactivity and reaction w ith  purified human 
sue transglutam inase10 (tTG) revealed only one patient 
th gluten ataxia that was strongly positive for AEA and 
G. Duodenal biopsies revealed CD in five patients, re­
ts were normal in six patients, and the procedure was 
performed in two patients.
Immunocytochemistry on human CNS tissue. Consis- 
tly strong stain ing of Purkinje cells was seen using  
'-calbindin D28K (figure 1A) as a positive control. Sec­
tions incubated either w ithout primary or w ithout second­
ary antibody showed consisten tly  absen t Purkinje cell 
stain ing (see figure IB).
In the 5 patients w ith gluten ataxia, positive sta in ing of 
Purkinje cells was seen at all dilutions up to 1:800 (see 
figure 1, C, D, and E) w ith strong stain ing up to 1:400. The 
stain ing persisted at higher d ilutions in three patien ts. At 
dilutions of 1:800, sera from the control groups showed no 
stain ing (see figure 1, H and K). However, at dilutions of 
1:200, stain ing was seen in 2 of 5 patien ts w ith  CD but no 
neurologic illness (see figure II), in 1 of 5 patien ts w ith  
ataxia of a different cause, and in 1 of 5 healthy control 
subjects (see figure IF).
Immunocytochemistry on rat CNS tissue. Sera from 12 
of 13 patients w ith gluten ataxia showed strong sta in ing of 
Purkinje cells at 1:100, 1:300, and 1:600 d ilutions (figure 2, 
A through C), w ith marked stain ing particularly of cell 
somas and dendritic processes even at dilutions of 1:600. 
None of the subset o f sera from three patien ts w ith  gluten  
ataxia tested at 1:1,200 dilution showed any recogn izable 
stain ing. In contrast, sera from 4 o f 12 h ealthy control 
subjects showed only weak stain ing at 1:100 dilution (see  
figure 2D), w ith  no further stain ing detected at higher  
d ilutions (see figure 2, E and F). No stain ing was seen  
using serum from six control patien ts w ith  ataxia. The 
sera from 5 of 19 patients w ith CD w ithout neurologic 
dysfunction showed strong stain ing of Purkinje cells at 
1:100 and 1:300 d ilutions (see figure 2, G and H) but only  
weak stain ing at a dilution of 1:600 (see figure 21). W eak  
stain ing was seen in n ine patients and no stain ing w as
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Figure 2. Immunohistochemical stain­
ing of rat cerebellar Purkinje cells using 
sera a t different dilutions from a p a ­
tient with gluten ataxia (A-C), a healthy 
blood donor (D-F), and a patient with 
celiac disease without neurologic dys­
function (G-I). Dilutions used were 
1:100 (A,D,G), 1:300 (B,E,H) or 1:600 
(C,FJ). Calibration bar = 65 pm.
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seen in  six. Sera from 10 patients w ith  gluten ataxia  
showed weak or absent stain ing of the striatum, corpus 
callosum , hippocam pus, brain blood v essels , choroid 
plexus, and ependyma. The more consistently stained cells 
in the cortex were large stellate-like cells (not pyramidal 
neurons) in cortical layers IV and V (figure 3A) and sm all 
polymorphic cells in the layer VI (see figure 3B), especially 
in the frontal cortex. Large neurons of the deep cerebellar 
nuclei (see figure 3C) and neurons of the reticular forma­
tion and pontine gray in the brainstem (see figure 3D) also 
stained. Sera from two of six patients w ith CD but no 
neurologic illness showed stain ing of cortical layer VI but 
no stain ing of any other structures. The sera from healthy  
control subjects did not stain cells in any brain area except 
for one case w ith w eak stain ing in cortical layer VI.
Reactivity of sera and anti-gliadin antibody with human 
cerebellar tissue after adsorption with crude gliadin. Com­
mercial rabbit anti-gliadin antibody stained human cerebel­
lar Purkinje cells, at an optimal dilution of 1:800, w ith a 
pattern identical to that seen using sera from patients with  
gluten ataxia.
Stain ing with commercial anti-gliadin antibody at a di­
lution of 1:1,600 (figure 4A) was abolished after adsorption 
of the antibody for 1 hour at room temperature w ith  crude 
gliadin (see figure 4B). Comparative adsorption experi­
ments were performed using sera (dilution 1:200) from 
patients w ith gluten ataxia (see figure 4, C and D) and 
patients w ith CD but no neurologic dysfunction (see figure 
4, E and F). The stain ing persisted but was weaker even 
after adsorption w ith  gliadin when using sera from pa­
tients w ith gluten ataxia. The stain ing was eliminated  
when using sera from patients with CD and no neurologic 
dysfunction. None of the postadsorption sera tested posi­
tive for the presence of antigliadin antibodies.
A summary of all immunocytochem istry results can be 
seen in the table.
• i s c u s s io n .  T h e se  r e su lts  su g g e s t  th a t  p a tie n ts  
ith  g lu te n  a ta x ia  h a v e  c ircu la tin g  an tib od ies d i­
rected  a g a in s t  cereb ellar P u rk in je  ce lls , w ith  som e  
re a ctiv ity  se e n  w ith  d eep  cereb e lla r  n u c le i  b ra in stem  
an d  cortical n eu ron s. S om e w e a k  s ta in in g  w ith  b oth  
ra t and h u m a n  cereb ellu m  w a s  se e n  u s in g  se r a  from  
oth er  p a tie n t  grou p s. A t low  d ilu tio n s  so m e  se ra  
from  n o rm a l con tro l su b je c ts  a lso  sh o w e d  w e a k  
s ta in in g . S u ch  s ta in in g  o f P u rk in je  c e lls  a t  lo w  d ilu ­
tio n s  is  th o u g h t to be n o n sp ec ific  an d  h a s  b e e n  d e­
scrib ed  before.11 S tron g  an d  p e r s is te n t  s ta in in g  a t  
h ig h er  d ilu tion s  w a s on ly  se e n  w h e n  u s in g  se r a  from  
p a tie n ts  w ith  g lu ten  a ta x ia . T h e  a b sen ce  o f  s ta in in g  
u sin g  sera  from  th e  group  o f  p a tie n ts  w ith  o th er  
ca u se s  o f  a ta x ia  su g g e s ts  th a t  th is  is  n o t  j u s t  an  
ep ip h en om en on  o f  P u rk in je ce ll lo ss . H o w ev er , th e  
p resen ce  o f  s im ila r  a lth o u g h  w e a k e r  s ta in in g  w ith  
se ra  from  on ly  som e p a tie n ts  w ith  C D  w ith o u t  n e u ­
rologic d ysfu n c tion  im p lies  th a t  th e s e  a n tib o d ie s  are  
n o t  n ece ssa r ily  neu rotoxic. T h e d em o n stra tio n  o f  r e ­
a ctiv ity  o f  com m erc ia l IgG  a n t ig lia d in  a n tib o d y  w ith  
h u m a n  P urkinje ce lls m a y  be th e  re a so n  w h y  sera  
from  p a tie n ts  w ith  CD b ut no n eu ro log ic  d y sfu n c tio n  
s ta in  P u rk in je ce lls . H ow ever, p a tie n ts  w ith  g lu te n  
a ta x ia  p o sse s s  a d d itio n a l a n tib o d ie s  a g a in s t  P u r­
k in je ce lls  a s d em on stra ted  b y  th e  a d so rp tio n  ex p e r ­
im en ts . T h ese  an tib od ies a re  d iffer en t  to a n t ig l ia d in  
an tib od ies an d  ap pear to b e p r e s e n t  e x c lu s iv e ly  in  
p a tie n ts  w ith  g lu ten  a ta x ia . A n t ig lia d in  a n tib o d ie s  
are p resen t  in  a lm ost a ll p a tie n ts  w ith  ce lia c  d is e a s e  
w ith  g a stro in te s t in a l sym p tom s. Y e t  o n ly  6%  to  10% 
o f p a tie n ts  w ith  es ta b lish ed  C D  d evelop  n eu ro lo g ic  
d ysfu n c tion . O ne h y p o th e s is  m a y  be th a t  a n t ig lia d in  
an tib od ies on ly  becom e n eu rotox ic  i f  th e y  g a in  a c c e ss  
to th e  C N S. A n tig lia d in  a n tib o d ies  h a v e  b een  fou n d  
in  th e  C SF  in  p a tie n ts  w ith  g lu te n  s e n s i t iv i ty  an d  
n eu rologic d y sfu n c tio n .12 T h e m e c h a n ism  b y w h ic h  
an d  reason  w h y  a n tig lia d in  a n tib o d ies  m a y  g a in  a c ­
ce ss  to th e  C N S rem a in s ob scu re. T h e p r e se n c e  o f
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igure 3. Immunohistochemical staining obtained using 
erum from a newly diagnosed untreated patient with glu- 
n ataxia in different brain areas (dilution 1:600). Pur- 
inje cell staining is shown in figure 2A. The approximate 
osition of the high magnification photographs is indi- 
ated by the letters marked on the camera lucida drawing  
a sagittal section of rat brain (top panel). In the cortex, 
nly a subset of cells was stained, comprising principally 
orizontal or polymorphic cells in layers V  (A) and VI (B). 
he deep cerebellar nuclei stained strongly a t the level of 
uronal cell somas and processes (C), as d id  the pontine 
ay nuclei (D). Calibration bar =  65 pm. wm  =  white 
atter.
ciphocytic in f i ltr a tio n  o f  th e  p er iv a sc u la r  sp a ce  
d th e  n eu rop il by C D 4 an d  C D 8 T c e lls13 in  ca se s  
f  g lu te n  a ta x ia  su g g e s ts  c e ll-m ed ia te d  re sp o n se s  
a y  a lso  p la y  a  p art. C e ll-m ed ia ted  in fla m m a tio n  
a y  com p rom ise th e  b lo o d -b r a in  b arrier  a llo w in g  
r th e  en try  o f a n tig lia d in  a n tib o d ies  in to  th e  C N S. 
It rem a in s  u n c lea r  w h y  so m e  p a tie n ts  w ith  g lu te n  
n s it iv ity  p re sen t  so le ly  w ith  n eu ro log ic  d ysfu n c tion  
h ere a s  o th ers h a v e  g a str o in te s t in a l sy m p to m s or a  
u r it ic  ra sh . G e n e tic  s u s c e p t ib il ity  m a y  h a v e  a  
a ll role. A lth ou gh  70% o f  p a tie n ts  w ith  g lu te n  
a x ia  h a v e  th e  H L A  D Q 2 (found in  90% o f p a tie n ts  
'th  CD) an d  10% h a v e  th e  H L A  D Q 8 (u su a lly  fou n d  
th e  re m a in in g  10% o f  p a tie n ts  w ith  CD), 20% h a v e  
e H L A  D Q 1. H L A  D Q 1 h a s  n o t  y e t  b een  rep or ted  
a sso c ia tio n  w ith  ce liac  d ise a se  b u t m a y  be an  im - 
r ta n t  d ifferen ce in  g en e t ic  su sc e p t ib ility  to  g lu te n  
a x ia  com pared  w ith  CD.
Figure 4. Immunohistochemical staining of human Pur­
kinje cells using a commercial rabbit anti-gliadin anti­
body at a dilution of 1:1600 (A), serum from a patient 
with gluten ataxia a t dilution 1:200 (C), and serum from  
a patient with celiac disease without neurologic dysfunc­
tion at dilution 1:200 (E), both before (A,C,E) and after 
adsorption (B,D,F) o f antigliadin antibodies by incubation 
with crude gliadin. Calibration bar =  65 pm.
T h e s ta in in g  o f  P u rk in je ce lls  u s in g  sera  from  p a­
t ie n ts  w ith  g lu te n  a ta x ia  a g re es  w ith  th e  n eu ro -  
p ath o log ic  f in d in g s from  p ostm ortem  ex a m in a tio n  o f  
p a tie n ts  w ith  g lu te n  a ta x ia .3’5 T h e m o st  c o n s is te n t  
fin d in g  is  th e  lo ss  o f  P u rk in je ce lls . A lth o u g h  th e  
cereb e llu m  an d  in  p articu lar  th e  P u rk in je c e lls  ap­
p ea r  to b e  m o st su scep tib le  to d a m a g e  in  p a tie n ts  
w ith  g lu te n  a ta x ia , o th er areas o f  th e  b ra in  are n o t  
sp ared . O ur r e su lts  d em on stra te  th a t  se ra  from  p a­
t ie n ts  w ith  g lu te n  a ta x ia  react w ith  b o th  b r a in s tem  
an d  cor tical n eu ro n es  in  ra t  C N S t is su e . S u c h  in ­
vo lv e m e n t  h a s  b een  repor ted  b o th  c lin ica lly  an d  n eu -  
rop ath o log ica lly : p a tie n ts  w ith  g lu te n  a ta x ia  m a y  
ex h ib it  m yoclon u s (p ossib ly  cortical in  or ig in 14), d e­
m e n t ia ,15 an d  b ra in stem  s ig n s .16
T h e cro ss-rea ctiv ity  o f  a n ti-g lia d in  a n tib o d ies  w ith  
cereb e llar P u rk in je ce lls su g g e s ts  th a t  g lia d in  p ro­
te in s  an d  cereb e lla r  P u rk in je ce lls  sh a re  com m on  
ep itop es. S u ch  com m on ep itop es a lso  h a v e  b een  d em ­
o n stra ted  to e x is t  b e tw een  g lia d in  p ro te in s  an d  en- 
te r o c y te s .17 A  r e c e n t  s tu d y  in v e s t ig a t in g  h u m a n  
gen om e sea rch  in  CD u s in g  g lia d in  cD N A  a s probe  
d em o n stra ted  th a t  sev era l g en e s  h a v e  p a r tia l g lia d in  
h o m ology .18 T h e n a tu re  o f  th e  a n tig e n s  reco g n ized  by  
sera  from  p a tie n ts  w ith  g lu te n  a ta x ia  is  s t i l l  u n ­
k n ow n . A  sp ec ific  large  sc a le  sc re en in g  ap p roach  o f
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u m an  b rain ex p re ss io n  lib ra r ie s  is  e n v isa g e d  to  
ch ieve th e  id en tifica tio n  o f  a n tig e n s  recogn ized  b y  
e g lu te n  a ta x ia  a n tib o d ie s . C h a r a c ter iza tio n  o f  
e se  an tib od ies b y  im m u n o b lo ttin g  m a y  provid e a  
efu l m ark er for th e  d ia g n o s is  o f  g lu te n  a ta x ia  in  a  
an ner an a logou s to  th e  u s e  o f sp ec ific  a n tib o d ies  as  
arkers o f  p aran eop lastic  cereb e llar  d egen eration .
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Summary
We previously have described a group of patients 
with gluten sensitivity presenting w ith ataxia (gluten  
ataxia) and suggested that this disease entity m ay  
account for a large num ber o f patients with sporadic  
idiopathic ataxia. W e have therefore investigated the 
prevalence of gluten sensitivity am ongst a large 
cohort o f patients with sporadic and fam ilial ataxia  
and looked at possible genetic pred isposition to glu­
ten sensitivity am ongst these groups. Two hundred  
and twenty-four patients with various causes o f  
ataxia from North Trent (59 fam ilial and/or positive  
testing for spinocerebellar ataxias 1, 2, 3, 6 and 7, 
nd Friedreich’s ataxia, 132 sporadic idiopathic and  
3 clinically probable cerebellar variant o f m ultiple 
stem  atrophy M SA-C) and 44 patients with spor- 
dic idiopathic ataxia from  The Institute o f  
eurology, London, were screened for the presence  
f  antigliadin antibodies. A  total of 1200 volunteers 
ere screened as norm al controls. The prevalence o f  
ti gliadin antibodies in the fam ilial group was eight 
ut of 59 (14% ), 54 out o f 132 (41% ) in the spor- 
ic idiopathic group, five out of 33 (15%) in the 
SA-C group and 149 out o f 1200 (12%) in the
norm al controls. The prevalence in the sporadic id io­
pathic group from  London w as 14 out of 44 (32% ). 
The d ifference in prevalence between the idiopathic 
sporadic groups and the other groups was highly sig­
n ificant (P < 0.0001 and P  < 0.003, respectively). The 
clin ical characteristics o f  68 patients w ith gluten  
ataxia were as follows: the m ean age at onset o f the 
ataxia was 48 years (range 14-81  years) with a m ean  
duration o f the ataxia of 9.7 years (range 1-40  
years). Ocular signs were observed in 84% and dys­
arthria in 66% . Upper lim b ataxia was eviden t in 
75% , lower lim b ataxia in 90% and gait ataxia in 
100% of patients. Gastrointestinal sym ptom s were 
presen t in only 13% . M R I revealed atrophy o f the 
cerebellum  in 79% and wh ite m atter hyperintensities 
in  19% . Forty-five percen t o f patients had neurophy- 
siological evidence o f a sensorim otor axonal neuropa­
thy. G luten-sensitive enteropathy was found in 24% . 
HLA DQ2 was present in 72% o f patients. Gluten  
ataxia is therefore the single m ost com m on cause of 
sporadic idiopathic ataxia. A ntigliadin antibody test­
ing is essential at first presentation of patients with  
sporadic ataxia.
eywords: gluten ataxia; prevalence; gluten sensitivity; coeliac disease
breviations: MSA-C = cerebellar variant of multiple system atrophy; SCA = spinocerebellar ataxia
troduction
e term ‘gluten sensitivity’ refers to a state o f heightened 
unological responsiveness to ingested gluten in genetic- 
susceptible individuals (Marsh, 1995). Gastrointestinal 
ptoms caused by involvement of the small bowel (coeliac 
ase, also known as gluten-sensitive enteropathy) have in 
past been considered the most common presenting 
re. Prevalence studies have shown that coeliac disease
affects up to 1% o f the normal population (Fasano, 2001). It 
has been estimated that for every one patient with coeliac 
disease who presents with gastrointestinal complaints, there 
are seven patients with coeliac disease who have no 
gastrointestinal symptoms (Fasano, 2001). There is evidence 
to suggest that the small bowel is no longer the sole 
protagonist in gluten sensitivity. An itchy vesicular rash due
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to skin involvement (dermatitis herpetiformis) has been 
recognized as a separate manifestation since 1966 (Marks 
et al., 1966). Although neurological complications have been 
reported in association with established coeliac disease 
(Cooke and Smith, 1966), we have shown that gluten 
sensitivity can present solely with neurological dysfunction 
(Hadjivassiliou et al., 1996). Ataxia (gluten ataxia) is the 
most common neurological manifestation o f gluten sensitiv­
ity (Hadjivassiliou et al., 1998). Organ-specific manifest­
ations can occur in isolation or in combination with one 
another. Only a proportion o f patients presenting with 
neurological dysfunction associated with gluten sensitivity 
will also have an enteropathy (Hadjivassiliou et al., 1999). 
The remaining patients have no histological evidence o f small 
bowel involvement but have serological markers (serum 
antigliadin antibodies) in keeping with gluten sensitivity, a 
situation analogous to dematitis herpetiformis. Genetic 
susceptibility in the form o f the HLA typing may play an 
important role in this disease. HLA DQ2 is found in up to 
90% of patients with coeliac disease.
Referral bias in units with an interest in genetic ataxias has 
produced an impression of relative rarity of idiopathic 
sporadic cases. One aspect o f this study was to look at the 
prevalence of familial and sporadic ataxias in an unselected 
population from North Trent served by the Department o f  
Neurology, The Royal Hallamshire, Sheffield. We have 
suggested that gluten ataxia may account for a large number 
of patients with idiopathic sporadic ataxia. We present the 
prevalence of gluten sensitivity amongst a large cohort of 
patients with sporadic and familial ataxia and investigate 
possible genetic predisposition to gluten sensitivity amongst 
these groups. In addition, we present the clinical and 
radiological characteristics o f the largest ever reported cohort 
of 68 patients with gluten ataxia.
Methods 
Patient selection
Over the last 8 years, we have reviewed prospectively and 
followed-up at 6 monthly intervals all patients with the 
diagnosis o f cerebellar degeneration seen in a specially 
formed ataxia clinic based at the Department of Neurology at 
the Royal Hallamshire Hospital, Sheffield. The patients were 
identified from the disease register o f the Department o f 
Neurology, referrals from other neurology consultant col­
leagues based in North Trent and from the database o f  the 
regional Department o f Molecular Genetics. Patients were 
divided into three groups. The first group consisted of patients 
with a family history o f ataxia (autosomal recessive or 
dominant) and/or positive genetic testing for one of 
spinocerebellar ataxias (SCAs) 1, 2, 3, 6 and 7, and 
Friedreich’s ataxia. The second group consisted o f patients 
with sporadic idiopathic cerebellar degeneration without 
clinical evidence of the cerebellar variant o f multiple system  
atrophy (MSA-C). The third group consisted of patients with
clinically probable MSA-C as defined by the consensus 
statement on the diagnosis o f multiple system atrophy 
(Gilman et ah, 1999). Patients with a history of alcohol 
abuse, prolonged use o f the anticonvulsant medication 
phenytoin, laboratory evidence of multiple sclerosis, vitamin 
E deficiency, paraneopjastic cerebellar degeneration and viral 
cerebellitis were excluded. In an attempt to eliminate possible 
referral bias associated with our department’s involvement in 
research into the neurological manifestations o f gluten 
sensitivity, we also screened a group o f patients with sporadic 
idiopathic ataxia identified from the database o f the ataxia 
clinic o f  the Institute of Neurology, Queen Square, London. 
A ll o f these patients had been labelled as suffering from 
idiopathic late onset cerebellar ataxia, a term introduced by 
the late Professor Harding but now synonymous with 
sporadic idiopathic ataxia. Normal volunteers from the 
Trent region attending their primary care physician for 
unrelated problems (e.g. obtaining repeat prescription, 
accompanying relatives to their GP, common cold, etc.) 
were screened for the presence o f IgG and/or IgA antigliadin 
antibodies to estimate the prevalence of such antibodies in the 
local population. The study was approved by the South 
Sheffield Ethics Committee. A ll patients were tested for 
antigliadin antibodies, and the first 169 consecutive patients 
(apart from the normal volunteers group) also had their HLA 
type determined. All patients underwent full neurological 
examination. Patients with gluten ataxia were referred for 
duodenal biopsy.
Antigliadin antibody estimation and HLA typing
IgG and IgA antigliadin antibody estimation was done using a 
commercially available enzyme-linked immunoassay kit 
(ELISA) kit (Cogent Diagnostics Ltd, Edinburgh, UK) 
according to the manufacturers’ instructions. Briefly, 96- 
w ell microtitre plates pre-coated with purified gliadin were 
used. Test serum, positive and negative controls (all diluted to 
1:100) or standards were added and incubated at room 
temperature for 30 min. Antigliadin antibodies were detected 
follow ing incubation at room temperature for 15 m in with 
mouse anti-human IgG and IgA horseradish peroxidase 
conjugate and subsequent development with tetra-methyl 
benzidine (TMB) substrate at room temperature for 15 min. 
Sample optical density units were converted to Cogent 
arbitary units (U/ml) using the pre-calibrated standards. 
Concentrations o f controls and standards had to fall within 
pre-defined limits for acceptance o f assay validity.
HLA typing was performed at the regional blood transfu­
sion unit.
Duodenal biopsies
Duodenal biopsies were taken from the distal duodenum  
using biopsy forceps, through a conventional forward view­
ing endoscope (Key-Med, Southend, UK). Four biopsies were 
taken from the third part of the duodenum. The presence of
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Sporadic Ataxia
165
(74% )
Familial Ataxia
(26%)
Antigliadin
positive
54/132 (41%)
Antigliadin
positive
5/33 (15%)
Antigliadin
positive
14/44 (32%)
Antigliadin
positive
8/59 (14%)
Clinically probable 
MSA-C
Sporadic idiopathic 
No features 
of MSA-C 
132
(10 FA,12 no genetic 
defect)
Autosomal
(3 SCA2, 2 SCA6 
1 SCA7,32 no genetic 
defect)
Autosomal
dominant
Total num ber of patients 
with ataxia 
(North Trent)
224
Sporadic Idiopathic ataxia 
No features of MSA-C
(Patients from database of Institute of 
Neurology, London)
Normal Controls 
(North Trent) 
1200
Antigliadin positive 
149/1200 (12%)
Fig. 1 The prevalence of antigliadin antibodies in ataxia and control groups. FA = Friedreich’s ataxia; 
SCA = spinocerebellar ataxia, MSA-C = cerebellar variant of multiple system atrophy.
gluten-sensitive enteropathy was established by histological 
examination looking for evidence o f crypt hyperplasia, 
villous atrophy and increase in intraepithelial lymphocytes.
Statistical analysis
The %2 test was used for comparing the prevalence of 
antigliadin antibodies in each of the groups with that o f the 
normal controls group.
Results
Figure 1 summarizes the prevalence of IgG and/or IgA 
antigliadin antibodies in the various groups. A total o f 268
patients with ataxia were screened, 224 from the Trent region 
and 44 patients with sporadic idiopathic ataxia without 
evidence of MSA-C taken from the ataxia database of the 
Institute o f Neurology, London. Of the 224 patients from the 
Trent region, 59 had a family history (36 autosomal 
dominant, 23 autosomal recessive) and/or were positive on 
genetic testing for SCA 2 (three patients), SCA 6 (two 
patients), SCA 7 (one patient) and Friedreich’s ataxia (10 
patients). A total o f 132 patients had sporadic idiopathic 
ataxia without any evidence of MS A-C. Thirty-three patients 
had clinically probable MSA-C. All 165 patients from the 
latter two groups tested negative for SCA 1, 2, 3, 6 and 7, and 
Friedreich’s ataxia. Forty-four patients with sporadic idio­
pathic ataxia without evidence o f M SA-C taken from the
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database o f the Institute o f Neurology, London were screened 
for gluten sensitivity but only 31 attended for clinical 
examination. A total o f 1200 normal volunteers were 
screened as controls.
The prevalence o f significant titres of circulating IgG and/ 
or IgA antigliadin antibodies amongst healthy control 
subjects from the Trent region was 149 out of 1200 (12%). 
This was not significantly different from the prevalence in 
patients with familial ataxia, where the antigliadin antibodies 
were present in eight out o f 59 (14%). Of these eight patients, 
three had Friedreich’s ataxia, one had SCA2 and one had 
SCA7. The remaining three had no genetic diagnosis. The 
prevalence in familial ataxia compares with 54 out o f 132 
(41%) in the group with sporadic idiopathic ataxia without 
features o f MSA-C group from North Trent (P < 0.0001), five 
out of 33 (15%) in the group with clinically probable MSA-C
Table 1 Characteristics o f 68 patients with gluten ataxia
Male to female ratio 35 : 33
Mean age at onset of ataxia 48 years
(range) (14-78 years)
Mean duration of ataxia 9.7 years
(range) (1-40 years)
Occular signs 84%
Dysarthria 66%
Upper limb ataxia 75%
Lower limb ataxia 90%
Gait ataxia 100%
Gastrointestinal symptoms 13%
Cerebellar atrophy on MRI 79%
White matter hyperintensities on MRI 19%
Sensorimotor axonal neuropathy on 45%
neurophysiology
Gluten-sensitive enteropathy on biopsy 24%
HLA DQ2 72%
(not significant) and 14 out o f 44 (32%) in the group with 
sporadic idiopathic ataxia from The Institute o f Neurology, 
London (P <  0.003). Three o f  the eight antigliadin antibody- 
positive patients in the familial group had IgA antigliadin 
antibodies, but all were also IgG antigliadin positive. One of 
the five antigliaBin antibody-positive patients in the MSA-C  
group was positive for IgA antigliadin antibody only. Only 
six out of 68 patients with gluten ataxia had IgA without IgG 
antigliadin antibodies.
HLA DQ2 was found in 27 out o f 70 (39%) patients tested 
with sporadic idiopathic ataxia and in 13 o f  31 patients tested 
(40%) with familial ataxia (not all patients from each group 
had HLA typing performed). The prevalence o f HLA DQ2 
amongst normal controls from the Trent region was 35% 
(data from the regional Blood Transfusion Unit); thus the 
prevalence o f DQ2 in patients with sporadic idiopathic ataxia 
(without gluten sensitivity) and in those with familial ataxia 
was not significantly different from the control population. 
HLA DQ2 was present in 49 out o f 68 (72%) patients with 
gluten ataxia (54 patients from North Trent plus 14 from The 
Institute of Neurology, London). S ix percent had the HLA  
DQ8 and the remaining 22% had HLA DQ1.
Table 1 summarizes the clinical, radiological and neuro- 
physiological characteristics o f 68 patients with gluten ataxia 
(54 patients from North Trent plus 14 from The Institute o f  
Neurology, London). There were 35 men and 33 women. The 
mean age at the onset o f the ataxia was 48 years (range 14-81  
years). The mean duration o f the ataxia was 9.7 years (range 
1-40 years). Ocular signs (spontaneous and gaze-evoked  
nystagmus and/or abnormal saccades) were observed in 84% 
of patients. Dysarthria was present in 66%. Upper limb ataxia 
was present in 75%, lower limb ataxia in 90% and gait ataxia 
in 100% of patients. Gastrointestinal symptoms (diarrhoea, 
abdominal bloating, weight loss) were present in only 13% o f
30
^  25 - D0)
Gluten Ataxia C oeliac  d ise a s e  only Norm al con trols
Fig. 2 Quantitative IgG antigliadin antibody titre in 30 patients with gluten ataxia, 13 patients with coeliac disease without neurological 
illness and 12 healthy control subjects.
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patients. There was no correlation between the presence of 
gastrointestinal symptoms and evidence o f an enteropathy on 
biopsy. MRI revealed atrophy of the cerebellum in 79% and 
white matter hyperintensities in 19% of patients. Forty-five 
percent of patients had neurophysiological evidence o f  a 
sensorimotor axonal neuropathy. Evidence of coeliac disease 
was found in 12 out of 51 (24%) patients with gluten ataxia 
who underwent gastroscopy and duodenal biopsy. IgG 
antigliadin antibody titre was higher in a cohort of 13 
patients with coeliac disease and no neurological deficit when 
compared with a cohort o f 30 patients with gluten ataxia 
(Fig. 2).
Discussion
In our experience of 59 patients with familial ataxia and/or 
positive genetic testing for SCA 1, 2, 3, 6 and 7, and 
Friedreich’s ataxia, genetic diagnosis was only achieved in 16 
(27%), leaving 73% without a genetic diagnosis. Sporadic 
idiopathic ataxias still account for the vast majority of 
patients with ataxia (74%). Of these, 20% had clinically 
probable MSA-C. Thus, in the majority of patients, the 
aetiology of ataxia still remains obscure. Our finding that 
gluten ataxia accounts for up to 41% o f cases of sporadic 
idiopathic ataxia makes it the single most common cause of 
ataxia in this cohort of patients. This figure was slightly lower 
(32%) in patients with sporadic idiopathic ataxia from The 
Institute of Neurology in London, but the difference was not 
significant. The prevalence o f gluten sensitivity amongst 
familial ataxias as well as clinically probable MSA-C from 
the Trent region was no different from that found in the 
normal population, suggesting no aetiological link between 
these types o f ataxia and gluten sensitivity. There was, 
however, a small but not significant trend for the prevalence 
of gluten sensitivity in the MSA-C group to be higher than in 
the other control groups. This may reflect the fact that definite 
diagnosis o f MSA-C on clinical grounds is impossible. Thus 
it is conceivable that a small number of patients with 
clinically probable MSA-C may prove to have gluten ataxia. 
This can only be determined by their response to gluten-free 
diet or by the pattern o f progression of the disease.
Follow ing our first publication on gluten ataxia 
(Hadjivassiliou et a l,  1998), other groups have published 
prevalence figures. The small number o f patients screened 
and the lack of information on the prevalence o f gluten 
sensitivity amongst the control population limits the value of 
some reports.
In a study from Italy (Pellecchia et a l,  1999), patients with 
sporadic ataxia were found to be more likely to have coeliac 
disease (three out o f 24) than a group X ) f  patients with familial 
ataxia (zero out of 23). The authors did not quote the 
prevalence o f antigliadin antibodies in their normal popula­
tion and did not report any patients with circulating 
antigliadin antibodies who did not have coeliac disease. All 
their patients with ataxia and coeliac disease had circulating 
IgG antigliadin antibodies but not necessarily IgA antigliadin
or antiendomysium antibodies. Yet the last two antibodies are 
reported to be highly specific for gluten-sensitive enteropathy 
(Fasano, 2001). This observation suggests that IgA anti­
gliadin and antiendomysium antibodies may lack sensitivity 
and specificity when used in a neurological population. Their 
observations support our contention that IgG antigliadin 
antibody is a better marker o f the whole spectrum of gluten 
sensitivity irrespective o f the organ involved. Possible 
reasons why these authors did not find patients with ataxia 
and circulating IgG antigliadin antibodies who did not have 
an enteropathy (representing 76% of our patients with gluten 
ataxia) include the fact that their antigliadin assay is set so as 
to have high specificity for coeliac disease perhaps at the 
expense of low sensitivity. This is what we have demon­
strated by showing that the IgG antigliadin antibody titre in 
patients with gluten ataxia is lower than that in patients with 
coeliac disease without neurological illness. By increasing 
the antigliadin assay specificity for coeliac disease (i.e. 
increasing the threshold antibody titre defined as ‘positive’), 
the sensitivity for the diagnosis o f gluten ataxia w ill be 
reduced. Given that only 24% of our patients with gluten 
ataxia had gluten-sensitive enteropathy, potentially 76% of 
these patients may remain undiagnosed if  such a high 
threshold value for positivity is adopted.
In a study from Germany (Burk et al., 2001), the 
prevalence o f gluten ataxia amongst, sporadic idiopathic 
ataxias was found to be 12 out o f 104 (11.5%). Like us, the 
authors found a number o f patients with positive IgG  
antigliadin antibodies and no enteropathy, but the appropriate 
HLA for coeliac disease. The prevalence o f IgG antigliadin 
antibodies amongst normal controls was said to be 5%. This is 
lower than the 12% we have found in this study but again may 
relate to the assay. The authors did not attempt to separate 
those patients with clinically probable M SA-C from the 
idiopathic ataxia group. A more recent study from Germany 
(Abele etal., 2002) found the prevalence o f gluten sensitivity 
in the sporadic ataxia group to be 13% compared with 6% in 
patients with genetic ataxias and 5% in the normal popula­
tion. The prevalence o f antigliadin antibody positivity in 
patients with M SA-C was 9%. The authors, however, 
included not just patients with clinically probable MSA-C  
but also patients with possible MSA-C, thus potentially 
reducing further the accuracy o f the clinical diagnosis o f 
MSA-C.
A study from the USA (Bushara et a l ,  2001) found a high 
prevalence of antigliadin antibody positivity in both sporadic 
(27%) and familial ataxias (37%). The numbers screened 
were small (26 sporadic and 24 familial). The prevalence of  
IgG antigliadin antibody alone, however, was higher in the 
sporadic ataxia group (15%) than the familial group (8%). 
Those authors offer no figure for the prevalence o f antigliadin 
antibodies in the normal population for comparison.
A  study from Finland (Luostarinen et al., 2001) found the 
prevalence of coeliac disease in sporadic ataxias (44 patients) 
to be 16.7%, with the prevalence o f coeliac disease in the 
normal population being -1.6% .
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A  report from Spain (Combarros et al., 2000) describes 32 
patients with idiopathic ataxia who were screened but not 
found to have antigliadin antibodies. From the limited clinical 
data provided, 16 of these patients had features suggestive o f  
MSA-C, leaving only 16 patients with sporadic idiopathic 
ataxia. The authors offer no figure for the prevalence o f  
antigliadin antibodies in the normal population.
Finally, a much smaller study from Ireland (Lim et al., 
2001) reported coeliac disease in three o f seven patients 
presenting with sporadic ataxia.
Despite possible methodological differences (e.g. antiglia­
din assay) and geographical variations that may contribute to 
differences in prevalence, all but one o f these studies confirm  
our original findings o f the existence of gluten ataxia as a 
disease entity. No combination o f clinical features is suffi­
ciently specific to enable a clinical diagnosis o f gluten ataxia 
to be made with confidence, except perhaps in patients with 
established coeliac disease. The clinical features described in 
Table 1 are also seen in patients with other forms o f sporadic 
and inherited ataxia, and this emphasizes the importance of 
maintaining a low  threshold for suspicion o f gluten sensitivity 
in patients presenting with ataxia.
IgG antigliadin antibodies by definition remain the best 
diagnostic marker for gluten ataxia. Although it is generally 
accepted that IgG antigliadin antibodies have a very high 
sensitivity for gluten-sensitive enteropathy, they are said by 
most gastroenterologists to lack specificity. In the context o f a 
range of mucosal abnormalities seen in this disease, ranging 
from normal to irreversible hypoplastic atrophic lesions 
(Marsh, 1995), and the concept o f potential coeliac disease 
(Maki et al., 1991), meaning a histologically normal mucosa 
but altered T-cell subpopulations, IgG antigliadin antibodies 
may be the only available immunological marker for the 
whole spectrum of gluten sensitivity, o f which gluten- 
sensitive enteropathy is only a part. Further support for our 
contention comes from our HLA studies. Within the group of 
patients with gluten ataxia (defined by the presence of IgG 
antigliadin antibodies), we have found an HLA association 
similar to that seen in patients with coeliac disease: 12%  of 
patients have the HLA DQ2 (35% in the general population), 
6% have the HLA DQ8 and the remainder have HLA DQ1.
We have looked at the prevalence of HLA DQ2 in both 
familial and sporadic idiopathic ataxia in an attempt to clarify 
whether the high prevalence of gluten ataxia in sporadic 
idiopathic ataxias may be related to a high prevalence o f this 
HLA type within this group. Our results show no significant 
differences o f the prevalence of this HLA type amongst 
normal controls, familial or sporadic idiopathic ataxias. The 
high prevalence o f gluten ataxia in the group of patients with 
sporadic idiopathic ataxias cannot simply be explained on the 
grounds of the prevalence o f HLA DQ2 within this group. It is 
likely, however, that the prevalence of HLA DQ2 in the 
general population may have some influence on the preva­
lence of gluten-related diseases. It would be interesting to 
study the prevalence o f gluten ataxia in Japan where the 
prevalence of HLA DQ2 is only 1%.
The introduction o f more coeliac disease-specific serolo­
gical markers such as endomysium and, more recently, tissue 
transglutaminase antibodies may have helped in diagnosing 
gluten-sensitive enteropathy, but their sensitivity as markers 
of other manifestations o f gluten sensitivity (where the bowel 
is not affected) is, by definition, low. This reflects our findings 
with patients with gluten ataxia. Endomysium and tissue 
transglutaminase antibodies are positive in the majority but 
not necessarily all o f the gluten ataxia patients with an 
enteropathy. Patients with an enteropathy represent only a 
small proportion o f patients with gluten ataxia (24%).
Intestinal mucosal damage in gluten-sensitive enteropathy 
is both humoral and T cell mediated. Such inflammation is 
not, however, confined to the gut, as activated HLA-restricted 
gliadin-specific T cells and antigliadin antibodies are found 
system ically (Sollid and Thorsby, 1993; Jensen et a l,  1995). 
Antigliadin antibodies are also found in the CSF (Chinnery 
et al., 1997). Post-mortem findings from two o f our patients 
with gluten ataxia has shown perivascular cuffing with both 
CD4 and CD8 cells. This inflammation was seen primarily in 
the white matter o f the cerebellum. There was also marked 
but patchy Purkinje cell loss. We have also found antibodies 
against Purkinje cells in patients with gluten ataxia 
(Hadjivassiliou et al., 2002b). Our research suggests that 
antigliadin antibodies cross-react with epitopes on Purkinje 
cells from human and rat cerebellum. Characterization of the 
anti-Purkinje cell antibodies by immunoblotting may provide 
a useful marker for the diagnosis o f gluten ataxia in a manner 
analogous to the use o f  antiendomysium antibodies as a 
marker for coeliac disease, or the anti-Yo and other 
antibodies in paraneoplastic cerebellar degeneration. This 
w ill eliminate the potential problem o f overdiagnosing gluten 
ataxia by 12% given that antigliadin antibodies are found in 
12% of the normal population. What is unclear at present (due 
to lack of definition) is whether the prevalence o f gluten 
sensitivity (with or without an enteropathy) in the general 
population could be as high as 12%.
Evidence is emerging that a gluten-free diet may be 
beneficial in the treatment o f gluten ataxia in terms o f both the 
symptoms o f ataxia and the neurophysiological assessment o f  
the peripheral neuropathy (Hadjivassiliou et al., 2002a). The 
timing o f the diagnosis and treatment o f these patients 
appears to be crucial because o f the loss of Purkinje cells 
which is irreversible. Thus, antigliadin antibodies should be 
an essential part o f the investigation o f  patients with sporadic 
idiopathic ataxia at first presentation, and a gluten-free diet 
should be advised even in the absence o f an enteropathy.
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